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ABSTRACT 
Previous research indicates that there is a major challenge caused by the late diagnosis of 
Alzheimer’s disease (AD), with no suitable diagnostic tool available for use in primary care. 
Aim: 
This research is aimed at identifying patterns in the early signs and symptoms of AD to 
suggest the development of a predictive model for the early detection of AD. 
Objectives: To; a) map, synthesise and appraise the quality of existing literature on the signs 
and symptoms preceding the diagnosis of AD via the systematic scoping review of the 
literature; b) identify patterns in signs and symptoms preceding the clinical diagnosis of AD 
in general practices via a retrospective medical record review study (RMRRS); c) explore the 
clinicians perspectives regarding the early signs and symptoms, issues surrounding the late 
diagnosis and collect recommendations for overcoming barriers to timely detection of AD 
via a semi-structured interview.  
Methods: 
This was a mixed method research comprising a systematic scoping review of literature from 
1937-2016, undertaken using the descriptive analysis on the sequence and the timing of 
signs and symptoms preceding the diagnosis of AD. Methodological quality of studies was 
assessed with the QUADAS-2 tool as well as PRISMA guidelines and descriptive analysis 
followed. A RMRRS followed using the logistic regression analysis and a semi-structured 
interview of general practitioners (GPs) in Milton Keynes (MK) and Luton, using the 
framework analysis. 
 
Results: 
The findings from the review suggest that neurological and depressive behaviours are an 
early occurrence in early-onset AD with depressive and cognitive symptoms in the measure 
of semantic memory and conceptual formation in late-onset AD. It appears that there is a 
big variation in the patterns of signs and symptoms with cases of misdiagnosis. However, 
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there was limited evidence due to the limited number of studies of this kind. The nested 
case control design of 109 samples indicates that auditory disturbances could have 
diagnostic value, with a range of signs and symptoms that appears at different time. While 
the interviews highlight and confirm areas for consideration in the primary care and NHS. 
Additionally, the study reports practices in relation to the early diagnosis of AD. However, 
the result is not an overall representation of the views of GPs. 
Conclusion: 
Findings suggest that individuals with auditory disturbances have increased odds of AD. This 
was more striking in the white female population, with borderline significance due to 
limited data that is too small to detect such an uncommon symptom(s).  
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CHAPTER ONE: Introduction 
1.1 Background 
Alzheimer’s disease (AD), named after Alois Alzheimer, is a neurodegenerative disease in 
which the nerves cells gradually degenerate, due to the deposition of β-amyloid plaques 
(Seiko & Dennis, 2001; Fonte et al., 2001; Shoji et al., 2001; Zhan et al., 2015) and twisted 
intracellular strands of protein tau in the brain cells (Igbal et al., 1986; White & Lon, 2009; 
Flammang et al., 2012; Liu et al., 2013). This results in memory loss, cognitive and 
functional decline (Jack et al., 2014; Barnes & Yaffe, 2014). 
A century has passed since the discovery and description of the clinical and 
neuropathological characteristics of AD, including the genetic and environmental risk 
factors as well as potential treatment. In particular, the last two decades have witnessed 
research on the early signs and symptoms, which led to the formation of the diagnostic 
criteria by the National Institute of Neurological and Communicative Disorders - AD and 
Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984). The diagnostic 
criteria have allowed early identification of this disease, but there is a gap between the 
number of early diagnosed and undiagnosed cases due to diagnostic uncertainties, 
including a lack of a recognised pattern of the signs and symptoms preceding the 
diagnosis of the disease. 
There is a discourse in the meaning of early diagnosis, which is interwoven both in 
understanding the disease and ways to deal with it. Early diagnosis is considered as a set 
of interpretive packages that make sense of diagnostics (Mueller et al., 2005; Whitehouse 
& George, 2008; Cuijpers et al., 2014). In the context of healthcare technology (HCT), this 
involves value for money, changing health care, innovation trajectories, changing the 
definition of AD, steps on the road to medication and early management (Dubois et al., 
2007; Cuijpers et al., 2014). Early diagnosis here refers to the diagnosis at the lowest 
threshold of the disease or at the stage of mild cognitive impairment (MCI) with a cluster 
of early signs and symptoms, as well as the diagnosis of the pathology of AD before 
dementia. 
The late diagnosis of AD has become a public health issue (Health and Social Care 
Information Centre (HSCIC), 2014) despite the research conducted and the financial 
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expenditure on the disease. Indeed, the number of individuals receiving a late AD 
diagnosis remains high among the ever-increasing ageing population in the United 
Kingdom (UK) that accounts for about 11 million of older adults aged 65 years and 14.7 
million aged 60 years and over. This is more than the number of 18 years old in the UK 
(National Statistics, 2014). The situation is similar in countries campaigning for early 
diagnosis. 
It has been estimated that one in four individuals (25%) with the disease in the UK have 
been diagnosed (HSCIC, 2014), and late diagnosis of AD is documented to result in severe 
health consequences to individuals affected and their caregivers. In a study to describe 
the factors associated with a late diagnosis of AD, 62% of patients remained undiagnosed 
for a year after their symptoms were first presented to the physician for diagnosis 
(Knopman, Donohve & Gutterman, 2000). The current trend in the UK is that it takes two 
to four years before an AD diagnosis is established (National Health Service, 2014). 
However, a timely diagnosis in the UK varies depending on locality. In some areas, less 
than 40% of individuals with the signs and symptoms of the disease have received a 
diagnosis (Alzheimer’s Society, 2014). This is attributed to a shortage in specialised 
diagnostic services, lack of training and lack of disease-modifying options, which makes 
the healthcare professional reluctant to give a diagnosis (Dubois et al., 2015) among 
other reasons. 
Furthermore, the All Party Parliamentary Group on dementia (2013) indicates that the 
Black, Asian and Minority Ethnic Groups (BAME) are less likely to receive a diagnosis or 
support than their white counterparts; the prevalence rate for these groups has not been 
updated since 2014. Waiting for a long time to be diagnosed can increase the 
degenerative processes, resulting in anxiety and depression. Globally, the picture is the 
same, as 78% of the 36 million individuals with the disease are yet to receive a diagnosis 
(World Alzheimer’s Report, 2015). Similar findings have been noted in other developed 
countries (Carpentier et al., 2010), such as in France where only 50% of AD patients were 
diagnosed in 2011 and the average time from first warning signs to AD diagnosis takes 
two years (Rapp et al., 2014). The situation is even worse in developing countries, with an 
estimated 90% of individuals with the disease in India as yet undiagnosed (World 
Alzheimer’s Report, 2015). According to Dementia Statistics, UK (2017), the number of 
21 
 
individuals diagnosed with all-cause dementia is 539,062; however, the number of those 
with AD dementia, which is the late stage of AD, is unknown.  
Studies indicate that this could be due to under-reporting by patients and their families, 
as the symptoms are confused with normal ageing and emerge so gradually that they are 
not recognisable (Ording & Sorensen, 2013; Jones et al., 2015). Additionally, there is a 
high cost of diagnosis and treatment (Alzheimer’s report, 2014), which arguably delays 
individuals and family members seeking help, and a subsequent concealment of 
symptoms that results in late diagnosis (Ording & Sorensen, 2013; NHS Choices, 2014; 
Alzheimer’s Report, 2014; Marquer et al., 2014). Other factors associated with the delay 
in diagnosis include the limited understanding of the differences between memory 
processes in ageing and AD by both caregivers and physicians (Knopman et al., 2000; 
Shim et al., 2013). The inaccurate specification/unclear pattern of the signs and 
symptoms also contribute to the late diagnosis. The pathological results of 119 of 533 
patients diagnosed with AD and retrospectively reviewed in a database study did not 
meet the diagnostic criteria for definite AD (Shim et al., 2013). An earlier post-mortem 
examination of individuals diagnosed with prion disease indicated that they actually 
suffered from AD (Schmidt et al., 2010). This may be attributed to technical reasons, 
however, a distinction in signs and symptoms of AD might have made the difference. 
Major advances in the identification of structural molecular neuroimaging and 
cerebrospinal fluid (CSF) biomarkers with cognitive assessment (Didic et al., 2011) have 
made the diagnosis of AD pathology possible (Holtzman et al., 2011; Dubois et al., 2014). 
However, these laboratory tests are restricted to tertiary care centres (academic centres 
and clinical trials) and are not available in primary care in the community (Albert et al., 
2012). Moreover, the examination of the proposed biomarkers (such as neuroimaging 
and PET scan) can be expensive and invasive, with an addictive value that could delay the 
diagnosis in clinical settings (Schoonenboom et al., 2012; Zahodne et al., 2013). 
Identifying patterns of the clinical manifestations of the disease, in measuring disease 
progression, can be a marker that can easily be assessable in primary care settings, 
potentially reducing the number of individuals waiting to be diagnosed and complement 
the assessment of biomarkers in the tertiary sector. 
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Additionally, the Mini-Mental State Examination (MMSE), a test carried out by clinicians 
in the general practice consisting of eleven series of questions and examinations to assess 
the changes in memory or other mental abilities, increases the time it takes for routine 
screening. It consists of many questions that need to be answered within a short time 
(Mendiondo et al., 2003). The test does not detect subtle memory loss in highly educated 
individuals (Costa et al., 2013), as this can be viewed as average intelligence. Moreover, 
the test is not appropriate for patients with learning or communication disabilities (NICE 
guideline, 2006) due to communication uncertainties in these individuals.   
In a Canadian survey of 398 caregivers, 78% were family members who manifested the 
symptoms of AD and comorbid conditions (Black et al., 2010). The financial expenditure 
for AD in the UK is approximately £26 billion annually, equating to a £30,000 annual cost 
of treating an individual, more than treating cancer (£5,500), diabetes (£2,500) and heart 
disease (£4,560) per patient put together (Alzheimer’s Research UK, 2014). This 
expenditure includes the medical (institutionalisation) and non-medical costs. A UK cross-
sectional observational study (18 UK sites) of 249 possible/probable AD indicated that the 
median and mean direct non-medical costs of care for individuals with AD were £168 and 
£2,924 per annum respectively (Jones et al., 2015). 
As affirmed by Barnett et al. (2014), the net benefit of early intervention, which is the 
intervention to delay the degenerative process and institutionalisation, economic and 
social benefit, is reduced by approximately 17% for every year intervention was delayed. 
Early detection and starting intervention early may be associated with less cognitive 
decline, longer survival and financial savings of about £7,000 per patient annually 
(Mittelman et al., 2006; Chamberlain et al., 2011; Getsios et al., 2013; Barnett et al., 
2014). An economic evaluation of early assessment of AD in the UK reported that early 
assessment reduces health care costs by £3,600 per patient and societal costs by £7,750 
per patient annually (Getsios et al., 2013). Late diagnosis is a burden to patients, family 
members, as well as health and social care (Black et al., 2009; Barnett et al., 2014; Jones 
et al., 2015).  
AD is a reverse causality for conditions such as cholesterolemia, hypertension and 
depression (Rao et al., 2014). It has been discovered that multiple comorbid pathologies 
or concomitant health conditions associated with advanced age contribute to the clinical 
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manifestation of AD, exacerbating the rate of cognitive decline (Feldman et al., 2014). 
These comorbidities include musculoskeletal, genitourinary, ear, nose and throat (ENT), 
vascular/heart conditions, gastrointestinal tract diseases, endocrine/metabolic, 
psychiatric conditions/depression and related dementias (Katz et al., 1997; Doraiswamy 
et al., 2002). They can act as a confounder, threatening the internal validity, or as an 
effect modifier, threatening the internal and external validity of empirical studies 
(Greenfield et al., 1993). This calls for a clear distinction between AD and the 
comorbidities for appropriate intervention. 
 
1.2. The prevalence of the disease and cost of treatment in the UK  
Globally, AD prevalence has been estimated to be about 36 million in 2014 in a world 
population of 7.3 billion individuals (United Nations, 2015), with a projected increase of 
about 115 million in 2050, due to the improvement in health and economic conditions 
(Alzheimer’s Research, UK 2014) (Figure 1.1). According to the Alzheimer’s report (2015), 
there are almost 900 million people aged 60 years and above living globally with AD due 
to the rising life expectancy; which is contributing to the rapid increase predicted in the 
number of patients diagnosed with AD and other chronic diseases such as cancer and 
diabetes.   
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Figure 1.1. The projected increase in the prevalence of AD. The graph represents the projected 
prevalence of AD in the world population in 35 years’ time. 
 
In the UK, an AD prevalence of 520,000 has been reported (National Statistics, 2014), 
which equates to 8.1% of the 64.1 million population and rising due to ageing and 
improved diagnostic techniques. There is an annual incidence of 62,000; the prevalence 
in the early onset AD (EOAD) accounts for approximately 40,000, 5% of the annual 
prevalence (NHS Choices, 2014). As expected, the frequency increases with age: 
approximately 1 in 20 (5%) adults aged 65 years and under, 1 in 14 (7%) adults over 65 
years, 1 in 4 (39%) adults 75 years and older, and 1 in 6 (17%) over 80 years and above 
are affected by AD (HSCIS, 2014) (Figure 1.2). The prevalence is high among the 75-year-
old plus due to the fact that late onset AD (predominant AD) begins at 65 years and 
above, which takes between 10–30 years before the onset of signs and symptoms, hence 
the highest prevalence in the group. 
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Figure 1.2: Prevalence of AD in the UK population. The X-axis represents the prevalence 
according to age and the Y-axis represents the ageing population; the prevalence among the UK 
population increases with age, with those aged 75 years and over accounting for 39% of the 
diagnoses. 
 
In Buckinghamshire, among the population of 521,922 individuals, a dementia prevalence 
of 7,000 (Buckinghamshire City Council, 2015) was recorded in 2015 and a prevalence of 
2,300 in Milton Keynes, of which 60–80% (1,380–1,840) was AD. The highest prevalence 
was recorded in individuals 85–89 years of age (Alzheimer’s Society, 2015; JSNA, 2015), 
with the prevalence declining after the age of 90 years due to increased mortality among 
this group. As the prevalence of the disease continues to rise in the ageing population, 
there is an increasing need to identify cases of AD early, so that patients can receive 
appropriate therapy and care, while carers and family members can be helped and be 
supported.  
 
1.3. The  study rationale  
The purpose of this research was to identify patterns in the sequence and timing of 
presentations preceding the clinical manifestation of AD for the development of a 
predictive model for early detection. Advances in AD research have led to the 
identification of appropriate biomarkers, including amyloid protein and phosphorylated 
tau that aid the diagnosis of the disease (McKhann et al., 2014; Dubois et al., 2007; 2014). 
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Nevertheless, the late diagnosis of individuals with AD is a major challenge. In the UK, it 
has been estimated that three-quarter of individuals with AD have not received a formal 
diagnosis (Alzheimer’s Statistics, 2014), the majority of whom belong to the ageing 
population also suffering from the degenerative process of ageing. Worldwide, studies 
have shown that adults of 60 years and above are projected to double from 2010–2025, 
the projection by 2050 is more than five times the number in 2010 in the upper medium 
income countries (Table 1.1). 
 
 
 
YEAR Higher Upper medium Lower middle Lower Worldwide 
2010 232.3 (30.4%) 116.4 (15.2% 356.2 (46.6%) 59.8 (7.8%) 764.7 (100%) 
2015 309.4 (34.6%) 319.8 (35.7%) 233.1 (26.0%) 32.9 (3.7%) 895.2 (100%) 
2030 403.9 (29.4%) 531.5 (38.7%) 386.0 (28.1%) 53.5 (3.9%) 1347.8 (100%) 
2050 482.5 (23.9%) 760.8 (37.7%) 665.3 (32.9%) 111.4 (5.8%) 2020.0 (100%) 
 
The diagnostic rate of AD varies across the country, from 39% in low-performance areas 
on the diagnostic procedure to 75% in the high-performance localities (Department of 
Health UK, 2013; Alzheimer’s Statistics, 2015). The reason for the late diagnosis of AD in 
the population is attributed to factors including the current diagnostic criteria (Chapter 
2.3), which are based on assessment of biomarkers, including only two clinical 
phenotypes that might not be the early symptoms, therefore, insufficiently address other 
aspects of the presentation of the disease, like the signs and symptoms (Rohrer et al., 
2012; Jones et al., 2015). The signs and symptoms are often not the same in all cases 
(Caselli et al., 2013) and could be misleading.  
The biomarkers or signature of AD has been a low level of Aβ_42 and high level of total 
tau (T-tau) and phosphorylated tau (P-tau) (Blennow et al., 2003; Leon et al., 2006; 
Galasko et al., 2009). Magnetic resonance imaging (MRI) and fluoro-2-deoxy-D-glucose 
positron emission tomography (FDG-PET) have indicated sensitivity for AD identification 
at the MCI and normal cognitive stages (Leon et al., 2001; Misconi et al., 2007; Blennow 
et al., 2010). Even though the diagnostic value is enhanced with cerebrospinal fluid (CSF), 
Table 1.1: Projected number of adults aged 60 years and above globally. 
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diagnosis of AD remains difficult mostly on clinical grounds, as there is variability in CSF 
collection methodology that results in variability of Aβ results (Dubois et al., 2007; Lucey 
et al., 2015). Access to biomarkers is restricted in some settings and the immunoassay of 
concern (Dubois et al., 2007; McKhann et al., 2011; Schicktanz et al., 2014; Laske et al., 
2015), which has made the replication of the results difficult. 
Furthermore, the low level of Aβ_42 has also been reported in plaque-free Creutzfeldt-
Jakob disease (CJD) and in bacterial meningitis (Sjogren et al., 2001; Wiltfang et al., 2003; 
Schmidt et al., 2010), while a high level of T-tau has been reported in normal ageing and 
CJD. Moreover, even though Aβ_42 is said to occur before the deposition of tau 
pathology, neurofibrillary tangle (NFT) formation and neuronal degenerations (Jack et al., 
2010; 2013; Trojanowski & Hampel, 2011), some researchers have shown that Aβ and tau 
occur 10–15 years before the onset of symptoms (Gustafson et al., 2007). Other 
researchers suggest that tau deposition precedes amyloid plaque pathology in predicting 
cognitive decline in healthy individuals (Braak & Braak, 1997), while Stomrud et al. (2007) 
states that CSF Aβ_42 reduction is more predictive of cognitive decline than high levels of 
tau. This variability including the inter-assay and inter-laboratory (Mattson et al., 2009; 
Verwey et al., 2009; Blennow et al., 2015) limits the ability to discriminate AD from other 
dementias and necessitates the consideration of other aspects of presentations, like the 
pattern in the timing and sequence of symptoms and signs of AD. 
There seems to be conflicting evidence of moderate knowledge of AD among health 
professionals (Smyth et al., 2013; Kada et al., 2015), including the knowledge of the 
course or pathology of the disease. Furthermore, there is a lack of understanding of the 
transitional stage of asymptomatic and symptomatic AD (Paton et al., 2004; Lowe et al., 
2014). An informal and interactive survey of individuals in twelve countries regarding the 
knowledge of the signs and symptoms of AD indicated that 5% of the surveyed individuals 
had a misconception of the signs and symptoms of AD with normal ageing (Alz.org, 2015) 
and these individuals would be unlikely to initiate or seek an intervention, hence the 
need to draw patterns in presentations. Moreover, there is no study that has been 
undertaken in the UK regarding the pattern of the signs and symptoms preceding the 
clinical diagnosis of the disease. Identifying the patterns that are specific to the different 
stages of the disease progression can improve the accuracy of diagnosis (Ganguli et al., 
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2011; Lenderking et al., 2014; Johnson et al., 2015; Laske et al., 2015) for early 
intervention.  
The researcher focusses on the limitations of early diagnosis encountered in the primary 
and secondary care settings and identifies patterns in the signs and symptoms at the 
preclinical stage, a strategy to help overcome late diagnosis that is yet to be fully 
researched. A better understanding of this has important clinical implications, particularly 
with regards to early detection (Albert et al., 2011; McKhann et al., 2014), as this period is 
the best time for therapeutic interventions (Reiman et al., 2009). 
Critics of the early diagnosis of AD (Le Couteur et al., 2013; Lock et al., 2013) are of the 
opinion that early detection will mainly lead to an increase in the prevalence with 
unnecessary investigations, side effects from premature treatment, stigmatisation and 
less support (Robinson et al., 2014). However, studies indicate that the early detection of 
AD is beneficial (Schicktanz et al., 2014) and that the AD label is not associated with more 
stigmatising reactions (Johnson et al., 2015). Detecting changes that reflect disease 
progression in a relatively short time before the obvious/noticeable signs and symptoms 
emerge will obviously decrease the number of patients waiting to be diagnosed. This will 
also support a screening system that will predict individuals at risk and inform the 
intervention that is most suitable for the individual to slow progression, affording them 
the opportunity to make informed choices (Mittelman et al., 1996; Solomon & Murphy, 
2005; Bruandet et al., 2009; Feldman et al., 2014) and delay institutionalisation. The 
Alzheimer’s Statistics (2015) in the UK indicates that delaying the onset of dementia by 
five years through the early detection and diagnosis of the disease would reduce deaths 
directly attributed to dementia by 30,000. 
Doctor’s surgeries, being the primary care providers and the first point of contact for the 
patients, have an important role in the early detection. Indeed, 90% of data recorded at 
general practices during the last seven years is appropriate to enable the identification of 
early signs and symptoms that might suggest screening strategies for primary care to 
improve the prognosis of AD (William et al., 2012). This will then serve as a coordinator 
between the primary and secondary specialist care providers to confirm the diagnosis, as 
the initiation of screening is made easy with the predictive model.   
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1.4. Aim 
To identify patterns in signs and symptoms preceding the clinical diagnosis of AD for the 
development of a predictive model for the early detection of the disease. 
1.4.1. Objectives 
1. To map, synthesise and appraise the quality of the existing evidence on the timing and 
sequence of signs and symptoms that will justify the clinical diagnosis of AD via a 
systematic scoping review. 
2. To identify patterns in signs and symptoms preceding the clinical diagnosis of AD in 
general practice notes and patients’ records, as these were presented by the AD patients 
before their clinical diagnosis. 
3. To explore the perspectives of GPs regarding factors that may contribute to late 
diagnosis and recommendations for overcoming barriers to timely diagnose AD. 
 
1.5. Description of research study plan 
Objective 1   
To map, synthesise and appraise the quality of existing literature on the timing and 
sequence of the signs and symptoms that will justify the clinical diagnosis of AD, via a 
systematic scoping review to inform the primary study. 
Method 1 – Systematic Scoping Review 
This objective was met and achieved with a systematic scoping review of research in the 
field of AD, which synthesised and interpreted components of the epidemiological 
evidence on timing and sequence of early signs and symptoms that justified a diagnosis of 
AD. This is an advancement to the literature review, which provided evidence and 
appraised findings from the entire field of study (Levac et al., 2010; Gough & Thomas, 
2012). The protocol for this method is presented in section 3.1, while the method is 
presented in chapter four and analysed with a descriptive analysis. 
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Objective 2  
To identify patterns in signs and symptoms preceding the clinical diagnosis of AD in 
general practice notes and patients’ records, as these were presented by the AD patients 
before their clinical diagnosis. 
Method 2 – Case-Control Design 
This objective has been achieved with the RMRR (case-control design) which was 
undertaken at GP surgeries in Milton Keynes and Luton. GP surgeries were approached 
for the study to allow access to case notes from patients diagnosed with AD in the year 
2006–2016. These notes were collected and reviewed retrospectively to identify patterns 
in the signs and symptoms preceding a diagnosis of AD. Probable AD met the diagnostic 
criteria of the NINCDS-ADRDA and screened with MMSE with a memory score of 15 and 
above. The signs and symptoms were measured with the Neuro-Psychiatric Inventory 
(NPI), which is explained in chapter three. Milton Keynes was chosen because it falls 
within the jurisdiction of South East England, which has the highest prevalence (n = 
121,512) of people with AD (Alzheimer’s Society, 2014), with a population of 16–65 year 
olds higher than the rest of England, while Luton has an ethnic diversity that will enrich 
the study results as detailed in chapter three. 
Comorbidities were taken into consideration and met the standard comorbidity 
measurement of Index of Coexisting Disease (ICED). The ICED is a valid and reliable two-
dimensional structure, measuring the severity of diseases and disability caused by 
comorbidity, especially useful when disability and mortality are the outcomes of interest 
(de Groot et al., 2003). The scores of the ICED are based on the existing signs and 
symptoms. The comorbidities are measured to correct confounding for internal validity, 
secondly to identify effect modifiers, thirdly to predict the outcome of the study and 
finally for statistical efficiency (de Groot et al., 2003). The statistical analysis was 
undertaken with the latent class (LC) logistic regression model explained in chapter three 
to generate subtle data patterns.  
Objective 3 
To explore the perspectives of GPs regarding factors that may contribute to late diagnosis 
and recommendations for overcoming barriers to the timely diagnosis of AD. 
31 
 
Method 3 – Qualitative Interviews 
This objective has been met with qualitative interviews of GPs in MK and Luton exploring 
the perspective, seeking to elaborate and enhance the results of the retrospective 
medical record review and systematic scoping review studies. Analysis of verbatim 
transcripts was inspired by interpretive descriptive statistics and framework analysis. 
 
1.6. The significance of the study and contribution to knowledge 
The study contributes to three main areas of literature. Firstly, this study extends the 
existing knowledge of the signs and symptoms preceding a diagnosis of AD through the 
identification of patterns in the sequence and timing of these presentations. This would 
have a significant impact on future patients as the study could help in identifying the 
disease early/earlier with potential physical, social and financial benefit to patients, 
families and the healthcare sector.  
Secondly, the diagnostic criteria are weighted more on biomarkers. The addition of an 
observable, non-invasive and cost-effective pattern of signs and symptoms suggest an 
additional early detection model that can be developed to be used in clinical settings. 
Thirdly, the research collected clinical data from GP surgeries, a field also underutilised, 
and helps fill the gap in the literature regarding the pattern of signs and symptoms 
preceding the diagnosis of AD, as there is no study that has been undertaken on this. 
In conclusion, the study has the potential to inform future policy on the early detection of 
AD due to a lack of literature of this magnitude for timely and effective therapeutic 
intervention, to reduce the degenerative process of the disease. 
 
1.7. Summary 
This chapter has described the problems of late diagnosis, the burden of the disease to 
individuals and the cost of AD to the healthcare sector (11.2% of disability years in adults 
60 years and above). The chapter also explained the benefits of early detection and issues 
that prevent the timely identification of the early signs and symptoms of AD, including 
confusing symptoms with other diseases (Jones et al., 2015), under-reporting of 
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symptoms by individuals or carers (Ording & Sorensen, 2013), high cost of diagnosis 
(Ording & Sorensen, 2013), lack of knowledge of the disease process (McKhann et al., 
2011; Hudson et al., 2012) and issues with the diagnostic criteria (Albert et al., 2011; 
Zahodne et al., 2013). This chapter has identified the need for the research to enable the 
identification of patterns of the signs and symptoms preceding the clinical diagnosis of AD 
to suggest the development of a predictive model.  
In order to demonstrate the need for identification of patterns, it is necessary to explore 
the scientific reasoning and data available, so the next chapter will proceed to view and 
summarise the available literature on the early signs and symptoms of the AD. 
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CHAPTER TWO: Review of literature 
 
Modalities to identify AD include biomarkers, the signs, and symptoms. After an extensive 
engagement with the literature, this chapter identifies and provides six major themes 
from the literature reviewed: Firstly, the chapter provides an overview and summarizes 
the state-of-the-art in terms of its knowledge of AD. Secondly, the current concepts of 
the early signs and symptoms or rather the MCI and subjective cognitive decline (SCD), 
which emphasize the timing of the appearance of these presentations, are discussed. I 
will guide the reader to understand the early stage and manifestation of the degenerative 
processes which will enable early detection. Thirdly, the diagnostic criteria which 
incorporate biomarkers and clinical phenotypes are discussed in relation to the early 
diagnosis of the disease. Fourthly, the current issues surrounding the late diagnosis of AD 
and the benefits of early detection of the disease are explored. 
The review includes a summary of individual signs and symptoms, how they relate to the 
stage of disease, the current debate as to which of the signs or symptoms appears first 
and their contribution to understanding the need to map their patterns of occurrence 
preceding a diagnosis of AD is also discussed. The literature is sought from a variety of 
different sources including magazines, newspaper articles, journals and articles, 
electronic databases including PubMed, MEDLINE, Web of Science, CINAHL, PsycINFO, 
AMED (Allied and Complementary Medicine), Scopus, Nursing Index, DH-data, King’s 
fund, Google scholar and conference proceedings including grey literatures. The chapter 
ends with a summary of the literature presented, the identification of knowledge gaps in 
this field and the need to identify patterns of the signs and symptoms preceding the 
diagnosis of AD, for the development of a predictive model.   
2.1. An overview of AD 
AD is the most prevalent form of dementia, accounting for 60-80% of all dementias. 
Dementia describes a group of diseases that share a syndrome typically chronic and 
progressive in nature and involves disturbances of multiple higher cortical functions, such 
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as memory, thinking, orientation, perception and behaviours among the elderly (Alz.Org., 
2014; Barnard et al., 2014). 
Just like any organ in the body, brain function declines with healthy ageing but it does not 
lose neurons, that is, a network of communication, metabolism and repair within the 
brain and its environ, in large numbers. However, as stated by the National Institute of 
Aging (NIA, 2014), the reverse is the case in AD, with extensive damage to the neurons, 
characterised by the loss of connectivity with other neurons. As a result, there are 
neuronal dysfunction and subsequent death. 
AD is characterised by the deposition of the extracellular protein fragment β- amyloid 
(plaques) and twisted intracellular strands of protein Tau in the brain cells (nerves), which 
causes a range of changes in the brain anatomy, biochemistry, genetics and functions 
(Selkoe et al., 2001; Jack et al., 2014). Cognitive normal individuals have AD pathology. 
There is amyloid deposition (Hyman et al., 2011) and neurofibrillary tangle (NFT) 
formation, which is almost universal in patients over the age of sixty-five, as indicated by 
the neuropathological studies of normal ageing, in the entorhinal cortex, as part of 
normal ageing or pathology (Bouras, 1994; Braak, 1995; Casselli et al., 2013). Their 
extension into the neocortical regions is not part of healthy ageing but attributed to AD. 
This might affect the ability of medical professionals to distinguish AD from normal 
ageing, for which fibrillary amyloid is very often detected, and other conditions with the 
same presentations can affect and interfere with the diagnostic algorithm. The 
biomarkers are thus explained. 
2.1.1 Signature of AD 
AD is characterised by  five established biomarkers that indicate the  presence of AD 
pathology in the brain; neuropathology that is presented by the widespread deposit of 
extracellular plaques consisting of amyloid βeta (Aβ) peptides and intracellular NFT 
consisting of phosphorylated tau (p-tau) (Serrano-Pozo et al., 2011; Hoglund et al., 2015), 
decreased levels of aβ42 with increased concentration of total tau (t-tau) and 
phosphorylated tau (p-tau), respectively in the CFS (Lewczuk et al., 2010), decrease 
glucose metabolism in the brain (Lowe et al., 2009) and cerebral atrophy (Dickenson et 
al., 2011). 
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2.1.1.0 Tangles and plagues 
Although AD manifests clinically with progressive memory impairment and cognitive 
decline, the hallmarks of extracellular senile plaques of amyloid-β (Aβ) protein and 
intracellular hyperphosphorylated or twisted strands of protein Tau, are considered to be 
the main inducers and biomarkers of AD (NIA, 2014). These protein plaques signal 
changes in the biological processes long before the onset of cognitive symptoms (Jack et 
al., 2013). The involvement in tangles eventually leads to synaptic loss and nerve cell 
death when viewed under the microscope. Tangles and plaques are closely associated 
with the degree of cognitive impairment in AD individuals (Mrak & Griffin, 2001), and 
presence along with the cognitive impairment to warrant a diagnosis of AD.  
2.1.1.1 Amyloid beta (Aβ) 
Glenner & Wong (1984) were able to determine the composition of the two pathological 
hallmarks of AD, by isolating and identifying beta (Aβ) protein, which becomes insoluble 
to form neuritic plaques in the brain. Enzymes called β secretase and γ secretase in the 
body are responsible for producing the insoluble Aβ protein when the protein is cut 
sequentially; an increase in the activities of the β secretase in AD leads to overproduction 
of the insoluble protein that sticks together to form neurotic plaque (Sinha et al.,1999). 
However, even with the strong suggestions that amyloid accumulation in the brain is 
responsible for AD, some researchers (Giannakopoulos et al., 2003) are of the opinion 
that the accumulation of the amyloid protein in the brain is not a strong predictor of the 
degree of cognitive impairment among adults with the disease. This is because some 
adults diagnosed with the disease had a low accumulation of amyloid protein in the brain 
(Haroutunian et al., 2008) while others with high accumulation of this protein consistent 
with AD, but exhibited normal cognitive function (Knopman et al., 2003; Bennett et al., 
2006). This can also interfere with the diagnostic procedure, leads to misdiagnosis, and 
consequent late diagnosis of the disease. A supportive measure could be the observable 
patterns in the signs and symptoms of the disease. 
2.1.1.2 T-tau and P-tau 
Soon after, a number of researchers (Wood et al., 1986; Grundke-Iqbal et al., 1986; Kosik 
et al., 1986) identified Tau protein that makes up the NFT. Tau is a protein in the brain; a 
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microtubule binding protein that helps maintain the structural integrity of microtubules, 
by primarily promoting stability (Drechsel et al., 1992). Tau becomes saturated in AD with 
the chemical phosphate in a process known as phosphorylation (Goode et al., 2000), 
which binds together to form NFT inside the neurons (Santa-Maria et al., 2012). 
The tau and tangle hypothesis by Mudher & Lovestone (2002), describes structural 
changes to tau and subsequent formation of NFT as being the primary cause of AD. But, 
this has received less support compared with the amyloid cascade hypothesis in the 
scientific community. However, evidence (Braak & Braak, 1991; Arriagada et al., 1992; 
Mitchell et al., 2002), suggests a significant relationship between the severity of the 
disease and accumulation of NFT compared to percentage neurotic plaques in the brain. 
Ironically, this hypothesis has its own limitation by the fact that genetic mutations to the 
tau protein do not lead to AD, but are known to cause fronto-temporal dementia, 
characterised by damage to the frontal and temporal lobes of the brain and changes to 
personality, behaviour, and language (McKhann et al., 2001). 
Changes, therefore, in an unknown pathway could be the cause of AD, due to the rising 
debate among the scientific community about the strength and limitations of both the 
amyloid cascade and tau and tangle hypothesis, which needs more investigation. 
Moreover, cost and physical discomfort are some of the barriers and limitations to 
collecting these biomarkers. If there are debates about the biomarkers as signatures of 
the disease, the non-invasive and observable symptoms may just be the help needed to 
detect the disease early. 
 
2.1.1.3 Other biomarkers 
2.1.1.3a Post-synaptic protein neurogranin (NG) 
Neurogranin is a postsynaptic protein involved in the regulation of synaptic signaling, 
through binding to calmodulin at low levels of calcium (Baudier et al., 1991). The protein 
is significantly increased in AD as compared to healthy individuals and correlate with 
rapid change in cognition in individuals at clinical follow-up (Kvartsberg et al., 2015). 
2.1.1.3b Axonal cytoskeleton protein filament (NF) protein 
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Numerous studies (Rosengren et al., 1999; Sjogren et al., 2000; Hu et al., 2002; Norgren 
et al., 2003; Pijnenburg et al., 2007) have suggested an increased in CSF levels of NF light 
(NFL) and NF heavy (NFH), two subunits of NF consisting of four subunits (NF-light, NF-
medium, NF-heavy, and Alpha-intermexin) in AD individuals.  Neurofilament is a 
prominent axonal cytoskeleton protein found exclusively in neurons for the maintenance 
of neuronal caliber (Gresle et al., 2006). 
2.1.1.3c Phospholipids 
Lower levels of ten different phospholipids were found in older adults with impaired 
memory compared to adults with normal cognition, who went on to convert from normal 
to impaired cognition, within a five-year period (Mapstone et al., 2014) suggesting that 
other biomarkers may accurately identify individuals at the pre-clinical stage of the 
disease. A simple blood test clinically could identify those with AD in place of the most 
advanced biomarkers that are expensive and intrusive. 
2.1.2 Stages of AD 
AD was initially thought to be a disease with one phase, describing only the later stages, 
when dementia is already present (National Institute of Aging and Alzheimer’s 
Association-NIA-AA, 2011). The practice was still the same especially in 1984, till the NIA-
AA, for the first time in 2011, revised the clinical diagnostic criteria for AD and 
incorporated the three stages of AD that covers the full spectrum of the gradual changes 
of the disease namely: 
2.1.2.1 Preclinical 
The significant clinical symptoms are yet evident at the preclinical stage, with the changes 
in the brain including the accumulation of amyloid protein and early nerve changes 
potentially in progress. The risk of progression to AD is unknown and can only be 
detected by the presence of biomarkers (CSF analysis) and brain (positron emission 
tomography-PET) scan, without some of the early brain changes and outward symptoms 
(Jack et al., 2011; Ritchie et al., 2016). The preclinical phase of cognitive deficits precedes 
the clinical diagnosis of probable AD by more than six years as described by the 
Framingham studies (Tan et al., 2003), but might last up to 20 years before the disease is 
pronounced. 
38 
 
2.1.2.2 Intermediate stage or MCI 
The intermediate stage is characterised by mild symptoms but without physical and 
mental incapacitation. Individuals may progress to Alzheimer’s dementia (Albert et 
al.,2011), with the biomarkers including elevated levels of tau or decreased levels of beta-
amyloid in the CSF, reduced glucose uptake in the brain as determined by PET, and 
atrophy of certain areas of the brain noticed with structured magnetic resonance imaging 
(MRI). 
2.1.2.3 Dementia due to AD or Alzheimer’s dementia (DAD) 
This is the final stage; pronounced symptomatical and interferes with daily activities. A 
decline in cognition such as aphasia (word finding), hallucinations (vision/ spatial issues), 
and agnosia (impaired reasoning or judgment) may be the first symptoms to be noticed 
and the most relevant for clinicians and patients (Guy et al., 2011). Progression of the 
symptoms of AD takes a long time and might be mistaken for old age, which calls for 
more attention to the pattern at each stage of the disease, as it has been observed that 
individuals even at the preclinical stage could be aware that something is not right in 
their biological system and might constantly seek the help of their GPs to identify what is 
wrong with them. 
2.1.3 Types of AD 
The cause of AD is unknown; while the disease is associated with old age from 60years 
and above, scientists have discovered that AD can develop in the 30s, 40s, 50s or 60s.  
Although scientists have discovered the degenerative processes of disease in the brain 
(Ridha et al., 2006; Williams, 2013), the reason it develops and affects some individuals is 
unclear. While individuals sometimes mistake the disease for old age, there are 
considerable differences between the disease and old age (Table 2.1). The disease is 
classified into: 
2.1.3.1. EOAD 
This occurs in individuals 30-60 years; before 65 years, rare and might be inherited 
(familial AD) or sporadic without a known cause (Brickell et al., 2006; Braskie et al., 2011). 
Early-onset Familial AD (EOFAD) is caused by a gene in chromosomes 21, 14 and 1 that 
triggers the formation of abnormal and mutation of the amyloid precursor protein (APP), 
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presenilin-1 (PSEN-1) and presenilin- 2(PSEN-2) respectively. Each of these mutated gene 
products plays a role in the breakdown of APP, a part of a process that generates harmful 
forms of amyloid plaque, a hallmark of AD (Ridha et al., 2006; Pottier et al., 2013; Sassi et 
al., 2014). Presenilin-1 accounts for about two-thirds of EOFAD cases (35-70%). 
2.1.3.2. LOAD 
Otherwise, known as sporadic AD, LOAD is the dominant type of AD that starts at 65years 
and above and account for 90% of all cases of AD. LOAD had been genetically associated 
with the Allele types 4 apolipoprotein E (apoE) (Corder et al., 2003). The autopsies of 
LOAD patients indicated the presence of cytokines in the brain, a pleiotropic (more than 
one effect) protein involved in various immune responses, inflammatory processes and 
hematopoiesis (Rubio-Perez et al., 2012; Latta et al., 2015). Cytokines, a Greek word 
meaning cell (cyto) movement (kines), are produced by monocytes and macrophages as a 
proprotein and released in response to cell injury and thus lead to apoptosis 
(programmed cell death). The many effects of cytokines have shown to be associated 
with rheumatoid arthritis and AD (Refseq, 2008; Mandal et al., 2015). The proteins aid 
cell-to-cell communication in immune responses, stimulate the movement of cells 
towards the site of inflammation and link to a genetic defect in chromosomes 14 (Mandal 
et al., 2015; Ebbert et al., 2016). The progression, however, is similar in both the early 
and late onset of the disease, with the youngest onset in the UK documented as early as 
27 years of age. Due to the fact that the progression is similar, establishing the different 
pattern of presentations in timing and sequence will help identify their differences. 
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TABLE 2.1: The difference between the signs and symptoms of ageing, in comparison with early 
and late signs and symptoms of AD. 
SIGNS AND SYMPTOMS OF NORMAL 
AGEING 
EARLY SIGNS AND 
SYMPTOMS OF AD 
LATE SIGNS AND 
SYMPTOMS OF AD 
Occasional memory loss of past event 
but not present events 
Episodic memory loss Worsening 
memory 
loss/dementia 
Difficulty in finding the right words 
occasionally without trouble having a 
conversation 
Apathy Aphasia 
Normal fear of frightful events only Irritability Phobia 
Occasional pause to remember 
direction for unfamiliar places or to 
speak 
Anosognosia Hallucination and 
delusion 
Calm except in danger Anxiety Opnea and 
restlessness 
Minor decline in olfactory function 
due to age 
Olfactory deficit Agitation 
Mobility Disinhibition Immobility 
Independence Aberrant motor 
behaviour 
Loss of 
independence 
  
 
2.2 Concepts in AD in relation to timing/stages of the disease 
There has been a proposition of multiple definitions to capture the intermediate stage 
between healthy ageing and mild cognitive changes and dementia (Figure 2.1); this has 
been in line with the efforts devoted to diagnosing the disease early by recognising the 
signs and symptoms that could be used as reliable predictive markers of the disease 
(Flicker et al., 1991; Stephan et al., 2010).  
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Figure 2.1: A model of the trajectory of AD. The stage of preclinical precedes MCI and 
encompasses the spectrum of the presymptomatic stage to the third stage of dementia. The signs 
and symptoms might not be present at the preclinical stage, subtle in the MCI stage and worse in 
dementia.  
 
The diagnosis of AD could be viewed from two perspectives. The first is the detection of 
the signs and symptoms that indicate the possibility of the disease (Albert et al., 2011). 
The second is the diagnostic biomarkers that establish the fact that the disease in 
question is actually AD as suggested by the diagnostic criteria. These variables not only 
have a direct influence on the diagnosis but play an important role in the early 
intervention of the disease. Two concepts have been proposed to capture the timing of 
symptoms presentations, these are: 
2.2.1   Concept of MCI 
MCI is a transitional period between normal ageing and AD in which persons experience 
memory loss to a greater extent than one would expect for their age, yet they do not 
meet the currently accepted criteria for the clinically probable AD (Petersen et al., 2001). 
When observed longitudinally, individuals at this stage progress to the clinically probable 
AD at a considerably accelerated rate compared with healthy age-matched individuals 
(Busse et al., 2003).  
Preclinical stage 
which is often 
called the pre-
symptomatic 
stage 
Dementia 
Mild cognitive 
impairment stage, 
with minor symptoms. 
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MCI has been the more successful and longer lasting of the two concepts in AD, the other 
being SCD (section 2.2.2). The term MCI, introduced two decades ago by Reisberg et al. 
(1988), included subjects who were identified based on the global deterioration scale to 
be at the intermediate stage. The MCI criteria became apparent as a sizeable group of the 
subject in a longitudinal study of ageing, were ‘in between ‘and the concept was then 
introduced to better identify these subjects (Petersen et al., 2001). The presence of 
memory complaints met by objective deficits on tests of episodic memory in individuals 
without dementia was required for the criteria to be met, within a normal cognitive 
function and the ability to carry out the daily life activities. 
The original concept was revised in 2003 and the international criteria for MCI became a 
much broader term, referring to a clinical syndrome with multiple profiles due to a 
variety of causes or ‘aetiologies’ (Winblad et al., 2004; Petersen et al., 2004). The new 
definition, initially directed specifically towards the detection of AD, was now restricted 
to a subtype of MCI (Jessen et al., 2014) and termed the Petersen criteria. 
According to the Petersen criteria, an individual needed to have the following: 
(A) Complain about memory by individuals or informants 
(B) Impaired memory function and a test performance of more than 1 standard deviation 
(S.D) below age- and education-specific norms. 
(C) Preservation of the general cognitive functioning. 
(D) Intact ability to perform activities of daily living. 
(E) The absence of dementia as assessed by the DSM-IV criteria 
In the criteria, mild deficits in cognitive domains other than memory were allowed, but 
not the isolated deficits in nonmemory domains. The criteria are common with regards to 
the aim and theoretical framework, even though researchers have suggested and put to 
use a variety of criteria for defining cognitive impairment (Winblad et al., 2004). 
2.2.1.1   Modification of the Petersen criteria  
Evaluation of the current state of the condition was carried out and defined by the same 
criteria as the original concepts of MCI and age-associated cognitive decline (AACD), with 
the exception of criteria (A), memory impairment. MCI became a broader construct 
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meaning a clinical syndrome with multiple clinical profiles due to a variety of causes 
(Petersen et al., 2004) and restricted to a subtype of MCI (Petersen et al., 2014), a 
condition initially directed specifically at detecting AD. 
MCI is a concept encompassing much more than preclinical stages of AD, useful both 
clinically and as a research entity (Winblad et al., 2004). The heterogeneity in aetiology, 
manifestations, and outcomes has been discussed as a weakness of the condition; 
persons followed over time with MCI have progressed to AD and other types of dementia 
and others became stable or even recovered (Winblad et al., 2008; Petersen et al., 2014). 
The current definitions of MCI (Windblad et al., 2004; Petersen et al., 2004; American 
Psychiatric Association, 2013; Petersen et al., 2014) suggest that a change in cognitive 
ability is necessary to be classified as MCI, taking into consideration the executive 
functions, attention, language, memory and visuospatial skills, which can be overlapped 
with a diagnosis of dementia. MCI and dementia differ in the further requirement for MCI 
cases to have preserved independence in functional ability (Petersen et al., 2014). No 
gold standard as to the neuropsychological test battery to use, but it is necessary to 
examine all the main cognitive areas, by gathering information from the individual 
(subjective cognitive complaints) or the next of kin that needs to be confirmed by 
objective cognitive measures (Feldman et al., 2007; Petersen et al., 2014). Subsequently, 
SCD became a concept.  
2.2.2 Concepts of SCD 
Evidence suggests that subjective cognitive decline may represent the first symptomatic 
manifestation of AD. SCD is the self-reported decline in an individual, which may or may 
not be associated with AD (Mckhann et al., 2011). 
Stage three of the preclinical AD is defined by biomarkers evidence for AD and subtle 
cognitive decline that has not reached the level of objective impairment for the diagnosis 
of MCI (National Institute on Aging-Alzheimer’s Association (NIA-AA criteria) and difficult 
to detect on cognitive tests. The difficulty in detecting this subtle decline in cognitive 
tests does not isolate self-experience of this decline in individuals with pre-clinical AD 
(Jessen et al., 2014), which is a core-criteria in the definition of MCI and prodromal AD 
(Dubois et al., 2007; Albert et al., 2011; Sperling et al., 2011). Evidence suggests that SCD, 
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even at the stage of normal performance on cognitive tests at the pre-MCI and pre- 
prodromal stages, is linked with an increased likelihood of biomarker abnormalities 
consistent with AD pathology, increased risk of cognitive decline in the future and 
dementia due to AD (Fortea et al., 2011; Rami et al., 2011; Amariglio et al., 2012; Wang et 
al., 2013; Jessen et al., 2014; Rabin et al., 2015). The decline may reflect the first effects 
of AD pathology on cognitive functioning between full compensation and the very first 
decline. Intervention at this stage might preserve cognitive function at the very high level. 
The subjective cognitive decline is however not specific to AD. It is related to numerous 
conditions like normal ageing, personality traits, psychiatric conditions, neurological and 
medical disorders, substance use and medication, and even the cultural background of an 
individual (Jessen et al., 2014). SCD is termed subjective cognitive impairment, subjective 
memory decline, subjective memory impairment, and memory complaints, among other 
terminologies (Abdulrab & Heun, 2008). However, SCD could be a simple method to 
assess the likelihood of memory decline among apo E carriers (Samieri el al., 2014). In a 
Nursing Health Study (NHS) in the US, Samieri et al. (2014) reported that individuals with 
the Apoe ε4 genes with self-assessed cognitive concerns appear to have worse memory 
with possibly accelerated memory decline than their counterparts. 
The results of the current studies on SCD indicate variability and an inconclusive picture 
regarding the rate of decline, the risk of conversion to AD dementia and the role of 
biomarkers in predicting the course of the disease (Reid & Maclullick, 2006; Mol et al., 
2007; Steward et al., 2012). Knowing the patterns of the self-reported declines that are 
reliable, present an opportunity for identifying and diagnosing the disease early, which 
can be achieved by a retrospective review of the patients’ medical record. The second 
perspective is the diagnostic biomarkers which are laid open below. 
2.3. The diagnostic framework 
The criteria for the diagnosis of AD have been in existence for more than three decades 
now. In 1984, The National Institute of Neurological and Communicative Disorders and 
Stroke – AD and Related Disorders Association (NINCDS –ADRDA) proposed a diagnostic 
criterion with the following principles. Firstly, the clinical diagnosis of AD could only be 
made post-mortem, therefore, “probable” was the indicative diagnosis while the 
individual was living. Secondly, the diagnosis could only be initiated with the disease 
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progression to an advanced debilitative state with memory loss and cognitive impairment 
(Mckhann et al., 1984; Dubois et al., 2007). The 1984 criteria resulted in low specificity in 
differentiating AD from other dementias (Dubois et al., 2007). This was as a result of the 
absence of the diagnostic criteria for other dementias and their biomarkers, which in turn 
resulted in the International Working Group (IWG) in 2007, advancing the diagnostic 
criteria with the introduction of biomarkers. 
 A conceptual framework was developed, which recognised AD in vivo and independent 
of other dementias with the presence of two requisite features (Dubois et al., 2007). The 
first requisite was the evidence of a specific episodic memory profile that is typical of AD 
patients and differs from the memory impairment observed in other dementias, 
Huntington’s disease, normal ageing or depression. This memory profile is characterised 
by a low free recall that is not normalised by a reminder/ hint or cueing and was included 
as a specific symptom typical of AD. The second was the evidence of a biomarker through 
the structural MRI, molecular neuroimaging with PET (scan), and CSF analysis of amyloid 
or tau (total or phosphorylated). However, the 2007 diagnostic criteria focus only on 
typical AD with memory deficits. Surely, the biggest problem for early diagnosis is 
sampling, as the brain tissue cannot be sampled where the disease is causing damage, 
unlike other diseases. An ideal marker in this instance will be one in urine or blood. 
In 2010, a refinement of the 2007 diagnostic criteria was undertaken by the IWG, which 
drew a distinction between the clinical disease and the disease pathology. It broadens the 
preclinical states in which AD pathology exists without symptoms but with biomarkers of 
AD (Sperling et al., 2011; Jicha et al., 2012). The refinement also included the “atypical” 
(unspecific and irregular) and “mixed AD” (the usual and irregular). However, no changes 
were made to the 2007 diagnostic criteria, except for the atypical specification, that is, 
the non-amnestic focal cortical syndromes that include locopenic aphasia, frontal variant 
AD, and posterior cortical atrophy. In 2011, the NIA-AA published a criterion to cover the 
full staging of the disease, with the recognition of three stages (high, intermediate and 
unlikely) of AD, and set diagnostic criteria for each stage supporting the diagnosis of 
asymptomatic AD with biomarkers information. 
The IWG recently refined its criteria to include a diagnostic algorithm based on the weight 
of biomarkers, suggesting that Amyloid and Tau (total and phosphorylated) should be 
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used in combination and CSF (the AD signature) should not be used as a standalone test 
(Dubois et al., 2014). However, the criteria (Table 2.2) focus on the cognitive domain and 
insufficiently address other aspects of the presentation (Jones et al., 2015). Incorporating 
non-biomarkers (clinical manifestations of the signs and symptoms) is necessary to 
support the diagnosis. As indicated by a number of studies (Jack et al., 2009; Reiman et 
al., 2012; Villemagne et al., 2013), the recently proposed criteria do not establish 
diagnostic criteria that can be used easily by the primary care; rather these biomarkers 
remain limited to individuals, and they are expensive and invasive (Dubois et al., 2014).  
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TABLE 2. 2: DIAGNOSTIC CRITERIA 
AUTHORS 
& YEAR 
DIAGNOSTIC ALGORITHM STRENGTH LIMITATIONS 
NINCDS-
ADRDA, 
1984 
Clinical diagnosis (CD) probable 
CD Post-Mortem 
CD with the progression of the disease to an 
advanced debilitative stage 
 
The first diagnostic 
criteria for AD 
The diagnostic criteria 
could initiate the 
diagnosis of AD at the 
advanced stage of the 
disease pathology, with a 
specificity of 70%, and 
sensitivity of 81%. 
Survived for over twenty-
five years. 
Absence of 
diagnostic criteria 
for other dementias 
without biomarkers 
IWG, 2007 CD with the evidence of episodic memory 
not normalised with cueing 
CD with the presence of a biomarker 
Recognised AD in vivo, 
and independent of other 
dementias 
 Introduction of 
biomarkers (MRI, PET 
SCAN & CSF testing 
Focus only on the 
typical AD with 
memory deficits 
IWG, 2010 Refinement of the 2007 Algorithm to 
include “Atypical AD” that is non-amnestic 
focal syndrome including the locopenic 
aphasia. 
Inclusion of the Atypical 
Non-Amnestic AD 
Non-inclusion of 
the full stages of 
the disease 
NIA-AA, 
2011 
 The recognition of the three stages of AD 
with three subtypes including typical AD 
with the clinical phenotype of episodic 
memory impairment and behavioural 
changes, atypical AD with no specific 
phenotype but a variant of posterior cortical 
atrophy as indicated by visuospatial 
dysfunction, bi-parietal with locopenic 
aphasia and frontal with apathy or 
behavioural disinhibition 
 A set of diagnostic criteria for each stage of  
the disease 
 The of asymptomatic AD with biomarkers 
information 
The recognition of three  
stages of AD 
 Supporting the diagnosis 
of asymptomatic AD with 
biomarkers 
 Multitude of 
proposed 
biomarkers 
Cost of diagnosis. 
Diagnosis based on 
biomarkers at the 
expenses of other 
diagnostic 
specifications 
IWG, 2014 A refinement to the previous DC, suggesting 
that Aβ & Tau be used in combination, and 
CSF should not be used as standalone tests 
More advanced 
integration of the 
biomarkers, with the 
inclusion of memory loss 
for LOAD 
 Non- inclusion of 
the pattern of the 
signs and 
symptoms of AD 
preceding the 
diagnosis  
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2.4. Current issues in the late diagnosis of AD 
The health, economic and social care burden of AD weighs heavily on individuals, society, and 
healthcare providers due to population ageing and increase in the prevalence of the disease. There 
is uncertainty in estimating the global burden of AD and growing concerns regarding the cost of the 
disease (Dodel et al., 2015). One of the limitations is the inadequate data available from low and 
medium income countries (LMIC) and Eastern Europe while the cost model relied largely on 
extrapolation (estimation) of economic conditions from higher to lower countries (Wimo et al., 
2013). Additionally, studies are largely undertaken on all dementias, limiting the ability to quantify 
the burden of AD in isolation. 
2.4.1. Burden on individuals  
The burden of a late diagnosis of AD on individuals with the disease is associated with non-
reversible symptom’s progression, especially memory loss and loss of independence that leads to 
institutionalization and an increased mortality rate in individuals with the disease (Leifer, 2009; 
Hyman et al., 2011). The physical burden is even higher in individuals with comorbidities than those 
with only AD (Duthie et al., 2011) and may accelerate the progression towards a state of cognitive 
and functional impairment (Solomon et al., 2011). Having a chronic debilitating disease is daunting 
and adding another one could be devastating with severe consequences. Globally, it is estimated 
that 43% of world cases need a higher level of care equivalent to that of a nursing home 
(Brookmeyer et al., 2007); this estimate has yet to be updated (Dubois et al., 2016). 
2.4.2. Caregivers burden 
Caregiver’s burden could be defined as the degree to which a carer’s emotional or physical health, 
social life or financial status had suffered as a result of caring for their relatives (Zarit et al., 1986). 
This is measured by the caregiver’s burden inventory (CBI) (Novak & Guest, 1989), a 24-item self-
rated questionnaire on time-dependence, developmental, physical, social and emotional burden 
(Razani et al., 2014). Among the dementias, AD caregivers showed a higher burden level which 
appeared to be associated with gender (female caregivers may amplify caregiver burden 
significantly than their male counterparts) and length of time of care (D’Onofrio et al., 2015). 
Although costing informal care could be complicated and sometimes controversial (Van den berg et 
al., 2006), family caregivers provide 80% of the care needed by dementia individuals, which can be 
costly to caregiver’s health (Bekhett et al., 2013). In a recent study, behavioural problems and 
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psychological symptoms were the primary factors associated with caregivers burden (Chiao et al., 
2015), and there was a strong relationship between caregivers burden and patients’ functionalities 
(Zawadzki et al., 2011). Caregivers’ burden, therefore, could trigger symptoms similar to symptoms 
of AD and exacerbate the burden of health care on the health and social care sectors. 
2.4.3. The burden on health care professionals 
The behavioural and psychological burden of the disease not only affects families of older 
individuals and AD patients but also the healthcare professionals. This is because caring for the 
ageing population especially those with a disability is challenging due to the high demand and heavy 
load of gerontological caregiving (Chiao et al., 2015).  In a study of the burden of AD on health care 
professionals, nursing staff experienced high emotional stress more likely related to contact with 
the resident or a relative especially in the process of care and decision making in the last phase of 
life and/or physical burden related to poorer clinical status of the resident (Albers et al., 2014). The 
earlier the disease is detected, the more individuals make sense of the disease, make lifestyle 
changes that improve cognition and lessen the burden on caregivers, as well as planning for a 
different future (Dubois et al., 2016). 
2.4.4. Economic burden 
As at 2009, the global costs of the economic burden of dementia was US$422 billion, translating to 
about $3,945 per individual annually in the lower middle income (LMI) to $12,196 in the higher 
income countries (HIC)(Wimo et al., 2013). The World Bank income classification of the per-capita 
costs of dementia varied considerably, from US$868 in low-income countries (LIC) to US$3,109 in 
LMI to US$6,827 in upper-middle-income countries (UMIC) to US$32,865 in HIC.  In a systematic 
review of the economic burden of AD in France, Germany, Italy, The Netherlands, Spain, UK and the 
USA, the client medical costs ranged from US$5,476 in France to US$27, 380 in Spain (Takizawa et 
al., 2015).  In the UK, the health and social care costs varied significantly by agitation, from £29,000 
per year with no agitation symptoms to £57,000 at the most severe levels of agitation (NPI agitation 
score=12; p=0.01), equalling £2 billion a year across all in the UK (Morris et al., 2015).  
2.4.5. Late diagnosis of AD and rate of general mortality 
The effect of late diagnosis of AD on mortality is that AD adds 11% per year to the overall mortality 
rates, once the disease has progressed to the late stage of neurodegeneration (Brookmeyer et al., 
2007; Phelan et al., 2012). The survival rate for the late-onset AD ranges from 3.3-7.9 years for the 
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male gender and 4.3-9.1 years for females (Brookmeyer et al., 2007; Dodel et al., 2015). In 2015, AD 
and other dementias replaced ischaemic heart disease as the leading cause of death in England and 
Wales, with about 11.6% of the 529,655 registered deaths (National Statistics, 2016). This is in 
individuals eighty years of age and above. The implications of this report need to be carefully 
considered to give individuals the opportunity to be diagnosed early for timely intervention. HIV 
individuals have a high survival rate due to the fact that the disease can be detected early and 
intervention met early to avoid the condition developing to AIDS; this is desirable in AD, as early 
diagnosis could slow the conversion to AD dementia and promote longer, quality lifespan without 
much stress.  
2.5.   Benefits of early detection and diagnosis of the disease 
Even with the few studies that have explored the benefits and risks of an early diagnosis of AD in the 
UK, an advantage of a diagnosis at the early stage, is the opportunity to reduce the 
neurodegenerative processes through timely intervention with disease-modifying therapy (Dubois 
et al., 2015). Hence, there is a need to develop an acceptable early detection model that is cheap, 
non-invasive and applicable to the primary care setting. There is a relief and subsequent 
improvement in the quality of life once an individual is diagnosed, due to access to support services 
or pathways of care, and planning for the future. If AD is detected and diagnosed early and 
therapeutic strategies lead to just a small delay in the onset and progression of the disease by a 
modest one year, there would be nearly 9.2 million fewer cases of the disease in 2050 globally 
(Brookmeyer et al., 2007; Sperling et al., 2011). In the UK, in comparison with the scenario without 
early assessment or pharmacological treatment, early diagnosis reduces health care costs by £3,600 
and societal costs by £7,750 per patient yearly (Getsios, 2012). 
Some critics of the early diagnosis have opined that there are risks or challenges associated with the 
timely diagnosis of AD, including ethical issues, discrimination, stigmatisation, competence issues 
(Mattsson et al., 2010; Gauthier et al., 2013; Gaugler et al., 2013), misdiagnosis and increased 
economic burden. In the UK, substantial misdiagnosis of AD among patients with dementia has been 
recorded, which resulted in substantial excess cost (Happich et al., 2015).  However, research has 
indicated that the benefits of an early diagnosis outweigh the challenges (Schicktanz et al., 2014) 
and that an AD label is not in fact, associated with more stigmatizing reactions (Johnson et al., 
2015). Delaying the onset by an average of two years, will globally decrease the prevalence of the 
disease by 22.8 million and even without therapeutic effect, that is whether the treatment is 
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beneficial to the patient or not, but just detecting the disease early, will reduce the prevalence by 
5.2 million (Brookmeyer et al., 2007). In summary, the burden of late diagnosis of AD is quite 
substantial and the benefits of early detection outweigh the challenges, which call for early 
detection and subsequent intervention to slow the progress of the disease. 
2.6. General symptoms and signs of AD 
A symptom could be defined as a subjective experience that depends not only on physiological 
process but also on patient recognition and the interpretation of this process (Teel et al., 1997; Cook 
et al., 2011). In contrast, a sign is an objective indicator or characteristics of a condition or disease, 
detected by the physician in the process of examination. AD is a slowly progressing disorder with no 
fixed events before its onset (Albert et al., 2011; McKhan et al., 2011; Sperling et al., 2011). This 
makes it particularly challenging for clinicians to identify transition points of asymptomatic to 
symptomatic pre-dementia phase for individual’s patients (Albert et al., 2011). The disease begins 
with the preclinical phase in which the neuropathology of AD starts to accumulate, although the 
cognitive performance might be normal (Vos et al., 2013). The symptoms of the disease are, 
therefore, suggestive to result when the threshold of the neurodegeneration is reached (Ringman et 
al., 2015), and increases with the progression of the disease (Seidl et al., 2009; Ringman et al., 
2015). Auguste D., the original patient of Dr. Alois Alzheimer, showed several cardinal features of 
the disease that are still being observed in patients today. These symptoms include progressive 
memory impairment; cognitive function decline; behavioural alteration including paranoia, 
hallucinations and delusions; and progressive aphasia (Wilkier et al., 2013).  
Bateman et al. (2012) study showed an increase in brain atrophy, which was detected 15 years 
before the onset of symptoms; cerebral hypometabolism and impaired episodic memory were 
observed 10 years before expected symptom onset. The global cognitive impairment as measured 
by the Mini-Mental State Examination and the Clinical Dementia Rating scale was detected 5 years 
with patients meeting the diagnostic criteria for dementia at an average of 3 years after expected 
symptom onset (Bateman et al., 2012). The individuals’ alertness, motoric and sensory functions are 
well preserved at the early and middle stages of the disease slow progressive process (Selkoe et al., 
2001; McKhann et al., 2011). However, as cognitive decline continues, motoric functions decline 
(slow gait and coordination), which often resembles extrapyramidal motor disorders like 
Parkinsonism (Selkoe et al., 2001). 
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2.6.1. Early onset / late onset signs and symptoms  
EOAD and LOAD are the two descriptions of AD with the same neuropathological characteristic 
hallmarks.  However, EOAD may clinically present differently than LOAD, with higher biomarkers 
found in EOAD frontal and parietal lobes of the brain (Palasi et al., 2015). The neuropsychiatric 
symptoms might differ between EOAD and LOAD (Takizawa et al., 2015; Shoemark et al., 2015). The 
rate of progression of symptoms is difficult to predict for each individual, especially those with an 
infection or on medication, with a distinction between those patients with EOAD that begins from 
30-60 years of age and LOAD that typically starts at age 65 years and above (Imitiaz et al., 2014). 
 A cognitive assessment of 172 AD patients, with the mean age of EOAD being 60 plus or minus four 
years (54% female) and the mean age of the LOAD 72 plus or minus five years (52% female), 
indicated that the EOAD presents with a different cognitive profile and the disease course seemingly 
different (Smit et al., 2012). The majority of EOAD present with non-amnestic presentations 
(Mendez et al., 2012) and performed significantly worse in attentional, verbal learning and 
imitational praxis (theory plus action) tests than the LOAD (Palasi et al., 2015). In LOAD, worse and 
frequent napping has been mentioned and associated with amyloid deposition, but it is unknown 
whether this is present in the earliest stages of the disease (Ju et al., 2013; Peter et al., 2015).  
Diagnosis of EOAD is often a challenge because of the frequency of atypical presentations (Smits et 
al., 2012) and less hippocampal memory presentations (Klimkowilz et al., 2014), which includes 
behavioural disturbance, dementia, involuntary movements, pyramidal signs, epilepsy and family 
history of early onset. A recent study (Joubert et al., 2016) on EOAD/LOAD discovered that both 
groups were affected in most cognitive domains including episodic, semantic (worldview) and 
working memory, executive functions, language, praxis and Visio constructional abilities. However, 
the LOAD group was substantially more impaired than the EOAD group on the test of semantic 
knowledge. 
2.6.2. Early symptoms 
The early symptoms of AD are those of MCI, although the stage of the preclinical precedes the MCI 
and encompasses the spectrum of pre-symptomatic autosomal dominant mutations carriers (Leifer, 
2009). The early signs include apathy, memory loss, agitation, anxiety, irritability, dysphoria, 
hallucination, aberrant motor behaviour and disinhibition (Casselli et al., 2013). In a cross-sectional 
study with proxy informants, behavioural and psychological symptoms (BPS) in particular apathy, 
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depression, anxiety and agitation frequently occurred in the early stage of AD (Harwood et al., 2000; 
Geda et al., 2013; Li et al., 2014).  Results of these studies indicate that some non-cognitive 
symptoms could relate to the cognitive dysfunction in AD, without indicating the sequence and 
timing of these symptoms.  
Consequently, the Alzheimer’s Association came up with ten pre-clinical signs and symptoms of the 
disease include amnesia (memory loss), challenge in planning and solving problems, difficulty in 
completing tasks, confusion in time and space, trouble understanding visual images and spatial 
relationships, words and speaking difficulty, decrease or poor judgement, withdrawal, and change 
of mood and personality (Alzheimer’s Association, 2014). However, as there is heterogeneity in 
studies on the signs and symptoms, knowing their sequence and timing preceding the clinical 
diagnosis of AD might help with the early detection of the disease. 
2.6.2.1. Memory loss 
 In the early stages, the initial symptom of AD is memory lapses (Arshavsky et al., 2010; Bateman et 
al., 2012), especially the episodic memory (short-term memory of events at a particular place and 
time, or about “what”, “where “and “when” (Didic et al., 2011). Difficulty in recalling names of 
friends or recent events is also common in normal elderly individuals, but to a certain extent 
(Mayeux et al., 2010). This is due to the fact that the hippocampus and the medial temporal lobe of 
the brain are the sites of early pathology underlying the initial memory impairments (Britton et al., 
2011), and the disruption of one of the anatomo-functional system (the brain) at the earliest stages 
of the disease, relates to the clinical symptoms experienced by individuals with the disease. In an 
earlier structured interview of close family members of individuals with AD, memory loss was not 
the earliest objective sign of change (Oppenheim, 1994). However, this could be argued that the 
information derives from proxies who are subject to memory loss themselves.  
2.6.2.2. Episodic memory   
Impairment of the episodic memory, which has also been defined as records of personal events 
registered within the spatiotemporal cortex, has been identified in the early stage of MCI as 
evidenced from Visio-spatial or verbal material (Ivanoiu et al., 2005; Belleville et al., 2014), with 
associative memory impairment and decline of recollection (Hudon et al., 2009; Belleville et al., 
2011), and hippocampal dysfunction. MCI is no longer considered to be an intermediary between 
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normal ageing and AD (Cortex-Canteli et al., 2014). Therefore, the episodic memory might well not 
be the earliest symptom.  
2.6.2.3. Working memory 
The working/procedural memory is impaired in MCI, especially involving tasks such as online 
manipulation of information like sentence span (Gagnon et al., 2011; Belleville et al., 2014). The 
visio spatial working memory (VWM) for reading and navigational space is affected, which is one of 
the earliest symptoms of AD (Tales et al., 2011). In a cross-sectional longitudinal study with healthy 
control (Bianchini et al., 2014), topographic disorientation (TD), a form of navigational disorders, 
was common among individuals that developed AD. Besides the memory problems including the 
VWM other deficit may be present at the early stage of AD such as attention control and executive 
function deficits (Pereira et al., 2014). In a cross-sectional analysis of clusters in a cognitive profile 
testing, 15% of the patients (atypical) presented with non-memory impairment, but with 
behavioural symptoms including seizures (Peter et al., 2014). This indicates the differences in early 
presentations of the symptoms and signs. 
2.6.2.4. Seizures 
Unprovoked seizures have been recorded in 10% to 22% of patients with AD, with higher rates in 
the familiar and early onset of the disease (Imfeld et al., 2013). In LOAD, it is speculated to precede 
cognitive impairment (Picco et al., 2011) and could be an early mechanism. In a transgenic mouse 
model, unprovoked seizures were recorded at a higher rate among the familial and early-onset AD, 
suggesting a cognitive impairment (Palop et al., 2009; Vossel et al., 2013). The activity in human has 
been widely interpreted as a secondary process resulting from advanced stages of the 
neurodegeneration. However, recent findings of the disease suggest that this could be a primary 
upstream mechanism and could rightly be attributed to humans (Vossel et al., 2013). This is 
because, the sporadic incidence of AD has a higher rate of seizures independent of the disease 
stage, and higher in the early-onset AD, autosomal dominant early-onset, and those with the major 
known genetic risk factor APOE E4 (Palop et al., 2009; Imfeld et al., 2013). The amyloid β peptide 
may contribute to the cognitive decline by eliciting similar aberrant behaviour in humans.   
2.6.2.5 Anosognosia  
At risk of AD individuals have been discovered to underestimate the cognitive dysfunction. 
Anosognosia (the denial of illness), has also been identified as a characteristic symptom at the mild 
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stage of AD, but not MCI (Kalbe et al., 2005). It is correlated with age, the age of onset and duration 
of illness (Kashwa et al., 2005). The symptom is a potential and a significant predictor of apathy in 
AD (Starkstein et al., 2014). The definition of anosognosia across AD domain is not well defined 
(Leicht et al., 2010), as a recent study (Lindau et al., 2014) indicates that anosognosia is present in 
AD but not in the preclinical or MCI stages. The symptom seems to increase with the disease 
progression to dementia, due to the right hemispheric alterations. However, if the symptom is a 
significant predictor of apathy in AD (Starkstein et al., 2014), then, this could be an early 
phenomenon. 
The symptoms and signs currently used to define the preclinical stage of AD are not always present 
in persons who develop the disease (Palmer et al., 2008; Hudson et al., 2012). Other signs including 
acalculia (acquired impairment that leads to difficulty in simple mathematical calculations), alexia 
(reading disorder) and anomia (inability to remember nouns) which are part of the semantic 
memory, are common in the early stage of AD (Tang et al., 2004), especially when there is posterior 
cortical atrophy in the atypical presentation. Mood disorders, anxiety, and agitation have been 
mentioned in both MCI and AD (Porter et al., 2014). Apraxia (difficulty in words) was observed to be 
common in AD in a Chinese study (Shea et al., 2015). But whether this is present in the early stage, 
remain to be confirmed. In addition, a CSF marker-based study of the subgroups of the disease, the 
potential diagnostic predictive value of hallucination, hypokinesia, paranoia, rigidity, and tremors in 
aged individuals with AD have been reported (Igbal et al., 2013). Although, it is unclear if these 
symptoms occur early in the disease progression. 
In an earlier study of AD in America to assess the frequency and severity of 10 behaviours, 80% of 
the subjects had measurable behavioural changes; the ten behaviours significantly increased 
compared with the normal subjects, with the most common behaviour exhibited as apathy 72%, 
agitation 60%, anxiety 48%, irritability 42%, dysphoria and aberrant motor behaviour both 38%, 
disinhibition 30%, delusion 22% and hallucination 10% (Mega et al., 1996); agitation, dysphoria, 
apathy and aberrant motor behaviours correlate with cognitive impairments.  
2.6.2. 6. Apathy 
Apathy (impaired ability to express emotions) has been mentioned as an early sign of AD. In a cross-
sectional study of 435 patients, the most common symptom associated with the preclinical AD was 
apathy (75%) and delusion (19%) was the least of the symptoms (Craig et al., 2005). Depression and 
apathy were the earliest to appear; hallucinations (especially visual hallucinations with visual 
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cataracts) elation/euphoria, and aberrant motor behaviour were the latest symptoms to emerge in 
the study, while irritability was the most prevalent in the early stage of the disease (Craig et al., 
2005; Ringman et al., 2015). The symptoms were reported without the timing from diagnosis to the 
first symptom presentation that will justify a diagnosis of AD. Apathy seems to appear at the earliest 
stage of the disease (Han et al., 2014). Although, apathy is associated with the progression of the 
disease from the MCI to AD in a non-depressed individual with the disease (Richard et al., 2012), 
studies indicate that there is no difference between MCI and AD symptoms, except the decreased 
metabolism in the posterior cingulate cortex in MCI individuals (Delrieu et al., 2015). 
2.6.2.7. Depression 
Depression is also mentioned as early symptom and a prediction for the conversion of MCI to AD 
(Geerlings et al., 2000; Monastero et al., 2009; Starkstein et al., 2014; Gracia et al., 2015); it has 
mostly been reported in younger adults (Chamberlain et al., 2011), and independently associated 
with cognitive impaired community-dwelling elderly people (Chang et al., 2014). Although 
depression in MCI signifies the progression to AD (Zahodne et al., 2013; Van et al., 2014), MCI with 
depressive symptoms showed more severe behavioural symptoms and more verbal agitated 
behaviour than AD without depressive behaviour (Stefan et al., 2012), it can occur early in the 
disease progression and diminish over time due to the decline in cognition and subsequent loss of 
insight or awareness. However, while the disease progresses and the fundamental and cognitive 
symptoms gradually worsen, the depressive symptoms do not, and may increase with ageing 
regardless of the type of dementia (Masters et al., 2015). Overall, depressive symptoms are not 
widespread among individuals with AD, as it remains a controversy and the result inconclusive 
(Chemerinski et al., 2014; Geerlings et al., 2014). Reverse causality could be the case, as the history 
of depression with the first onset before the age of 60 years represents a risk of developing AD in 
later life (Geerlings et al., 2008). Further studies to understand the neurochemical and 
histopathological characteristics of the AD that contributes to depressive symptoms, and different 
from cognitively normal individuals with depression is needed. 
2.6.2.8. Olfactory deficit 
Odour deficit is also identified as an early phenomenon indicating its superiority as an early marker 
for the detection of AD. The odour deficit proposed an initial chemosensory impairment in AD at the 
central lobe rather than the periphery (Nordin et al., 1998). The olfactory capacity is reported as a 
potential biomarker for identifying individuals at risk for the age-related cognitive decline and AD 
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(Sohrabi et al., 2009). Olfactory disturbance and apathy in AD might result as the disease pathology 
progress to a more advanced stage (Selyman et al., 2013).  In a recent review, there was significant 
poor olfactory function associated with AD and a marker for conversion of MCI to AD (Mangliano et 
al., 2014; Velayudhan, 2015), and in a more recent memory study, identification of odour 
impairment was superior to deficits in verbal episodic memory in predicting cognitive decline in 
cognitively intact subjects (Devanand et al., 2015). Neurological soft signs (NSS) scores (covered by 
five factors: ‘motor coordination’, ‘integrative functions’, ‘complex motor tasks’, ‘right/left and 
spatial orientation’) and ‘hard signs’  are, therefore, significantly higher in the early stage of AD 
(Urbanowitsch et al., 2015), and provide evidence that an impairment exists and a rationale for a 
more formal detection and evaluation for confirmation of the disease. 
2.6.2.9. Weight loss 
Weight loss or low body mass index (BMI) has also been observed in patients with AD, the 
observation was made before and during AD dementia onset (Gustafson et al., 2012). The low BMI 
emphasises or predicts rapid cognitive decline (RCD) (Soto et al., 2012). Recent research by Besser 
et al (2014) indicates that weight changes are associated with clinical progression in amnestic MCI 
(AMCI) and the early stage of the disease, however, AMCI associated with high BMI indicates slower 
progression, and AMCI with low or no weight changes also indicate a faster progression. AD is the 
related outcome of impaired nutrition and weight loss; the low BMI and weight loss could be the 
beginning of the pathological processes of the disease (Robertson et al., 2013; Panda et al., 2014). 
The signs and symptoms discussed and other factors could be present at the GP clinical records and 
could help initiate patterns based on the timing and sequence of appearance of these presentations 
in different subgroups of AD. This is because GP surgeries are the primary points of contact with 
patients and even without symptoms, individuals with AD sometimes seek the help of their GPs, due 
to their inclination that something is wrong and will want a clarification from their respective health 
care providers. 
2.7. Summary 
Findings indicate that there are inconsistencies with the biomarkers of the disease especially as they 
are present in normal ageing individuals; genetic mutations of tau protein do not lead to AD but to 
frontotemporal dementia, which is characteried by severe behavioural and personality and 
language changes. This indicates that tau might not be required for AD diagnosis and remained 
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uninformative, hence the need for clinical criteria for early detection. Accumulation of amyloid may 
not be a strong predictor of AD; this is because some of the individuals diagnosed with AD had a low 
accumulation of amyloid protein in the brain while others with the high level of the protein showed 
no signs of cognitive impairment. The current concepts in AD including the MCI and SCD, which are 
directed at finding the intermediate stage of the disease, to help identify the clinical phenotypes of 
these stages, have loopholes. MCI might not be the transitional stage between normal ageing and 
AD, as changes in cognitive ability, executive functions, attention, and language deficits are 
necessary to define MCI and the current knowledge in SCD are insufficient due to difficulties in 
detecting a subtle cognitive decline in a standardised cognitive testing.  
Past literature has shown that the current diagnostic criteria are expensive, invasive and 
heterogeneous in their reporting while extrapolating or extending the diagnostic criteria into 
general practice has its challenges such as having a wider meaning at different settings (Petersen et 
al., 2014). Furthermore, there are differences in presentations between EOAD and LOAD. This could 
be attributed to genes and the initial impact of neurodegeneration and NFT in the neocortex, as 
opposed to onset in the Transentorhinal cortex in typical amnestic AD. Aside from the biomarkers 
and mini-mental state examinations, there is heterogeneity in reporting the signs and symptoms.  
The two clinical phenotypes (episodic memory loss for typical AD and locopenic aphasia for atypical 
AD) incorporated in the diagnostic criteria, might not be the earliest symptoms in some individuals, 
hence, a more definite clinical marker is needed. Also, while some studies (Ivanoiu et al., 2005; 
Bianchini et al., 2014) state that episodic memory is the earliest sign to appear in AD, others (Craig 
et al., 2005; Han et al., 2014) affirmed that apathy is the first sign. The result of these studies could 
be due to the study design, the number of participants or the age of onset of the disease.   
Some studies (Kalbe et al., 2005; Starkstein et al., 2014) have shown that anosognosia precedes the 
diagnosis of apathy and could be the earliest symptoms, while Sohrabi et al. (2009), Mangliano et al. 
(2014) and Devanand et al. (2015), declared that odour deficit is superior to the verbal episodic 
memory deficit as the earliest symptom. The differences in the outcome of these studies, could be 
attributed to the sample size that ranged from forty-two to a cohort of 1417 people, individual 
difference and differences in studies designs; while some studies were longitudinal (Palmer et al., 
2008; Yoon et al., 2014), other designed were clinical evaluations with few subjects without the 
testing of subtypes (Linn et al., 1995; Elias et al., 2000; Michel et al., 2010; Peter et al., 2014). 
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In conclusion, most of the studies were comparative studies of the stage of AD (Toyota et al., 2007; 
Gronning et al., 2012; Yoon et al., 2014). Some of the studies looked at individual symptoms with 
measurement after the establishment of the disease (Craig et al., 2005; Sohrabi et al., 2009; 
Selyman et al., 2013; Vos et al., 2013) and others, compared AD and other dementias (Ballard et al., 
2000; Chiu et al., 2006; Fernandez et al., 2008; Thompson et al., 2010), rather than patterns in 
sequence and timing of these presentations preceding the clinical diagnosis of AD of which this 
study desired to identify. Although, the studies reviewed focus on one symptom or another; AD or 
dementia; EOAD or LOAD; however, none was undertaken to identify patterns of the signs and 
symptoms of the disease. There is little detailed statistical information on the patterns in signs and 
symptoms preceding the clinical diagnosis of the disease in the UK, with only a study with the title 
“pattern of cognitive decline” (Chen et al., 2001), undertaken prospectively after the diagnosis of 
AD. Determining patterns in timing and sequence of the earliest evidence signalling the onset of the 
disease is pertinent, as studies indicate that the preclinical phase of detectable lowering of cognitive 
function precedes the appearance of preclinical AD by many years (Linn et al., 1995; Elias et al., 
2000; Makowska et al., 2014).  
The literature review took an in-depth view of studies and theoretical perspectives on the 
pathophysiology and the signs and symptoms of AD. This is the foundation in identifying the early 
presentations of AD, which was further explored in a systematic scoping review, RMRRS and 
qualitative interview of GPs. The presence of biomarkers in normal ageing and their presence in AD 
do not prevent the discrimination of self-experience of individuals with the disease. Knowing the 
timing and sequence of these complaints before diagnosis will aid in suggesting a predictive model 
for early detection, therefore, this calls for further studies in this regard. 
Prior to this, the mixed method approach is reported in the next chapter, while the protocols for 
each method used in the approach to identify patterns are described in detail as well as the 
philosophical stance for the research. This is to intimate the reader with the methodology that is 
applied to the realisation of the objectives of the study. 
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CHAPTER THREE: Methodology 
3.1. Introduction 
This chapter introduces the research method that adopts a mixed method approach, which fits into 
a three-arm study including a systematic scoping review, a qualitative interview of GPs and a 
RMRRS. These will individually be discussed. 
3.2. The concept of epidemiology and epidemiological designs 
Effort to curb the spread of disease and infection is not new to  human society; epidemiology (a 
Greek word meaning ‘study upon population’ – Bhopal, 2008) is the science and study of the 
distribution and determinants of health-related states or events and disease, and the application of 
this study to the control of diseases and other health problems (World Health Organisation). The 
science of epidemiology involves the investigation of the causes and understanding the means to 
prevent and control problems or diseases (Bhopal, 2008). An individual is a unique entity with its 
history. Furthermore, there are unique and distinctive patterns of diseases that population groups 
have due to the variations in the exposure of individuals to the causes of diseases (Krieger, 2011). 
Some variations could, however, be due to genetic differences and the variations between 
individuals within the environment. Characteristics of individuals discriminate the patterns of 
disease in a population, with the environment (seasons, weather, and water) playing an important 
role in the development of problems or diseases (Bhopal, 2008). The description, understanding, 
and utilisation of these patterns to improve health are the presumptively inter-related ideas 
(Krieger, 2011), which my research seeks to achieve. 
Epidemiological designs and interpretation of the results depend on the subject of the research and 
desired inference. The researcher had considered epidemiological designs without a rigid view of 
science that is inconsistent with current practice and philosophy (Rothman, 1986); for example, a 
cohort study, otherwise known as a longitudinal and prospective study was considered. The design 
has the advantage of establishing the exposure of a condition or disease and allows for the accurate 
collection of information of exposure or the nature of a condition (Bowling, 2009). However, a very 
large sample is needed, takes time and requires an extended period of contact with the subjects of 
research (Shekaran & Bougie, 2010), all of which are limited to the researcher. Furthermore, a cross-
sectional design was considered, but because the design collects data at one point in time, which is 
contrary to what the study desires to achieve, a case-control was adopted, which is faster, cheaper, 
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more practical (Vandenbroucke & Pearce, 2012), and increasingly used in AD research (McKhann et 
al., 1984; Imfeld et al., 2012; Whitwell et al., 2012; Slattery et al., 2014; Beber et al., 2015). Case-
control studies identify individuals with (cases) and without (control) a particular disease or 
condition retrospectively to compare the prevalence or level of exposure to a risk factor (Lilienfeld 
& Stolley, 1994). In this study, the comparison is in the patterns of the signs and symptoms 
preceding the clinical diagnosis of AD. 
The case-control design has been selected over other observational designs including cohort and 
cross-sectional because the design is the best to answer the question of my study. The design offers 
the opportunity to identify patient’s records with the disease and the disease processes (signs and 
symptoms) which are compared retrospectively with referents records without the disease in GP 
practices in Milton Keynes and Luton. It allows the flexibility to compare the pattern of signs and 
symptoms with or without the disease and variables can be considered simultaneously (multiple 
exposures). The design allows the measurement and adjustment of confounding factors 
(comorbidities), which was taken more efficiently by group matching the cases and controls to 
present the true differences between the groups.   
Another reason for the choice of a case-control study is the fact that it is more cost efficient than a 
cohort and cross-sectional and will determine the relative importance of these presentations in 
drawing patterns of AD. Furthermore, the design is a more feasible option to study a disease such as 
AD with a long-latency period (Mann, 2003). The retrospective medical records review study 
(RMRRS) design is relatively cheap and uses a pre-recorded and patient focus data as the primary 
source of information (Wu & Aston, 1997) as the data needed for the study has been collected over 
time. RMRRS is a good design for generating patterns and behaviour. Although, the design could be 
labour intensive (Pope et al., 2000) and limit in scope; for example, the data might have been 
collected for a different purpose, and might not have captured the desired variables (Matt & 
Mathew, 2013), the design has pre-established degree of validity and reliability if the data is 
collected systematically (Jick et al., 1992; Sari et al., 2007; Boslaugh et al., 2007). Additionally, the 
data needed for this study is primarily collected in the GP surgeries and the desired conclusion is 
about the course of the disease. 
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3.3. Philosophical framework 
The philosophical framework considered in this research is less rigid, based on blended rules of 
deductive and inductive reasoning (Bowling, 2009).  Deductive reasoning is where the conclusion is 
logical, beginning from general to specific, reached from the premises that knowledge is based on 
what is already known and applicable to objectives one and two (RMRRS), and inductive reasoning 
in which a generalisation is argued on the basic statement that derived directly from sensory 
experience, from the specific to general statements, applicable to objectives one, two and three 
(qualitative interview) (Crotty, 1998; Karl, 2004). 
3.3.1. Pragmatic worldview 
The researcher also extends the views of the current rational philosophical framework and looks at 
the world through the eyes of a pragmatist, as this view does not ignore the relevance of 
epistemology and other concepts from the philosophy of knowledge (Morgan, 2008). The value of 
maintaining attention to epistemology issues in research methodology can easily be preserved with 
a pragmatic approach. Morgan (2008) further opined that the pragmatic approach concentrates on 
methodology as an area that connects issues at the abstract level of epistemology and mechanical 
level of actual methods. It builds on prior accomplishments in order to draw liberally from both the 
qualitative and quantitative assumptions of this research, which arise out of the consequence and 
application of what works best in this research. No wonder, many researchers (Harasty et al., 1999; 
Canon-Flinterman et al., 2005; Gao et al., 2006; Janzen et al., 2006) in the field of AD have assumed 
this worldview to draw from the qualitative and quantitative realities with success. 
Pragmatic philosophy as a worldview arises out of actions, situations and consequences rather than 
antecedence conditions of postpositivism (Creswell, 2013); researchers emphasises the problem of 
research and apply all approaches available to understand the problem rather than focusing on the 
methods (Figure 3.1), hence, the choice of pragmatism. The theory uses a pluralistic approach to 
obtain solutions to problems and provides a philosophical basis for research (Creswell, 2013). The 
quantitative and qualitative approaches are applied to solve the problem at hand; my research 
assumes the same approach by combining the qualitative interview and quantitative RMRRS to 
identify patterns and develop a predictive model. 
Additionally, researchers have freedom of choice of methods, procedures and techniques that are 
suitable for their research. The qualitative and quantitative data together, provide an excellent 
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understanding of a research problem. Pragmatism believes in the external world dependent and 
independent of the mind, and thus, opens the door to multiple methods (Creswell, 2013). Hence, 
the mixed methods approach to undertake this study. 
 
 
 
FIGURE 3.1 Pragmatic worldview. The figure points out the empirical emphasis on actual experience over  
a priori (non-experience) and fixed principles and combining different methods to solve problems. 
 
3.4. The research approach 
The research follows a mixed method approach, an approach that involves the use of more than one 
research method (scoping review, RMRRS and qualitative interview), theoretical perspectives 
(Denzin, 1978) or data collection (Denzin, 1997; Creswell, 2013), and helps to improve confidence in 
the result and outcome of the study, to overcome research bias (Murray et al., 1999). Multiple 
viewpoints allow for greater accuracy of research findings and can be used as complete information 
to inform theory and practice, through the unity of thoughts, logic and goal (Creswell, 2013). Still 
within the mixed method approach, a methodological triangulation, the between-method 
triangulation has been chosen, which employs techniques agreeing with both the qualitative and 
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the quantitative research traditions in the same study (Denzin, 1970; Thurmond, 2001; Bekhet, 
2012; Hussein, 2015). 
The concept of triangulation dates back to the work of Campbell and Fiske (1959), and the term 
derived from Navigation and military strategy in which multiple reference points are used to locate 
objects exact positions (Jack, 1979), and has been extended to the field of research. This approach 
has been chosen based on evidence from previous knowledge from the literature review and past 
researchers in the field of AD (Paton et al., 2004; Duggleby et al., 2011; Beard et al., 2013; Stone et 
al., 2013; Randhawa et al., 2015), who have adopted the same approach, that have produced good 
results. 
Similar to other designs, these researchers experienced some limitations including application of the 
design that can be problematic especially with the unit of analysis, lack of weighted clarity as to 
which method weigh more, theoretical paradigms that can amplify sources of error and bias (Begley 
et al., 1996; Greene & Caracelli, 2003; Sandelowski, 2010), and replication problems from mixed 
methodology (Jick, 1979). However, these limitations were overcome with the knowledge of the 
variables of study, a complementary test for convergence dissonance of ideas, decision rules to 
guide the analysis of data. Secondly, the analysis assumed the procedural approach, in which 
documents are compared, in each comparative step to ensure transparency and replicability (Meijer 
et al., 2002).  
Another challenge to this design is that I needed specialist training in both the quantitative and the 
qualitative arm of this research, which was time-consuming and expensive but enabled 
demonstration of how the three studies fit together to form a paradigm. I was well aware of this 
and acquired training in both the quantitative and qualitative methods of inquiry. Other challenges 
could have been information bias, the moderate reliability of data and hindsight bias (“knowing it 
all–along”), as new technologies for visualizing and understanding data, could heighten these 
challenges (Barnes et al., 2009). However, piloting and screening improved the quality of data used. 
Convergence coding matrix was applied to summarise the similarities and differences between the 
two sets of data. Comparison of findings with respect to meanings and interpretations of themes, 
the frequency, and prominence of themes, and specific examples was given while the convergence 
coding identified themes from each data. The dissonance of findings and similarities was assessed to 
review all compared segments and document different perspectives. Identification of key 
65 
 
differences in scope was assessed by comparing methods in order to enhance the completeness of 
findings (Farmer et al., 2006; Lewis, 2015). 
The strength of this design lies in the variations in themes provided, enabling each data set to 
provide part of a story for the research, by contributing to achieving a complete picture of the 
research study. The quantitative part of the design aimed at understanding the best predictors of an 
outcome and to test a theory deductively to generalize and replicate findings; while the qualitative 
interview looked at the subject of the research inductively. The combination of the deductive and 
the inductive reasoning is a scientific rationale; a reasoning that distinguishes the natural sciences of 
chemistry, metrology, and geography from mathematical subjects of set theories (Crotty, 2005). The 
quantitative approach enabled the researcher to study a large sample that is validated statistically 
and accurately reflects the population where the research was carried out (Vanderstoep et al., 
2010; Punch et al., 2013). 
3.5. Research design 
The design of this research is methodological triangulation (Figure 3.2); consistent with the chosen 
approach of a mixed method. The design includes a systematic scoping review, retrospective 
medical record review study (RMRRS) and a complementary qualitative interview that falls within a 
three-arm study and each component extensively discussed in the following sections (section 3.5.1, 
3.5.2 and 3.5.3).  
 
 
66 
 
 
Figure 3.2:  Mixed methods methodological triangulatory design. The aim of the study has been met by the 
combination of the scoping review, qualitative interview and the RMRRS. 
 
3.5.1. Systematic scoping review of empirical studies 
The first arm of the research design is the systematic scoping review. This section collects data 
systematically and synthesizes evidence on sequence and timing of the signs and symptoms, that is, 
the first symptoms reporting that justified a clinical diagnosis of AD, to draw patterns. 
Scoping reviews are described as a process of mapping the existing literature in the field of interest, 
in terms of the volume, nature, and characteristics of the primary research (Arksey & O’Malley, 
2005). They are particularly useful when the subject of the research has not extensively been 
reviewed or a complex or heterogeneous in nature (Mays et al., 2005). They are used to identified 
research gaps, summarise findings and identify the potential scope of systematic reviews (Davis et 
al., 2009). In this research, the scoping is useful as the topic of research has not been extensively 
reviewed and heterogeneous in nature. Just like a systematic review, scoping review can be used as 
a standalone project (Arksey & O’Malley, 2005); they both share the same processes of using 
rigorous and transparent methods to comprehensively identify and analyse relevant literature of 
the research topic (DiCenso et al., 2010; Hardwick et al., 2015). Their difference lies in the purposes 
and aims of the review, and while scoping maps out the body of literature from potentially large and 
diverse literature, systematic review sums up the best available studies of the specific question, 
Identifying patterns of 
AD signs and symptoms  
Qualitative study 
Scoping review 
Qualitative interview 
Quantitative study 
Quantitative 
retrospective medical 
record review study 
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from research on the topic (Arskey & O’Malley, 2005; Daudt et al., 2014). Although, scoping reviews 
are a relatively new approach for which there is not yet a universal study definition or procedure 
(Arskey & O’Malley, 2005; Levac et al., 2010; Daudt et al., 2013), they have become increasingly 
adopted approach and have been published across a wide range of discipline (Davis et al., 2008). 
This review was undertaken using the protocol for a systematic review but within a large and 
diverse literature. This was to map and appraise the existing literature by systematically searching 
so as not to miss any relevant literature and to bring meaning to the result (Armstrong et al., 2011; 
Pham et al., 2014). A detailed systematic scoping review protocol is provided (Appendix XII), with a 
clarification on the types of AD and theatres or field used to identify studies.   
3.5.1.1 Aim 
To map, appraise and synthesise the quality of existing evidence on the signs and symptoms 
preceding the clinical diagnosis of AD. 
3.5.1.2 Objectives 
1. To identify the sequence and timing of the presentation of signs and symptoms at the early stage 
of AD, to inform a primary study.  
2. To understand how far back from diagnosis the first symptoms that will justify a diagnosis was 
reported. 
3.5.1.3 Methods 
Criteria for considering evidence for this review includes: 
3.5.1.4 Inclusion criteria 
3.5.1.4a Types of studies 
Qualitative and quantitative empirical evidence undertaken in developed countries and relating to 
the early signs and symptoms in the early detection and diagnosis of AD were synthesised 
systematically.  
3.5.1.4b Participants 
Individuals aged 30-85 years of age, diagnosed with AD, were reviewed. The age restriction was 
because the pathophysiology takes between 10-30 years. The incidence of the disease among those 
30-40 years is rising (12.7% in 2009) (Harvey et al., 2003; Alzheimer’s Association Europe, 2009) 
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hence the inclusion of these group. The early-onset begins at age 65 and below while the late onset 
begins at age 65 and above. Studies of individuals with the mixed diagnosis were considered as long 
as the outcomes were reported separately.  
3.5.1.4c Index symptoms 
The majority of individuals with AD present with multiple signs and symptoms that begin years 
before the diagnosis of the disease. Studies have been carried out on the early signs and symptoms 
but few undertaken on the sequence and timing of these presentations. The index symptoms were 
utilised as patterns to suggest the development of a predictive model for early detection of AD in 
the primary care centres to complement the biomarkers examinations. 
The review included combinations of signs and symptoms alone, while studies restricted on single 
sign and symptom were excluded. 
3.5.1.4d Target condition 
All types and stages of AD were included in the review. 
3.5.1.5 Outcomes  
1. The sequence and timing of presentation. 
2. The timing between diagnosis and first symptom reporting that justify a diagnosis. 
3.5.1.6 Language of publication 
No language restriction was applied to the search so as not to miss relevant articles. Moreover, the 
University provides an environment where individuals from different countries with diverse 
languages, are available to translate if an article is not published in the English language. 
3.5.1.7 Exclusion criteria 
Studies focusing on developing countries, other neurological conditions, and non-empirical studies 
were excluded. Also, studies on other dementias and late stages of AD where it was not possible to 
separate data on early stage of AD were also excluded. 
3.5.1.8 Search strategy 
This implies the specific terms used in searching the database and the global approach to searching 
including the specific database to search.  
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3.5.1.9 Research evidence 
RefWorks was used as the referencing software. 
The databases used included but not limited to: 
• Specialist literature databases: Ovid MEDLINE (1946), PUBMED (1996), CINAHL (1937) 
(Ebsco), Psych INFO (1967), Web of Science, Scopus, Nursing Index (1994) and Health Technology 
Assessment Database (HTA). We searched each database from early inception in other to capture all 
evidence on the early signs and symptoms of AD. Hand searching of the reference list of systematic 
reviews, conference proceedings from Alzheimer’s Association and Dissertations Express were also 
undertaken. 
• Specialist systematic review databases:  Cochrane register of diagnostic test accuracy studies. 
Other literature sources included Google and Google Scholar. This approach uncovered literature to 
use in the review. There was a different search term for each database as their parameters were 
different (Jefferson et al., 2011). 
3.5.1.10 Publication status 
Published articles from a bibliographic database, specialists journals and reference lists from articles 
were considered. Unpublished (grey or fugitive literature) or informally reported studies as full 
papers, including theses, reports, book chapters and conference abstracts, were included as long as 
the full study details were available (Song et al., 2000). The studies were carried out in primary care 
centres, memory clinics, hospitals and community populations to capture and established a 
diagnosis of AD. 
3.5.1.11 Country of focus 
Countries classified as developed countries due to a high human development index (HDI) by the 
World Bank, were included. This was to ensure that the population from the review studies were 
the same as the study population in terms of economic status, standard of living, infrastructures 
availability, provision of amenities and locality. 
3.5.1.12 Keyword included 
In this research, I included both EOAD and LOAD. Early detection or diagnosis is different from the 
early-onset AD. The definition is based on the timing of the disease process when the 
neurodegenerative process has not or slightly began. The early term is used rather than the late-
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term that allowed me to find studies undertaken at the early stage of AD and report signs and 
symptoms before the full manifestation of the disease or dementia (the final stage of AD). These 
studies should have been undertaken retrospectively or prospectively, within a period of 10 years 
before diagnosis, as the neurodegenerative process takes between 10-30 years before the 
manifestation of these presentations(Bateman et al., 2012), while the early stage is approximated to 
be six years before diagnosis. Also, the disease theatre was the main theatre, followed by the timing 
theatre, then the basic theatre including country, onset and combination theatres, before duplicate 
was removed. This procedure was followed to systematically capture the desired data required for 
this review. 
Search one: 
Alzheimer’s disease AND Early detection OR early assessment OR early diagnosis OR early signs OR 
early symptoms OR early intervention OR dementia OR cognitive imbalance OR MCI  OR subjective 
cognitive decline OR biomarkers OR biological markers OR brain pathology OR neuropsychological 
tests OR neuropsychological index OR tomography OR CSF analysis OR MMSE OR screening OR 
magnetic resonance imaging OR MRI. 
Search two: 
Alzheimer’s disease  AND  (Early detection OR early assessment OR early diagnosis OR early signs OR 
early symptoms OR early intervention OR dementia OR cognitive imbalance OR  OR subjective 
cognitive decline OR behavioural symptoms OR psychiatric symptoms OR clinical presentations OR 
clinical features OR preclinical manifestations OR clinical presentations OR early manifestations OR 
early presentations OR early detection OR biomarkers OR biological markers OR brain pathology OR 
neuropsychological tests OR neuropsychological index OR tomography OR CSF analysis OR mini-
mental state examination OR screening OR magnetic resonance imaging OR MRI) AND (Andorra OR 
Argentina OR Australia OR Austria OR Bahrain OR Belgium OR Bermuda OR  Brunei OR Canada OR 
Chile OR Croatia OR Cyprus OR Czech Republic OR Denmark OR Estonia OR Faroe Islands OR Finland 
OR France OR Germany OR Greece OR Holy See (Vatican)OR Hong Kong OR Iceland OR Ireland OR 
Israel OR Italy OR Japan OR Korea South OR Kuwait  OR Latvia OR Liechtenstein OR Lithuania OR 
Luxembourg OR Malta OR Monaco OR Montenegro OR Netherlands OR New Zealand OR Norway OR 
Poland OR Portugal OR  Qatar OR SanMarino OR Saudi Arabia OR Singapore OR Slovakia OR Slovenia 
OR South Africa OR Spain OR Sweden OR Switzerland OR Turkey OR United Arab Emirates OR United 
Kingdom OR United States). 
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3.5.1.13 Data collection and analysis 
3.5.1.13a Quality assessment 
The criteria to assess the data quality included the Quality Assessment Diagnostic Accuracy Studies 
(QUADAS-2), which contains the assessment domain with signaling questions to select patients, 
index symptoms and timing (Whiting, 2011). The risk of bias was assessed with the QUADAS 
standard risk of bias template that rates studies based on good quality paper, poor quality paper or 
uncertain for bias (selection). The results were summarised in Table 4.1, Figures 4.3 & 4.4. 
 3.5.1.13b Missing data 
I understand that missing data could be pervasive. Statistical analysis based only on complete case 
subsamples could introduce biased estimates and standard error, while the impact of the missing 
value will reduce the sample size and concomitant loss of statistical power based on comparative 
datasets. However, there are conditions under which missing data can be ignored (Eff & Don, 2009; 
Stekhoven et al., 2012), which depend entirely on the relationship between the variable of interest 
missing and the available variable to help explain the missing value. 
Authors of empirical studies (Devier et al., 2010; Fox et al., 1998) with missing data were contacted 
for the full study reports while being clear as to the nature of data required (mean, median or 
standard deviation value). One author (Fox et al., 1998) was re-contacted again when there was no 
answer the first time and all correspondents were logged in (Appendix XIII).  I made sure that there 
were no publications missed from the search that contains the data missing; perhaps a study had 
been published after the search was completed, without limiting the language of publication, to 
avoid language bias. If the full data could not be retrieved after all these, the papers were excluded. 
This was stated as part of the challenges faced while undertaken the study.  
3.5.1.13c Study selection 
The screening process included title screening and abstract screening of primary studies on AD. This 
was based on the inclusion criteria to identify relevant articles and reduce waste of time and 
resources in reviewing articles that do not meet the necessary inclusion criteria. Title and abstract 
screening form was developed (Appendix XIII) and was pretested before the scoping review. The 
second level of review included the review of the full articles deemed relevant. Articles that were 
only available in an abstracts format and meet the inclusion criteria were included at the second 
level of review while acknowledging their inclusion limitations, to avoid missing out on recently 
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reported studies available only in abstract format (Boland, 2014). All other articles that did not meet 
the eligibility criteria were excluded. 
3.5.1.13d Extraction of data 
The data extraction forms and tables have been devised and were supposed to be piloted from the 
first five to ten studies, to know if the data extraction approach is consistent with purpose and 
questions. However, due to the dearth in data, the researcher piloted it in two studies under the 
guidance and approval of my supervisors and proceeded to use it as it was consistent with the aim 
of the study.  
3.5.1.14 Data synthesis 
Although data synthesis (collating, summarising and reporting) is minimal in a scoping review, 
quality assessment of the studies included was undertaken, to apply meaning to the results 
(Armstrong et al., 2011) and consider the implications of the findings within the broader research, 
policy and practice. This is because I intend to publish the result for use by a wider audience and 
reduction of duplication of effort that will guide in future research.  
There was no quantitative data plotted in (i) forest plots and (ii) ROC plots.  Hence, a synthesis using 
the weighted meta-analysis estimates where there is compatible design and heterogeneity was not 
considered reasonably (data quality as evidenced by CASP tools used across different designs 
including CASP cohort study checklist). Heterogeneity among the study results was examined using 
the sub-group analysis (Pham et al., 2014) in a descriptive analysis. The narrative synthesis was 
carried out with a summary of each study under the themes provided.  Reporting the results of the 
study assumed a two dimension 1) descriptively on study characteristics and 2) analytical on 
outcomes of the study (Boland, 2014). 
3.5.1.15 Assessment of reporting bias 
Formal assessment was reported based on symptoms interpretation with or without biomarkers 
examinations and PET scans. 
3.5.2. Retrospective medical record review study (RMRRS) 
The RMRRS used pre-recorded patient focus data as the primary source of information to answer 
the research question. The study design has guided research (Wu & Ashton, 1997) and is common in 
epidemiological investigations (Jansen et al., 2005). The source of information included physician 
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recorded notes prior to the diagnosis, by considering the types of the signs and symptoms preceding 
the diagnosis of the disease (Webb & Bain, 2010), to ascertain patterns. A clear definition of these 
variables and understanding of the health records is an essential prerequisite to developing the 
standard chart review abstraction instrument (Gearing et al., 2006).  
Additionally, RMRRS is a suitable design for the chosen topic of this research and an important 
design with a distinct advantage and valuable research opportunity (Gearing et al., 2006; Matt et al., 
2013). The study attempted to answer the research question that cannot be answered 
prospectively; as prospective studies are impractical to address studies on the pattern of disease or 
behaviour (Worster & Haines, 2004). The design has been reported to comprise 25% of all scientific 
articles in emergency medical journals (Woster & Haines, 2004). Moreover, notable researchers 
related to AD (Calder et al., 2002 -UK; Zeppegno et al., 2009 -Italy; Zonneveld et al., 2014 -
Amsterdam; Pankratz et al., 2015 -USA), have assumed the same methodology. The data was 
collected within a fixed period of four months. Although, the preparation and analysis of GP case 
notes are labour intensive (Pope et al., 2000), structured case notes are reliable and could detect 
adverse events that the research desired (Jick et al., 1992; Sari et al., 2007). 
3.5.2.1 Method: case-control study 
The methodological steps of conducting a RMRRS begin from the conception of the idea to the data 
abstraction, analysis and interpretation of result (Figure 3.3). 
A retrospective case-control study has been chosen. This is a population based study with cases 
matched with controls by age, gender and practice. The design has been chosen over other 
observational studies including cohort and cross-sectional because the design is the best to answer 
the question of my study. The design offers the opportunity to identify patient’s records with the 
disease and the disease processes (signs and symptoms) which are compared retrospectively with 
referents records without the disease in GP practices in Milton Keynes and Luton. It allows the 
flexibility to compare the pattern of signs and symptoms with or without the disease and variables 
can be considered simultaneously (multiple exposures). The design allows the measurement and 
adjustment of confounding factors (comorbidities). The approach to drawing a pattern is to examine 
the profile of the signs and symptoms of AD in individuals preceding their (current) formal diagnosis.  
Another reason for the choice of a case-control study is the fact that it is cost efficient than a cohort 
and cross-sectional. Furthermore, the design identifies individuals with (cases) and without (control) 
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a particular disease or condition retrospectively to compare the prevalence or level of exposure to a 
risk factor (Lilienfeld & Lilienfeld, 1979). In this study, the comparison is in the patterns of the signs 
and symptoms in sequence and timing preceding the clinical diagnosis of AD.  
 
 
Figure 3.3: Methodological Steps for conducting RMRRS.   The table indicates the conceptual framework 
for the data collection and analysis. 
 
Even though confounding variables and bias could be an issue with this research, the researcher 
took steps to sample the medical record of cases and control from the same GP practices to 
overcome sampling bias.  A sample from a specific register with AD was taken; however, 
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randomisation was not achieved for the cases due to few cases available and a non-probability 
sampling was assumed including all cases. My original plan of individual matching was not possible 
due to the few prevalences and I needed to maximised the opportunity, hence, more controls were 
added based on the matching criteria. The controls were constructed by selecting age and gender-
matched individuals from the same population to improve the external validity (Mann et al., 2003).  
Although, there are quite a number of instruments as checklists for the behavioural disturbances in  
AD, like the  Revised Memory and Behavioural Problems checklist (RMBPC) (Teri et al., 1992), the 
signs and symptoms  of AD are measured based on the Neuropsychiatric Inventory (NPI), which is a 
standardised measure for the behavioural disturbances in AD, obtained from caregivers familiar 
with patient’s behaviour (McKhann et al., 1984; American Psychiatric Association Diagnostic and 
Statistical Manual of Mental Disorders, Fourth Edition, Washington DC, 1994). The instrument is 
valid and reliable, and distinguishes between aetiologies, severity and frequency of behavioural 
changes, and minimise administrative time (Cummings et al., 1997). 
The prevalence rates of these signs and symptoms in AD are presented below; however, it is worthy 
to note that though they are present in cognitively healthy individuals at a less severe level 
(Lyketsos et al., 2002), they do not pose any disturbance to the individual. In MCI, the score of the 
prevalence of agitation is 11.3%, depression 20.1%, anxiety 9.9%, euphoria 0.6% apathy 14.7%, 
disinhibition 3.1%, irritability 14.7%, aberrant motor disturbance 3.8%, sleep disturbances 13.8% 
and eating disturbance 10.4% (Lyketsos et al., 2002). The prevalence is however higher in dementia 
due to AD, with a score in agitation of 30.3%, depression 32.3%, anxiety 21.5%, euphoria 3.1%, 
apathy 35.9%, disinhibition 12.7%, irritability 27%, aberrant motor disturbance 16%, sleep disorders 
27% and eating disorders 19.6%.  In MCI, the most frequent and clinically significant symptoms with 
a disturbance score of more than 4% are sleep disturbance 8.8%, irritability 7.5%, and depression, 
apathy and eating disturbance scoring 6.3% each. More than 80% of AD patients exhibit any 
symptom from the onset of the cognitive impairment (Lyketsos et al., 2002), indicating that there is 
always a sign or symptom to indicate the presence of an abnormality and that these signs increase 
in severity as the disease progresses. In an earlier study (Mega et al., 1996) to assess the 
psychopathology in dementia patients, the prevalence of these symptoms were high with apathy 
scoring 72%, agitation 40%, anxiety 48%, irritability 42%, dysphoria and aberrant motor disturbance 
38%, disinhibition 22%, hallucinations and euphoria 10%.  
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The outcome measure (AD) is classified according to the international statistical classification of 
disease and Related Health Problems with Revision ten (ICD-10), World Health Organisation Version 
for 2016. The codes are FOO.0* for AD with early onset, FOO.1* for AD with late-onset, FOO.2* for 
atypical or mixed AD and FOO.9* for the unspecified AD. The code classification is a medical 
classification list that contains codes for disease, signs and symptoms, abnormal findings, 
complaints, social circumstances and external causes of injuries or diseases; it permits tracking of 
many new diagnoses with a codes set of more than 14,400 different codes.  The disease was 
diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition 
(DSM-IV) for dementia and National Institute of Neurological and Communicative Disorders and 
Stroke, Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA). 
3.5.2.1a Inclusion criteria 
CASES-: Records of adult patients diagnosed with AD in MK and Luton GP surgeries, from 2006-
2016. 
Control: Records of adult individuals without AD disease in GP surgeries in MK and Luton. 
Group matching was restricted to gender, locality, ethnicity, comorbidities and age (18-100 years 
plus or minus one year difference). 
3.5.2.1b Exclusion criteria 
Records of individuals with diagnosis outside AD were not included and those outside MK and Luton 
or below 18 years of age and above 100 years of age. 
3.5.2.2 Data collected 
Data collection is an important and integral aspect of a research study (Neuman, 2005). The 
accuracy of data collection can affect the research positively if adequately collected or negatively if 
not collected properly, which can lead to invalid results (Bowling, 2009). Simplicity and clarity were 
maintained for uniformity in the collection of data while maintaining a logical order. Data was 
collected by consulting medical records of participatory GP surgeries and assigning codes to 
variables. A variable was paired with a response section to capture the required information. This is 
to standardise the data and enhance internal validity (Jansen et al., 2005). The data abstraction 
instrument was electronic (case report form and excel), which reduces input error and allows for 
generalization and access to data. The electronic data retrieval method also assists with the 
management of data statistically and quality control (Woster & Haines, 2004). 
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Each data was listed and captured in the data abstraction instrument, describing where the data is 
located in the health records, with a clear protocol for extraction. This is to increase the inter-rater 
reliability (the rate or percentage of agreement among the observers of the data abstraction), which 
was calculated using the Cohen’s Kappa (κ) that has the value of -1 (perfect disagreement) to 1 
(perfect agreement) (Cohen, 1960; VonKoss Krowchuk et al., 1995). The GP surgeries' established 
guideline for data abstraction was adhered to. 
Before the commencement of the study, consideration was taken into account as to who may 
access the data charts, space available to read the charts, operation hours, policies regarding the 
use of computers and clarification met before commencement (Gearing et al., 2006). The 10% 
proportion of the abstracted data was randomly checked for accuracy of abstraction, as the 
recommended percentages. Although confounding variables and bias could be an issue with this 
research, the researcher has taken steps to sample the medical record of cases and control from the 
same GP (convenient sampling) practices to overcome sampling bias.   
The signs and symptoms that are presented before the diagnosis, were evaluated and assigned a 
specific checklist in terms of present and not present, type of symptom (locopenic aphasia, episodic 
amnesia, visual hallucination etc.) if stated, and a subscale in order to classified two categories; 
“presence of reported symptoms” and “presence of unreported symptoms”. The desired medical 
record data was recorded in such a way that the patients cannot be identified (i.e by the researcher 
or others), via linkage codes assigned to the data directly or indirectly. This means that the names, 
National Health Service numbers, or any other patient identifiers cannot be associated or linked to 
the data set. Consequently, the resulting research data set was subsequently and completely 
anonymous and once the data was collected from the patient’s record, the researcher could not add 
or subtract information from the records.  
It is understood that each patient’s data is composed of different interpretations of different 
scenarios, and that the free–text format commonly used in collecting patients’ record is challenging 
both with the legibility and interpretation (Wu & Aston, 1997; Woster et al., 2005; Pourasghar et al., 
2008) and leads to validity and reliability problems with the recorded information. However, the 
quality of data used in RMRRS is not always inferior, especially if the data is recorded essentially 
without subjectivity and the introduction of electronic medical recording in place of paper recording 
(Zhan & Miller, 2003; Matt et al., 2013).  Medical records were reviewed to collect the following 
data: A register with a ten year demographic (age, age of onset of AD, gender, ethnicity, onset and 
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type of first symptoms, comorbidities), behavioural (dietary habits including water intake and 
physical activities), and health and developmental (environmental factors, education, MMSE) 
factors were also considered (Suresh et al., 2011).  
To draw a pattern and a distinction, the researcher considered the fourteen signs and symptoms 
previously reported and unreported, covering dimensions of AD and taking into consideration 
gender and comorbidities. These signs and symptoms included apathy, agitation, anxiety, 
anosognosia, aberrant motor behaviour, acalculia, alexia, anomia, disinhibition, dysphoriaa, 
irritability, hallucination, olfactory disturbances and weight loss. Gender, age of onset, 
education/occupation and comorbidities were included as concomitants (association/ occurring to 
predict class membership). 
Although, there are quite a number of instruments as checklists for the behavioural disturbances of 
AD, like the Revised Memory and Behavioural Problems Checklist (RMBPC) (Teri et al., 1992), the 
signs and symptoms of AD are measured based on the Neuropsychiatric Inventory (NPI), which is a 
standardised measure for the behavioural disturbances in AD, and could also be obtained from 
caregivers familiar with patient’s behaviour (McKhann et al., 1984; Guelfi, 2004). The instrument is 
valid and reliable, and distinguish among aetiologies, severity and frequency of behavioural 
changes, and minimise administrative time (Cummings et al., 1997). 
3.5.2.3 SAMPLING TECHNIQUE 
The sampling of the RMRRS is based on the fact that data has been collected retrospectively over 
time and this is an advantage as the information can be accessed once (Zhan et al., 2003).  The 
commonly used sampling methods in a retrospective medical record review studies include the 
convenient, quota and systematic sampling (Gearing et al., 2006). The choice of each method 
depends on a number of factors including epidemiological nature and prevalence of the disease, 
importance of probability sampling, population size, research budget and time constraints (Gearing 
et al., 2006) all of which have been taken into consideration.  
Probability sampling was intended to be used in this study as it gives the opportunity for all cases to 
be included in the study and selection can be implemented to categories (Saunders et al., 2011). 
Furthermore, a feature that distinguishes the quantitative from the qualitative approach is 
probability sampling (Sandelowski & Margarete, 2000; Neuman, 2005). Notable RMRRS researchers 
(Rubin et al., 2012; Flower et al., 2013; Hunter et al., 2013; Schuetz et al., 2014; Hooper et al., 2015) 
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that have researched on the symptoms of diseases, have assumed the probability sampling for their 
sample selection. However, and as stated in the constraints for RMRR sampling, only three GP 
surgeries signed up for the study with a low prevalence of AD in the participating GP surgeries. 
Therefore, all cases available were included as a consecutive sampling, which is the best sampling 
method next to the probability sampling as all eligibility is included. The limitations in this sampling 
strategy lie in the fact that the sample might be similar in ethnicity, street and house, or have a 
seasonal and terminal trend, which this study is devoid of, as the sample includes individuals from 
diverse ethnic and socio-economic conditions.  
3.5.2.4 SAMPLE SIZE 
Every retrospective medical record review requires a statistical power analysis to determine the 
appropriate sample size (Abel Ickowicz, 2006; Kadam et al., 2010; Naiji et al., 2013). This is to 
provide valid and robust conclusions and permits the generalisation of the results of the study. 
Retrospective chart review sampling usually uses the number of variables of the study to calculate 
and determine the sample size, that is, ten charts to a variable.  The larger the sample size, the 
greater the precision and power to detect an effect/difference between the means and proportion 
of cases and controls (Gogtay, 2010). Means (u1 and u2) in numerical data is the average of data 
that can be measured or calculated in numbers, while proportion (p1 and p2) in a categorical data, 
is the characteristic in a group with or without mathematical meaning. Simply put, it is the 
difference between the signs and symptoms in patients with AD and those without AD; a shift from 
the conventional to the unconventional. 
Although the concepts underlying most methods of sample size calculation are similar, they are not 
the same in all research approaches. The concepts are based on the primary research question and 
whether the data is numerical (quantitative), which requires large sample size or categorical 
(qualitative) requiring small sample size (Nakagawa & Cuthill, 2007). In this research, the data is 
both numerical and categorical; hence, a larger sample size is required. The formula engaged will 
determine the minimum sample of cases and controls required to draw distinct patterns of the signs 
and symptoms in AD and control group. This will require power and two side type 1 error probability 
α (alpha)- usually set at an industrial standard of 5%, or α = 0.05. The power of statistical procedure 
is the ability to show that the null hypothesis (H0) is false when it is actually false (Kasiulevicius et 
al., 2006; Charan et al., 2013). It is related to effect size/true events which are a statistic estimate of 
the magnitude of an effect (e.g. mean difference, regression coefficient, Cohen’s d, and correlation 
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coefficient), sample size and significance level (Nakagawa & Cuthill, 2007). In my research, the effect 
measure to identify patterns is the odds ratio and a generalisation of the odds ratio will be 
undertaken with the LC regression, a quantifying measurement for investigating and identifying 
patterns. The usual values for power are 80%, 85%, 90% & 95%, with the formula as β=1-power.  
Results from previous studies (McKhann et al., 1984) indicate that the diagnostic accuracy of these 
signs and symptoms range from 65% - 96% sensitivity (percentage of individuals with the signs and 
symptoms that are true positive) and 23% - 85% specificity (percentage of individuals without the 
signs and symptoms that are true negative). The standard, however, of the diagnostic accuracy is 
not the same in all studies and therefore, the accuracy has not been fully established (Lim et al., 
1999; Petrovitch et al., 2001; Kazee et al., 1993; Dubois et al., 2007). In a more recent study (Dubois 
et al., 2014), the sensitivity test ranged from 46% - 88% and specificity of 37% - 90% of MCI cases. 
While an earlier cohort study (Jicha et al., 2006) indicated 70% sensitivity and 30% specificity. I will 
use the 95% CI to draw a pattern. 
Based on the previous reports of the prevalence of the signs and symptoms of AD, the researcher 
estimates the percentage in the control group to be 20% (Table 3.1). 
The odds ratio (OR) provides a relative measure of effect, which allows the comparison of the signs 
and symptoms in patients with AD relative to the control group. This sample size has 95% CI to 
detect a true event size (OR) of 4.89%, for the majority of the signs and symptoms of AD and a 95% 
confidence level that repeatedly; the result will be the same. 
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Table 3.1: Sample size calculation:  calculated according to Sullivan et al (OpenEpi, 2009). 
Sample Size for  Case-Control Study 
For:      
 Two-sided confidence level (1-alpha) 95  
 Power (% chance of detecting) 95  
 Ratio of controls to cases 1  
 Hypothetical proportion of controls with exposure 20  
 Hypothetical proportion of cases with exposure 55  
 Least extreme odds ratio to be detected: 4.89  
   (Fleiss with CC)  
Sample size – cases   53  
Sample size - controls   53  
Total sample size:   106  
 
However, due to the low prevalence in the GP practices that participated in the research, the 
sample size consisted of 37 cases and 72 controls; assuming the ratio of controls to cases is 2:1, 
hypothetical proportion of controls with signs and symptoms is 16% and that of the cases is 40%, 
the least extreme odds ratio to be detected will be OR=3.5 for all signs and symptoms. The 
prevalence of the signs and symptoms is variable and not the same in all cases, hence the variation 
in the result presented in chapter five, which could also be a bias. 
3.5.2.5 INCLUSION CRITERIA 
Case notes of adult patients in the GP surgeries with AD (cases) and without AD (controls) were 
included in the study;  EOAD case ever recorded in the UK was aged 27 years (Zoe Bottrell story; 
Mail online - health, 2015), while the late-onset begins at 65 years and above. The age restriction is 
to enable the researcher to detect changes at the earliest onset, by examining and analysing data 
ten years before the diagnosis of the disease, to understand the prevalence and pattern of 
neuropsychiatric symptoms.  The neurodegeneration progresses 20 - 30 years before the signs and 
symptoms appear; the data will also reflect the preceding signs and symptoms of AD (Mann, 2003; 
Hennekens & Buring, 1987).  
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3.5.2.6 EXCLUSION CRITERIA 
Case notes of patients with a diagnosis of other neurological conditions, accident cases, an 
inconclusive diagnosis, and/or are outside the age bracket. 
3.5.2.7 DATA ANALYSIS 
The literature review reveals that the population of AD is divided into five groups namely: the early 
onset group, the late-onset group, the typical presentation group, atypical presentation group and 
AD with comorbidities. In this arm of the research, the analysis assumed the logistic regression 
which is ideally suitable for a study as this, an analysis that uses the concomitant variable to predict 
class membership. In recent years, they have become increasingly popular strategy for quantifying 
measurement in investigating and generating patterns from signs and symptoms of disease (Severo 
et al., 2012; Smart et al., 2012; Baumert et al., 2014;  Birkeflet et al., 2014; Simpson et al,. 2014; 
Lawrence et al., 2015), and have reported plausible  results. The LC analysis explains the relationship 
among categorical variables stating the existence of a latent or unobserved classifier to conditionally 
make them independent and items are treated as fallible indicators of unseen true states (Chung et 
al., 2006); class is the probability that indicates the chance that the variable takes on certain values. 
Covariates predict class membership through binary or polytomous logistic regression by the 
extension of this to traditional LC models, and logistically predict the value of the categorical 
outcome. The dependent variable (AD) is categorical with a number of possible values, which is 
either yes or no (Bandeen-Roche et al., 1997). 
Signs and symptoms-predict AD (binary diagnosis) 
The LC model is written as: 
  
Where T is the number of latent classes 
Pt is the unconditional probability that  should sum up to one 
A pint is a conditional probability. 
Initially, descriptive statistic and analysis were applied to describe variables, before the final and 
more advanced analysis with the logistic regression model. 
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3.5.2.8 PILOTING 
Piloting is undertaken in this research to assist with the clarification of the data abstraction 
protocol, the reliability of the data abstraction sheet, the process of pulling charts and evaluate of 
any sampling concerns (Smith, 1996; Wu & Ashton, 1997; Jansen et al., 2005). Moreover, piloting is 
the most effective method to determine the development of any problem with missing data. The 
research, therefore, commenced with the piloting, with five charts, according to the standard 
guidelines of piloting (Wu & Ashton, 1997; Perry, 2001), without concern. Although, there is no 
universal method for tackling the issues of missing data, a protocol to address this issue is the 
piloting to determine the development of issues with missing data. The issue of missing data is 
clarified in chapter five.  
3.5.3. QUALITATIVE INTERVIEW  
3.5.3.1 BACKGROUND 
This section of the thesis is the protocol for a qualitative interview. The study fits into a three-phase 
research study; adopting the qualitative approach, focusing on creating patterns of the signs and 
symptoms of AD and reflecting the perspective of professionals. Although AD researchers (Paton et 
al., 2004; Somme et al., 2013; Brorsson et al., 2013; Cuijpers et al., 2014; Chaney et al., 2015; 
Gambina et al., 2015; Forsgren et al., 2015) have adopted the same data collection design, this study 
provides the first insight from the GP’s view of the preceding signs and symptoms before the 
diagnosis of AD, perception of late diagnosis and recommendations to tackle the issue of late 
diagnosis. This is because the GPs are the primary point of contact with the service user, and are in 
the best position to know the presentation of the disease prior to an official diagnosis.  
A sample of 16 GPs was initially proposed out of the general practices in Milton Keynes and Luton 
area. However, seven GPs agreed to participate which coincided with the saturation point. All have 
attended to individuals with AD or related disorders, with the recurrent theme of (1) identifying 
early clinical symptoms, which occur prior to diagnosis, as early signs of AD (2) the reluctances to 
formally diagnose AD (issues around labelling and “putting off a formal diagnosis” and (3) future 
recommendations against barriers to early detection. The interviews were semi-structured 
respectively for numerical and verbatim excerpts. The results of the interview complemented the 
retrospective study, which focuses on patient notes, and suggested guidelines for the early 
screening and subsequent earlier diagnosis of the disease. 
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3.5.3.2 OBJECTIVES  
To explore the perceptions of the GPs, explore their definition of the signs and symptoms that 
precede the diagnosis of AD, determine the problem of late diagnosis and identify the current 
barriers to early diagnosis. 
3.5.3.3 RESEARCH DESIGN 
This is a complimentary (embedded) interview that adopts a qualitative technique, seeking to 
elaborate and enhance the results of the first study that looks at patients’ notes for pre-diagnosed 
common signs and symptoms that may indicate the early onset of AD. 
3.5.3.4 PARTICIPANTS 
Participants are GPs from the surgeries in Milton Keynes and Luton who have worked within the GP 
surgeries in the city, between 2006-2016, without consideration of their age, gender, ethnicity or 
specialty.  They were purposely a self-selected group based on their desire to participate in the 
interview and enable the study. 
3.5.3.5 SAMPLE SIZE 
Sixteen GPs were proposed but only seven were able to participate based on availability for 
interview. This gave the research student the experience of planning and structuring interviews, 
conducting and transcribing. Additionally, the saturation, quality and depth of data, matter more 
than the quantity in qualitative interviews (Burmeister & Aitken, 2012; Fusch, 2015). This view is 
supported by Baker et al (2012), who opined that one respondent is all you need, that is, your 
person of interest.   Generally, however, the four thumb rules is ideal that you keep asking the 
question as long as the responses keep coming differently and reporting fully, how the question can 
be resolved.  
3.5.3.6 ANALYSIS 
A framework analysis was used to analyse the interview data based on the content of the data that 
had cases and codes that needed a flexible approach to a content analysis, and as a way of getting 
closer to the data and developing a deeper appreciation of its content; the summary was in a matrix 
output of rows and columns. Furthermore, it offers an accessible and theoretical, flexible approach 
to qualitative data analysis, and not attached to any particular epistemology or ontological positions 
(Joffe & Yardley, 2004). 
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In a framework analysis, the steps to follow are transparent and bring forth highly structured 
outputs of summarised data (Gale et al., 2013). The framework analysis is part of a broad method of 
analysis termed thematic or qualitative content analysis; it identifies commonalities and differences 
in qualitative data before focusing on the relationship between different parts of the data (Gale et 
al., 2013). Defining its feature is the matrix outputs which are rows (cases), columns (codes) and 
cells of summarised data, providing the means for systematic analysis of the case or coded data 
(Ritchie & Lewis, 2013). According to Gale et al. (2013), the method seeks to draw conclusions 
descriptively and/or explanatory around themes and is widely employed in health research. It is 
seductive in nature, as its methodical processes and ‘spread sheet’ approach aligned more closely 
with quantitative paradigm (Pope & Mays, 2009). The clear steps to follow, the ability to combine 
different data and identify themes from the data, has influenced the choice of the framework 
analysis. 
Due to the nature of the framework method, that is a highly systematic method of organising and 
categorising cumbersome quality data, qualitative research skills are needed to adequately and 
appropriately interpret the data set while hastening the generation of descriptions, categories, 
explanations, and typologies. As with other methods, the framework method requires reflexivity, 
rigour, and quality analysis to succeed (Gale et al., 2013); the researcher is well aware of this and 
took steps to minimise this by gaining the desired knowledge and experience for the framework 
analysis. As the analysis presents the systematic element of content analysis (quantitative in 
nature), permitting the combined analysis of frequency of codes with analysis of meaning; it will be 
approached inductively (coding and themes are generated and directed by the content of the data), 
and deductively (coding and themes are pre-selected and directed by the existing concepts) (Joffe & 
Yardley, 2004; Braun & Clark, 2006). This is in relation to the research question, rational scientific 
framework and objective of the interview. The difference lies in how themes are selected. 
Qualitative data analysis including grounded theory, discourse analysis and ethnomethodology (pays 
attention to language and its use in social interaction) as well as phenomenology and narrative 
method (experience, meaning and language are important) are based on philosophical ideas that 
shaped the analysis process and associated with specific disciplines (Crotty, 1998). However, the 
framework analysis is not affiliated with any epistemological, philosophical or theoretical approach, 
but can be adapted with many qualitative analyses, due to its flexibility. The framework analysis 
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facilitates constant comparative techniques through the review of data across matrix and not 
necessarily concerned with generating social theory (Gale et al., 2013). 
The Graneheim & Lundman (2004) framework analysis description that is thematic in nature was 
adopted which includes: 
Transcription: This is the verbatim (word-for-word) transcription of the content of the interview, 
which should have adequate line spacing and large margins for subsequent coding and notes 
making. The process is an opportunity to immerse in the data. 
Familiarisation: This is the process of emersion in the data by listening to the recording several 
times, to become familiar with the contextual or reflective notes. 
Coding: This is the phase of generating labels (codes) succinctly that identify data that is relevant to 
the research question, and involves coding the complete dataset, collating all the codes and 
relevant data for the analysis stage. 
Development of analytical framework: The next step is the process of abstraction and comparing 
labels on a set of codes to the transcripts. Codes should be categories and clearly defined using a 
tree diagram if needed. The researcher will consider the use of the ‘other’ code under each 
category, to include data that does not fit. 
The analytical framework: A detailed analysis of each theme based on the scope and focus of each 
theme, to determine the story of each theme (Braun & Clark, 2006).  Categories were refined to 
informative name for the analysis before charting began (Ritchie et al., 2002). Indexing of transcripts 
was undertaken using the existing categories and codes, and assigning a number or abbreviation to 
codes for easy identification. Particularly useful at this stage to speed up the process of transcription 
and ensure easy retrieval of data is the Computer Assisted Quality Data Analysis Software 
(CAQDAS). This is an effective way of data storing and organising for accessibility and analysis. 
Charting data into framework matrix: Information from the recording was finally charted according 
to the codes and indexes. A spreadsheet was used to generate the matrix. This is a process of 
summarising the data by category from each transcript and includes references to illustrative and 
interesting quotations using CAQDAS or NVIVO that generated the framework matrix. The 
researcher is aware that an hour interview can generate between 15-30 pages of text and that it 
takes approximately half a day per hour-long transcript to be charted, which might take longer in 
some cases.  
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Mapping and interpretation: Data was finally mapped according to themes and the result 
interpreted. 
Interviewer effect, which is a drawback of the qualitative interview was minimised with consistency 
in the collection of data, and the delivery of the questions provided in the same format and order to 
every respondent (Esterberg, 2002; Payne, 2016). The interview was conducted while considering 
the location, balance of control, good rapport, respect, active listening and probes. 
3.6. Study location 
This research study was undertaken in Milton Keynes in Buckinghamshire and Luton in Bedfordshire 
Counties, United Kingdom. Each city is introduced individually as follows: 
3.6.1 Milton Keynes  
Milton Keynes is located in the southeast of England and became a new town on the 23 January 
1967, as a result of the British Government decision to generate new housing to relieve housing 
congestion in London. The city encompasses the existing towns of Wolverton, Stony Stratford, and 
Bletchley (Figure 3.4) with a population of about 229,941 in 2011 (Census, 2011), and an area of 
about 34 square meters (m2). Recently, the Joint Strategy Need Assessment (JSNA, 2013) estimated 
the population to be about 255,700, with 274,383 individuals registered within the twenty-seven GP 
surgeries in 2014, a university hospital in the Eagle’s Stone district of the council, and a small private 
hospital known as the Saxon clinic. The Milton Keynes University Hospital is an NHS general hospital 
with Accident and Emergency unit and associated with the University of Buckingham medical school 
for medical teaching purposes. The GP surgeries include: Ashfield Medical Centre, Grove Surgery, 
King Fisher Surgery, Parkside Surgery, Watling Vale Medical Centre, Dulverton Drive Surgery, 
Newport Pagnell Medical Centre, Bedford Street Surgery, Sovereign Medical Centre West Field Road 
Surgery, Bur chard Crescent Surgery, Cobbs Garden Surgery, Griffith Gate Surgery, Stony Medical 
Centre, Stone Dean Practice, Hilltops Medical Centre, Water Eaton Health Centre, Neath Hill 
Surgery, Purbeck Surgery, Purbeck Health Centre, Oakridge Park Medical Centre, 2 Solar Court 
Surgery  and  Milton Keynes village practice. 
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Figure 3.4: Map of Milton Keynes. The map indicates the different areas of MK where the research was 
undertaken; the surgeries were based in Fisher mead which is in the central MK and Middleton areas. Source: 
Free media repositories, accessed 05/06/2016. 
 
The name of the city was taken from the existing village of Milton Keynes on the site and was 
deliberately located with the distance equally from London, Birmingham, Leicester, Oxford, and 
Cambridge, to be self-sustaining and become a regional centre in its own right (JSNA, 2013). Milton 
Keynes was chosen for the following reasons: Firstly, it is located in a region (south-east) with the 
highest prevalence of AD (121,572) among the nine regions of England (Alzheimer’s Society, 2014). 
Secondly, even though the Isle of Wright Clinical Commissioning Group (CCG) has the highest 
prevalence of dementia (46.4%) and the Tower Hamlets with the lowest (15.5%), Milton Keynes has 
a very high growth rate, that is, the second fastest growth rate of all local authority within England 
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(HSCIS, 2014; MK Clinical Counselling Group, 2015). The city has a population that consists of 65.3% 
16-64 years olds compared with 63.8% of England as a whole; this is the population at risk of 
developing dementia. To plan ahead for the anticipated incidence in this group will be ideal. 
In 1990, migration accounted for 80% of the city population, with the highest number of the 
population within the 25-39-year-old age group (39,600 out of the population of 145,800) (Kerswill 
& Williams, 2000).  Those within this age would be in their late fifties or early sixties now and this 
population (60-65 years) is ageing faster than the national average and forecasted to increase to 
about 95% from 3,635 in 2010 to 7,060 in 2026, with an increase in long-term illnesses including AD 
(JSNA, 2015). However, the demography of MK is not evenly distributed in terms of age; the 
deprived areas are skewed toward the younger population when compared to the affluent areas. 
Thirdly, the disease diagnosis rate of 53% has been achieved within the last year, and there is a 
focus on the identification of people at risk of dementia and the offering of a memory assessment in 
their GP surgeries. This study supports the identification of patterns prior to the current point of 
diagnosis of AD and I aimed to develop a predictive model for early detection. This will subsequently 
be used to identify those who might benefit from more expensive or invasive diagnostic testing. 
Finally, the researcher’s prospect of negotiating access to the study sites is taken into consideration, 
as the researcher is local to the area.   
3.6.2 Luton 
Luton is a large city/ town situated in the South of England, in Bedfordshire County (Figure 3.5). The 
town was founded by the Anglo Saxon in the sixth century and had a population of 214,700 in mid-
2015 (National Statistics, 2015). It shares borders with Aylesbury in the east; Stevenage in the west; 
west of London in the north and Milton Keynes in the south. According to the 2011 census (Luton 
Census Demographics, UK 2011), the average age of individuals living in Luton was 35, with a 
median age of 32, consisting of 67% white, 6.3% Pakistanis, 3.1% Bangladesh, 2.6% India, 2.3% Irish, 
1.2% Scottish, 0.9% Jamaican, Nigerians and Zimbabweans and 0.7% Kenyans.  
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Figure 3.5: Map of Luton. The map indicates the areas within the metropolis, with Luton in the center; an 
area where I carried out the research, which is large and diversified (Google maps, 2017). 
 
In 2015, Luton’s population was approximately made up of 35% Black and Minority Ethnic (BME) 
groups including Pakistani, Bangladeshi, Indian and African Caribbean and has an annual growth rate 
of 1.8% faster than the national average with 0.8% (Luton Demography, 2016). This population is 
serviced by thirty-seven GP practices including Lea Vale Medical Group; Barton Hills Medical Group; 
Bell House Medical Centre; Blenheim Medical Centre; Bramingham Park Medical Centre; Bute House 
Medical Centre; Castle Street Surgery; Conway Medical Centre; Dr A Zaman’s Practice; Dr Mirza & 
Partners, Gardenia & Marsh Farm Practice and Lea Vale Medical Group with two surgeries each; 
Hochwell Ring Med Pract-Mirza; Kingfisher Practice; Kingsway Health Centre; Larkside Practice;  
Leagrave Surgery; Lister House Surgery; Medici Medical Centre; Medina Medical Center; Moakes 
Medical Centre; Neville Road Surgery; Oakley Surgery; Pastures Way Surgery; Stopsley Village 
Practice; Sundon Medical Centre; Sundon Park Health Centre; The Ashcroft Practice; The Link 
Surgery; Town Centre GP Surgery; Wenlock Surgery; Whipperley Medical Centre and Woodland 
Avenue Practice. 
Even though Luton has a younger population than the national average due to international 
migration, with a net migration of 1,700 in 2015, the population of those between the ages of 30-64 
is quite high, about 43.5% of the entire population. This is the population at risk of EOAD as well as 
LOAD and as expected this population will double in the next decade.  
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Dementia Luton (2015) has recognised that there is an increase in the prevalence of dementia in the 
black community, which the significant and diverse BME community in Luton could lend itself due to 
the diminished recognition of dementia as a condition in this group and the South Asian community. 
Additionally, there is a misunderstanding and sometimes, lack of knowledge of the symptoms of 
dementia as well as issues within the older people’s mental health; language barriers, the stigma 
surrounding mental issues and risk of misdiagnosis and delayed treatment among these 
communities could present issues regarding the prevalence of the disease. Moreover, the 
prevalence is not really established, as the number of individuals on GP registers with dementia is 
560, while the national data figure is approximated to be 900 (Dementia Luton, 2015) per all the 
registered patients in the GP surgeries. Even though the prevalence of early-onset AD is much 
smaller, the needs and circumstances of these young adults could be different from the older 
counterpart. Careful planning with regards to early diagnosis, treatment and support, and total 
commitment is needed in anticipation of the rise in prevalence of the disease in the near future. 
3.7. Ethical issues. 
The first ethical concern of a researcher is the respect for the dignity and autonomy of participants.  
Four principles or moral commitments are linked with data sharing (Gillion, 1994; Beauchamp & 
Childress, 2001). These principles include respect for autonomy (respecting the decision-making 
capacities of autonomous individuals); non-maleficence (refraining from causing harm); beneficence 
(to do good) and justice (the fair distribution of benefits, risks and cost). These principles have been 
described as “prima facie “principles (Ross, 1939), meaning that they are binding unless they conflict 
with others. The principles help researchers to make informed decision regarding moral and ethical 
issues in research (Brakewood & Poldrack, 2013). Morality here refers to norms about right and 
wrong and standards of conduct that are generally acknowledged by those in the medical and 
healthcare profession (Ross & Stratton-Lake, 2002). Good ethical practice is an obligation to shared 
data, however, the decision to be morally right lies solely with the researcher. It is with this moral 
obligation that the researcher sought ethics approval from the regulating authority to enhance the 
validity and gain trust with the research. 
One of the designs of this research collects and analyses patients’ anonymised data and seeks the 
opinion of GPs through a qualitative interview; the National Health Service (NHS) data is increasingly 
being used for medical and health research, which include data from approximately one million 
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individuals treated every 36 hours (William et al., 2012). The research had to be undertaken in an 
ethical way to maintain the trust of patients and individuals. 
Ethics was subsequently sought and approved by the IHR Research Ethics Committee (REC) of the 
University of Bedfordshire, my alma mater and the first responsibility for making sure that the 
research is undertaken within the good ethical practice. Furthermore, approval was sought from the 
institutional review boards (NHS REC, North of Scotland and London) and HRA for the GPs interview 
and RMRRS through the Integrated Research Application System (IRAS). The process, which is long 
and overwhelming for the committee and investigators alike is necessary due to the standardisation 
of the application to local RECss (Jamrozik, 2004; William et al., 2012), and is geared towards 
overcoming the inconsistencies in paperwork required by different committees (IRAS, 2016). Even 
with the frustration experienced due to delays in gaining approval from the NHS REC (Dixon-Woods 
et al., 2016) and issues of publication and outcome reporting bias in the UK (Begum & Kolstoe, 
2015), the system is highly regarded in ensuring patients’ safety and confidentiality of data sharing 
in medical research. There was no issue regarding consent and withdrawal from participating GPs 
and surgeries, deception, confidentiality and anonymity.  
3.7.1. Consent 
For the qualitative interviews, GPs were informed verbally and provided with an information sheet 
(Appendix VII). All of their questions were answered to their contentment before the 
commencement of the research. Participants were also told that they are under no obligation to 
decide or to participate and that they could withdraw personally from the research at any time.  
Anonymised data from interviews and the RMRRS is used in this research, after ethics approval from 
the ethics review board and participating GP surgeries. 
3.7.2. Confidentiality 
This research does not involve analysing sensitive data that is protected by civil right like personal 
information. The researcher adhered to both the data protection Act, 1998 (Act, D.P., 1998) and the 
Health and Social Care Act 2001 (Act, H.S.C.A, 2001). The code of the confidentiality of the 
participating GP surgeries was adhered to, for confidentiality of all held data.  The data was held on 
a password protected and non-networked computer which could only be accessed by the 
researcher, under lock and key. All data is anonymised and pseudonyms or codes assigned for the 
collection and analysis of data. Nothing is attributed by name or any personal identifier but by codes 
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or pseudonyms. Also for the quantitative data, the researcher reduced the precision of variables 
that might be identifiable like postcode while being careful for distorting the qualitative data and 
emphasising access restriction through a password protected and non-networked computer, 
accessed only by the researcher.  
While this chapter discussed the methodology in detail, the next chapter mapped, synthesised and 
appraised the evidence available on patterns in signs and symptoms of AD through a systematic 
scoping review of literature. The synthesis is provided to highlight the current evidence and the 
need for more research in this regard. 
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CHAPTER FOUR: Systematic scoping review 
4.1 Background 
 
Owing to the diversity of presentations among the AD groups, it is pertinent for a systematic scoping 
review of previously reported symptoms and signs, as well as their sequence and timing to increase 
awareness for early diagnosis and for timely intervention. Even though there are studies on the 
frequencies and prevalence of the symptoms of AD, to date there is no systematic review of the 
timing and sequence of the early symptoms and signs of AD. This review will therefore encourage 
researchers to undertake such research to produce studies that will enable the generalisation of the 
results. Similarly, it is supplemented with a literature review to synthesise and produce the best 
available evidence on patterns in the presentations of AD. 
 
4.2 Objectives 
The objectives of this review are: (i) to identify the sequence and timing of the presentation of signs 
and symptoms at the early stage of AD to inform a primary study and (ii) to understand how far back 
from diagnosis the first symptoms that will justify a diagnosis were reported. 
 
4.3 Search methods 
This is extensively explained in the protocol in chapter 3.5.1.9. 
 
4.4 Selection criteria 
The reviewer included all empirical evidence as explained in the protocol. 
 
4.5 Data collection and analysis 
The outcomes of this review were: (i) the sequence and timing of signs and symptoms preceding the 
clinical diagnosis of AD and (ii) the timing from the report of the first symptom that justified the 
clinical diagnosis of AD to the clinical diagnosis of the disease. Only one study by Devier et al. (2010) 
reported on outcomes related to this review. Even though there were limitations in the studies on 
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the sequence and timing of the signs and symptoms preceding the diagnosis of AD, I identified three 
additional studies with outcomes of interest from the 3,528 unique citations reviewed at the title 
and abstract level; these were: (a) emergence of first clinical symptoms to dementia phase, (b) from 
first assessment to appearance or symptomatic assessment and (c) clinical onset of symptoms and 
signs to case fatality or death. However, the data on these outcomes was also limited.  
A descriptive/narrative analysis was undertaken due to the heterogeneity in the objectives of the 
included studies. A quality assessment was conducted with the QUADAS-2 assessment tool. 
 
4.6 Main results 
Four articles (Amieva et al., 2008; Devier et al., 2010; Fox et al., 1998; Schmidt et al., 2010) were 
used in this review, which reported data from 593 individuals diagnosed with AD; one study (Amieva 
et al, 2008) was conducted in a community setting and three others in secondary/specialist settings. 
The overall quality of studies was good, except for the heterogeneity in review objectives.  
4.6.1 Outcome I:  
Of the 148 participants in the study by Devier et al. (2010), 39 (26%) converted to AD and all the 
converters were 55 years at baseline indicating EOAD. There was heterogeneity in first symptom 
reported, which included memory loss and depression. 
4.6.2 Outcome II:  
The timing from the report of the first symptom to the diagnosis of AD ranged between 19–176 
months, with an average of 62 months. 
4.6.3 Outcome III:  
Amieva et al. (2008) reported the timing from the report of the first clinical symptom to dementia. 
Cognitive decline was the first to appear 12 years before dementia in the measure of semantic 
memory and conceptual formation, closely followed by depressive symptoms and verbal memory 
decline two years later. Four years after the cognitive decline, converters became more dependent 
on their activities of daily living (ADL), subsequently visual disturbances were recorded which 
worsened until the stage of dementia. 
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4.6.4 Outcome IV: 
Outcome four was the timing from the first assessment to the symptomatic assessment of 
individuals at risk of FAD. Out of the 63 subjects in the study by Fox et al. (1998), 15.9% converted to 
AD with a mean time (± SD) from initial assessment to symptomatic assessment of 3.1 ± 1.5 years. 
Episodic memory loss was the most common and noticed on average 6 months before symptomatic 
assessment. The only subject with a MMSE score of 25 in the study remained stable for 2 years, 
consistent with family members with the same score that remained healthy throughout. 
4.6.5 Outcome V: 
Schmidt et al. (2010) investigated rapidly degenerating AD that indicated additional focal symptoms 
consistent with a form of prion disease, CJD. The outcome measure was the timing from symptoms, 
median life span from clinical onset of the disease to case fatality or death. In total, 35 distinct 
neurological, psychiatric and autonomic symptoms and signs were reported, with the sequence and 
timing (in months) in the early stage between 2.0–51.1 months.  
4.6.6 Author’s conclusions 
Further studies regarding the timing and sequence in presentations of AD are needed because there 
is a paucity of data regarding this topic and research on the presentations has been on the 
prevalence and most common signs and symptoms of AD. Therefore, this review has insufficient 
data to make recommendations on the timing and sequence of these presentations to aid the early 
detection of AD. However, it is worthy to consider the additional focal symptoms of rapidly 
progressive AD and an MMSE score of 25 in the inherited dominant familiar AD in discriminating the 
disease from other dementias. 
 
4.7 Plain language summary 
This review aimed to identify the sequence and timing of early presentations of AD (please refer to 
chapter 2.1) to inform a primary study. The early signs and symptoms have been identified from 
previous epidemiology studies (Mega et al., 1996; Cumming et al., 1997; Palmer et al., 2008; Igbal et 
al., 2013) as the characteristics of the early stage of AD. The early stage here means the stage at 
which the pathology of the disease is just beginning and at the lowest threshold; the preclinical 
phase of detecting cognitive deficits which is estimated to be about five years (Linn et al., 1995; 
Forstil & Kurz, 1999). These signs and symptoms include those mentioned in chapter 2.1; they are 
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not always present in an individual, with their timing and sequence in appearance different in each 
type of AD. The reviewer searched a wide range of resources and found 3,219 unique citations 
reviewed at the title and abstract level. Forty academic papers were reviewed fully; thirteen articles 
deemed fit, however, after further review, four were finally included in the review. The review 
included studies in the community (people living in the community with AD) and secondary 
institutions (specialist clinics for referrals). 
 
4.8 Scientific summary; Background 
4.8.1 Target condition under review 
The target condition for this review is AD (please refer to chapter 1.2 for the prevalence and 2.1 for 
description of the disease). The early stage of AD is characterised by the pathology of biomarkers 
(Villemagne et al., 2015; Mufson et al., 2016) rather than observable signs and symptoms and is 
known as the preclinical or asymptomatic phase. As stated in chapter 2.1, the heterogeneous 
nature of the disease presentations leads to challenges in the early diagnosis, which can result in 
late diagnosis or misdiagnosis with a potentially inappropriate intervention that could worsen the 
prognosis. 
4.8.2 Index symptoms 
The index symptoms as described in chapter 2 (Mega et al., 1996; Albert et al., 2011; Dubois et al., 
2014; Morris et al., 2014; Hirao et al., 2015) have different scores across studies and individuals 
(Mega et al., 1996; Kang et al., 2004; Craig et al., 2005; Ringman et al., 2015). The timing and 
sequence of the presentations are not clearly defined, with few studies undertaken on timing from 
the first symptom manifestation to diagnosis (Palmer et al., 2008; Devier et al., 2010; Shea et al., 
2015), which deserve research attention, as they have clear potential to impact on early diagnosis of 
AD to inform timely intervention that will slow down the degenerative processes of the disease. 
4.8.3 Objectives 
Scoping reviews map and appraise the quality of existing evidence (Arskey & O’Malley, 2005) and 
are similar to systematic reviews but with broader and more comprehensive objectives 
(Sandelowski et al., 1997; Glasziou et al., 2001). This has been undertaken using the protocol for a 
systematic review but within a large body of diverse literature and guided by specific objectives. 
This was to understand the whole of the literature by systematically searching so as not to miss any 
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relevant articles and to bring meaning to the result. It is therefore neither a diagnostic nor 
intervention study but a study to identify the sequence and timing of the signs and symptoms 
preceding the clinical diagnosis of AD to inform a primary study. 
 
4.9 Methods 
Criteria for considering studies for this review 
4.9.1 Types of studies 
All studies were considered where participants were assessed with the index symptoms and 
reference standard diagnostic assessment within any health care setting. No study design was 
excluded if the study was empirical and appraised as good quality.  
4.9.2 Participants 
Participants in studies undertaken at an early stage with the signs and symptoms of AD were 
included if they were between the ages of 30–85 years, with the study in primary care, memory 
clinics or secondary care settings. The objectives of this review were to identify the sequence and 
timing of presentations at the early stage of AD, therefore studies on presentations in the late stage 
of AD (AD dementia) were excluded. The rate of progression and timing in this group can be 
reviewed separately. Also, other dementias and neurological conditions were excluded, as well as 
studies that were undertaken in developing countries. 
4.9.3 Index symptoms 
The reviewer considered fourteen symptoms which have been identified at the early stage of the 
pre-clinical and MCI (details in background and chapter 2.1). 
4.9.4 Comparator tests 
There are no comparators or alternate tests, as the review is not about testing diagnostic tools but 
reviewing the sequence and timing of the signs and symptoms preceding the clinical diagnosis of 
AD. 
4.9.5 Target condition 
AD and any subtypes including early onset and late onset AD. 
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4.9.6 Reference standard 
Studies that used the reference standard set out in the protocol for this review, which is the 
standard for diagnosing AD, were included. The reference standard used in this review was the 
National Institute of Neurological and Communicative Disorders and Stroke and AD and Related 
Disorders Association (NINCDS-ADRDA), a commonly used criteria for AD dementia. NIA-AA criteria, 
more recent criteria that use biomarkers to support the diagnosis, Diagnostic and Statistical Manual 
of the American Psychiatric Association (DSM-IV, American Psychiatric Association, 1994), DSM-5 
(Freedman et al., 2013) were considered. A study on post-mortem verification was included because 
of the timing of presentations at the early stage of the disease. 
4.9.7 Exclusion criteria were: 
• Participants with other dementia or neurological conditions 
• Inaccurate diagnostic criteria 
• Single reference symptom 
• Late stage AD dementia 
4.9.8 Search criteria for identification of studies 
The researcher searched OvidSP MEDLINE (1950–May 2016), PsycINFO (1806–May 2016), Nursing 
Index and the Cochrane register for diagnostic and intervention studies. 
Terms describing the sampling frame or setting of studies are not standardised, hence, there was no 
attempt to restrict the search to studies, which would have lessened the sensitivity of the search. 
No language or publication restrictions were applied. The researcher used theatres to standardise 
and improve the search; a disease theatre as the main, followed by a basic theatre including 
timing/onset and country, and the combination of theatres before duplicates were removed. 
4.9.9 Searching other sources 
Manual searching of studies was undertaken, even when there was little evidence to support this 
(Glanville et al., 2012), with reference lists of relevant papers. Also, the Health Technology 
Assessment (HTA) database via Cochrane Library, Database of Abstracts of Reviews of Effects and 
the Grey (Science Citation Index, Thesis and Conference Proceedings) literature through the Web of 
Science were searched. No unpublished data was found. 
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4.10 Data Collection and analysis 
4.10.1 Selection of studies 
Studies were selected based on the inclusion criteria. Titles of articles identified were scanned by 
the reviewer to exclude irrelevant articles. The reviewer and librarian independently scanned the 
titles and abstracts of the studies deemed relevant with an agreement; the reviewer reviewed the 
full text versions, then together with one of her supervisors, considered the studies to be included 
(Figure 4.1). There was no disagreement. 
The reviewer independently extracted data on the study characteristics (study design, participants’ 
characteristics, inclusion and exclusion criteria, recruitment period, country of study, health care 
settings, diagnostic criteria and clinical signs and symptoms). A two by two table was not possible 
due to the nature of the data reviewed; however, any discrepancy was resolved with the 
supervisors. The data abstraction form as well as the title and abstract form (Appendices XIII &XIV) 
were piloted and reviewed by my supervisors before the final abstraction was undertaken. 
4.10.2 Assessment of methodological quality 
The reviewer independently assessed the quality of included studies using the QUADAS tool. Details 
of the quality assessment tool and coding criteria based on the QUADAS tool (Whiting et al., 2011) is 
outlined in Table 4.1; assessment of methodological quality. 
 
 
 
 
 
 
 
 
 
 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: A flow chart of the inclusion criteria. The reviewer reviewed the title, abstract, and full text of 
studies included.  
 
 
 
 
 
Are the symptoms and signs the early presentations of AD 
rather than other presentations of AD? If another 
presentation, exclude at abstract level. 
Is the study on individual symptoms rather than a collection 
of symptoms? If on individual symptom, exclude at abstract. 
 
Is this a study on all types of dementia? Can the AD 
population be differentiated? Can the early stage be 
defined? If not, exclude at abstract. 
Is there a reference standard? If not certain, then exclude 
at abstract. 
Is this a diagnostic test accuracy (DTA) study? A DTA study 
is a diagnostic utility study (sensitivity, specificity, 
predictive value, likelihood ratio) or any report that makes 
the circulation of the above possible. 
If this is a DTA, label as such, obtain the full study for the 
possibility of being included in the review. 
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Table 4.1: Quality assessment with the QUADAS tool. 
DOMAIN PARTICIPANT SELECTION INDEX TEST REFERENCE 
STANDARD 
FLOW AND TIMING  
Description Describe methods of 
participant 
selection: Description 
included participants (prior 
testing, presentation, 
intended use of index test 
and setting) 
Describe the index 
test (symptoms 
and signs) and how 
it was conducted 
and interpreted 
Describe the 
reference standard 
and how it was 
conducted and 
interpreted 
Describe any participants who 
did not receive the index test(s) 
and/or reference standard or 
who were excluded from the 
2x2 table (refer to flow 
diagram): Describe the time 
interval and any interventions 
between index test(s) and 
reference standard 
Signalling questions 
(Yes/no/unclear) 
Was there a consecutive or 
random sample of 
participants enrolled? 
 
 
 
 
 
 
 
Was a case-control design 
avoided? 
 
 
 
 
Did the study avoid 
inappropriate exclusions? 
Were the index 
test results 
interpreted 
without 
knowledge of the 
results of the 
reference 
standard?  
 
 
If a threshold was 
used, was it pre-
specified? 
 
 
 
Is the reference 
standard likely to 
correctly classify 
the target 
condition? 
 
 
Were the reference 
standard results 
interpreted without 
knowledge of the 
results of the index 
test? 
 
Was there an appropriate 
interval between index test(s) 
and reference standard? 
 
 
 
 
 
Did all participants receive a 
reference standard? 
 
Did all participants receive the 
same reference standard? 
 
Were all participants included in 
the analysis? 
Risk of bias 
(High/low/unclear) 
Could the selection of 
participants have introduced 
bias? 
Could the conduct 
or interpretation 
of the index test 
have introduced 
bias? 
Could the reference 
standard, its 
conduct, or its 
interpretation have 
introduced bias? 
Could the participant flow have 
introduced bias?  
Concerns regarding 
applicability: 
(High/low/unclear) 
Are there concerns that the 
included participants do not 
match the review question? 
Are there concerns 
that the index test, 
its conduct, or 
interpretation 
differ from the 
review question? 
Are there concerns 
that the target 
condition as defined 
by the reference 
standard does not 
match the review 
question? 
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4.10.3 Statistical analysis and data synthesis 
Due to the heterogeneity in the objectives of studies included, statistical analysis was not possible. 
Instead, a descriptive analysis was undertaken and the studies presented individually accordingly. 
QUADAS-2 was used to assess the study quality to determine the overall risk of bias and strength for 
each study. 
The data was extracted from the four distinguished studies that reported on the early and late 
stages of AD and presented in the study. A bivariate random-effects approach is appropriate if the 
threshold of sensitivity and specificity was reported and was consistent (Reitsma et al., 2005). 
4.10.4 Heterogeneity investigations 
Heterogeneity in the included studies was assessed with the QUADAS-2 tool.  
4.10.5 Assessment of reporting bias 
Formal assessment of reporting bias was not undertaken in this review as the objective of the study 
was not the accuracy of tests, but the timing and sequence. Moreover, there are uncertainties in the 
assessment of reporting bias in diagnostic test accuracy reviews (Deeks et al., 2005). 
 
4.11 Results 
4.11.1 Search results 
A total of 3,210 articles were identified, screened and selected for the review including duplicates 
(318), nine others were identified bringing the total to 3219. Of these, 3,179 were excluded based 
on titles and abstract alone (Figure 4.2). Forty full text versions were reviewed, 13 were initially 
included but 9 later excluded due to technical reasons, finally 4 were selected for review. The 
agreement between the reviewer and the supervisors on the full text screening was good. 
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Figure 4.2: Flow diagram indicating the articles included in the study. 
Studies included in 
the narrative analysis 
(n = 4) 
Studies included in 
quantitative analysis 
(meta-analysis) 
(n = 0) 
Articles identified 
through database 
searching  
(n = 3,528) 
Articles after 
duplicates removed 
(n = 3,219) 
Full articles 
excluded  
(n = 36) 
Full articles assessed 
for eligibility 
(n = 40) 
Additional articles 
identified from other 
sources 
(n = 9) 
Records excluded 
(n = 3,179) 
Title and abstract 
screened  
(n = 3,219) 
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4.11.2 Reasons for exclusion 
Exclude discussions on reliability and timing of presentation 2; Interviews 2; looking at 
commonality of symptoms 5; Establish diagnosis 1; Comparing VAS and AD 2; Retrospective 
survey of symptoms between AD dementia 1; Prediction of extrapyramidal signs 2; 
Behavioural syndrome study 2; Single symptoms studies 2; Accuracy of diagnosis 1; Clinical 
clips 1; Association studies 3; Cognitive profile 1; Data research dissertation 1; Trajectory of 
cognitive decline1. Studies that were reviewed in detail but excluded have fully been 
referenced (n = 9). 
• Exclude discussions on reliability and timing of presentation 2; 
• Interviews 2; Looking at commonality of symptoms 5;  
• Establish diagnosis 1; 
• Comparing VAS and AD 2;  
• Retrospective survey of symptoms between AD dementia 1; 
• Prediction of extrapyramidal signs 2; 
• Behavioural syndrome study 2; 
• Single symptoms study 2; 
• Accuracy of diagnosis 1; 
• Clinical clips 1; Association studies 3; 
• Cognitive profile 1; 
• Data research dissertation 1;  
• Trajectory of cognitive decline 1; 
 
Initially, thirteen studies met the inclusion criteria and were reviewed in full. However, four 
studies on dementia (Yoon et al., 2014; Masters et al., 2013; Kang et al., 2004; Di Ilio et al., 
2010), one study undertaken in a developing country (Lopera et al., 1997), another on 
caregivers’ distress (Craig et al., 2005), one single case study (Shea et al., 2015), one study 
with incomplete data (Jost et al., 1996) and one without a reference point for the diagnosis 
of AD (Palmer et al., 2008) were then excluded, so that four studies were included in the 
final review. The excluded studies are presented in the characteristics of excluded studies 
table. 
Summary of findings 1: Four studies were included and had a total of 593 participants with 
AD (Amieva et al., 2008; Devier et al., 2010; Fox et al., 1998; Schmidt et al., 2010). One study 
was conducted in a community setting (Amieva et al., 2008) and three in secondary care 
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settings (St Mary’s Hospital, London, Fox et al., 1998; memory clinic, Devier et al., 2010; a 
post-mortem retrospective analysis in the National CJD Surveillance Unit in Germany, 
Schmidt et al., 2010).  
4.11.3 Methodological quality of included studies 
The methodological quality in each domain was assessed individually, with two authors 
contacted for more information on the methodological quality. The QUADAS-2 scores for 
each domain of the studies included in the review are shown in Figure 4.3 and 4.4 
respectively. This review aimed to identify the sequence and timing of the early symptoms 
and signs preceding the clinical diagnosis of AD disease therefore patient selection was 
based on the best available options. With regards to the protocol, there was no 
discrimination on design as long as it was empirical within the inclusive criteria. The studies 
included a nested case-control with random sampling (Amieva et al., 2008), longitudinal 
follow-up of MCI (red-flag) patients (Devier et al., 2010), longitudinal prospective study of 
individuals at risk of autosomal dominant familial AD (ADFAD)(Fox et al., 1998) and a 
retrospective case study (post-mortem)(Schmidt et al., 2010). For the case studies (Devier 
al., 2010; Fox et al., 1998; Schmidt et al., 2010), there was no inappropriate exclusion and 
sample selection was consecutive, which reduced the risk of selection bias. However, 
applicability could be a risk as these were case studies with few samples, even though 
underestimation of diagnostic accuracy could result from the exclusion of red-flags of the 
target condition or those easier to diagnose (QUADAS-2 tool). 
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Figure 4.3. Graph representing the risk of bias and applicability concerns. Each domain is 
represented as a percentage across the included studies, red indicates high risk, green indicates low 
risk, but no studies had an unclear risk of bias and applicability concerns (QUADAS-2 tool). 
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                      Risk of Bias               Applicability Concerns 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Summary of the risk of bias and applicability concerns: reviewer’s judgement on each 
domain for the included studies is shown with a high risk of bias and applicability concerns on index 
test. 
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The interpretation of the index tests (signs and symptoms) was not influenced by the knowledge of 
the reference standard in three studies (Amieva et al., 2008; Devier et al., 2010; Fox et al., 1998). 
The index test domain was judged at a high risk of bias in the study by Schmidt et al. (2010) due to 
the fact that the index tests (symptoms and signs) was interpreted based on the knowledge of the 
disease (post-mortem). Regarding applicability, the conduct and interpretation were different from 
the review question in Fox et al. (1998) and Schmidt et al. (2010); the Fox study identified the mean 
time from first assessment to the report of the appearance of symptoms, while the Schmidt study 
determined the symptoms median time span from clinical onset of the disease to the fatal end 
point. 
With regards to the reference standard domain, all studies were undertaken using an internationally 
recognised standard reference that could correctly classify the condition with masking in all. The 
Schmidt et al. study (2010) on rapidly progressive AD was undertaken post-mortem, the gold 
standard of diagnosing AD. However, none of the studies reported how the reference standard was 
applied, so they were assessed as being at low risk of concerns about applicability. 
Concerning the flow and timing domain, there was an appropriate interval between the appearance 
of symptoms and signs and the reference standard, as the aim of this review was to identify the 
timing from diagnosis to the report of the first symptoms that justified a diagnosis. However, these 
symptoms varied across participants. There was no mention of treatment in between the timing and 
all the participants received the same reference standard except in Schmidt et al. (2010), which was 
a post-mortem diagnosis, the gold standard of AD diagnosis.  
 
4.12 Findings 
The outcomes for this review are stated in chapter 4.5. Only one study (Devier et al., 2010) reported 
on the review objectives, however, three studies with outcomes of interest were included. These 
outcomes included: timing in presentation of symptoms from MCI to dementia stage (Amieva et al., 
2008), timing in presentations from first assessment to symptomatic assessment (Fox et al., 1998) 
and timing of clinical presentations to case fatality or death (Schmidt et al., 2010). Consequently, 
this review had five outcomes of interest. 
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4.12.1 Setting 
I) Community setting: Participants 65 years and older (LOAD) were sampled in the PAQUID 
population study in France, with a mean age at diagnosis of 86.2 (SD, 5.6) years. The symptoms 
were reported in the following sequence: memory loss, followed by a cognitive decline, depression 
visual disturbance and verbal memory loss. ADL scores followed two years later. MMSE scores 
slightly declined (0.05% point/year) from 11 years. Throughout the fourteen year longitudinal study, 
memory loss was experienced 12 years before clinically defined AD dementia, cognitive decline in 
semantic memory was observed 12 years before dementia, the MMSE score started to decline in 
the fifth year of the study, visual disturbance occurred at 5–6 years and ADL score declined 8–9 
years into the study before dementia. 
II) Memory or secondary care setting: This refers to specialist units. Three studies were carried out 
in secondary care settings Devier et al. (2010), Fox et al. (1998) and Schmidt et al. (2010) in the US, 
UK and Germany respectively. However, as mentioned previously, the study by Schmidt et al. (2010) 
was a post-mortem retrospective case analysis. 
4.12.2: Outcomes 
OUTCOME 1 
Of the 148 participants in this study, 39 (26%) converted to AD and all converters were 55 years at 
baseline indicating an early onset AD (EOAD) and had a lower MMSE score compared with non-
converters. In the early stage, memory decline was reported first in 118 (80%) of the cases, 
depressed mood in 13 (9%), change in language in 6 (4%), change in performance of higher 
order/cognitive activities in 4 (3%), disorientation in 3 (2%) personality changes and behavioural 
changes in 2 (1%), with no group difference in reporting of symptoms. Sequentially, memory decline 
was the first, followed by performance changes, changes in language, disorientation, personality 
changes, depressed mood, behavioural changes and psychosis consecutivel 
Outcome II 
The timing in reporting the first symptom to diagnosis was as follows: memory decline was 
experienced in 38.5 months before diagnosis, depressed mood in 37.4 months, performance in 36.8 
months, personality changes in 32.5 months, behavioural changes in 31.1 months, language 
difficulties at 29.2 months, disorientation in 29.1 months and psychosis at 14.0 months prior to the 
diagnosis. 
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Outcome III  
Amieva et al. (2008) reported the timing from the report of the first clinical symptom to dementia 
and the presentations in timing and sequence. Cognitive decline was the first to appear 12 years 
before dementia in the measure of semantic memory and conceptual formation. Depressive 
symptoms appeared concomitantly with the cognitive decline, followed two years later with verbal 
memory decline. Two years later, converters became more dependent on their activities of ADL, 
subsequently visual disturbances were recorded and worsened until the stage of dementia. 
Outcome IV 
This outcome was the timing from first assessment to the symptomatic assessment of individuals at 
risk of familial AD (FAD). Of the 63 subjects in the study of Fox et al. (1998), 10 probably converted 
to AD and the mean time (±SD) from first assessment to the appearance of symptoms was 2.6 ± 1.4 
years. Episodic memory loss was the most common and observed on average 6 months before 
symptomatic assessment. The study suggested that cognitive decline is present 2–3 years before 
symptoms and 4–5 years before individuals fulfil the criteria for probable AD. There was no 
distinction in presentations with regards to age, gender and handedness and verbal memory was 
superior to semantic memory in differentiating AD and normal ageing, with the lowest MMSE score 
of 25 in a subject remaining stable for 2 years consistent with family members with the same score 
that remained healthy.  
Outcome V 
The study by Schmidt et al. (2010) on rapidly progressive LOAD indicated that the additional focal 
symptoms were consistent with CJD, a form of prion disease. The outcome measure was timing 
from symptoms median life span from clinical onset of the disease to case fatality or death. Thirty-
five distinct neurological, psychiatric and autonomic symptoms and signs were reported, with the 
sequence and timing (in months) in the early stage as follows: disinhibit ion 51.1, spasticity 31.1, 
dysphagia 21.6, akinetic mutism 20.0, significant weight loss 20.0, apraxia 19.5, apathy 17.0, sleep 
disorder 16.0, delusions 15.0, myoclonus, hallucinations, seizures 13.0, impaired concentration 4.5, 
depression 4.0 and disorientation 2.0, with others following after. The study identified additional 
early focal symptoms consistent with CJD including myoclonus and seizures. A third of RPAD 
experienced rapid weight loss and sleep disorder indicating their significance in discriminating the 
disease from other dementias. 
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4.12.3 Symptoms 
A pooled estimate was not possible due to the heterogeneity in the objectives of the studies. Of the 
148 participants in the study by Devier et al. (2010), 39 (26%) converted to AD and the hazard of 
conversion increased with age; in the < 60 year old participants, 6% (2/35) converted, 15% (6/39) 
converted in the 60–67 year age group, 31% (11/36) converted in the 68-74 year group and 53% 
(20/38) converted to AD in the ≥75 years age group. MCI was required at baseline in this study, with 
memory complaints 6 months to 10 years prior to enrollment. The study began long before the MCI 
criteria definition by Petersen et al. (2004). Memory loss was observed on average at 38.5 months, 
depressed mood at 37.4 months, performance at 36.8 months, personality at 32.1 months, 
behaviour deficits at 31.1 months, language deficits at 29.2 months, disorientation at 29.1 months 
and psychosis at 14.0 months prior to enrollment in the study.  
The study by Fox et al. (1998) of autosomal dominant inherited AD pedigree, an EOAD, measured 
the time between the first initial assessments to first symptoms assessment. For the 10 converters 
in the study, the mean time (± SD) from initial assessment to first symptomatic assessment was 3.1 
± 1.5 years (range 1–5 years). The most common presentations were symptoms of very mild 
episodic memory. Two of the ten subjects already had deficits in verbal memory and were the first 
to be symptomatic, verbal memory deficit was observed 1–5 years during the symptomatic phase 
indicating early sensitivity than the semantic memory and cognitive changes 2–3 years before the 
symptomatic phase. Individuals fulfilled the criteria for probable AD 2–3 years later without the data 
for the timing to diagnosis provided. There was no difference observed between cases and non-
converters in terms of age, gender, handedness or MMSE at initial assessment and symptomatic 
assessment. 
Schmidt et al. (2010) conducted a post-mortem examination of rapidly progressive AD, a LOAD. The 
median disease duration was 26.4 months and the median age at clinical onset was 73 years. The 
time measurement was from clinical manifestation to disease fatal end point and the symptoms 
were presented as the median time to symptoms onset in months. The reviewer was unable to 
obtain a summary of the data from the onset of the symptoms to disease diagnosis.  
All the studies scored the recommended points to AD diagnosis (Table 4.2) and were carried out 
with standardised diagnostic criteria. The measurements of the thresholds were undertaken with 
the recommended measurement with diagnostic accuracy. 
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Table 4.2: Summary of findings 1. Overview of studies and population characteristics 
 
Populations/participants Participants met the inclusion criteria in four populations: 
1. general population (PAQUID STUDY), regardless of a perceived 
problem with memory 
2. participants that presented in the memory clinic with MCI 
3. familiar dominant inherited EOAD 
4. rapidly progressive LOAD 
Settings Community study but measurements were undertaken in the 
secondary care settings; secondary care settings 
Index tests  Clinical symptoms and signs of early stage of AD  
Reference Standard The National Institute of Neurological and Communicative Disease 
and Stroke-AD and Related Disorders Association (NINCDS-ADRDS) 
diagnostic criteria for AD, with the use of additional laboratory 
tests, CSF analysis and MRI. Post-mortem brain examination for the 
rapidly progressive AD 
Target condition All types of AD 
Included studies 4 studies (593 participants) 
Quality concerns All the studies were at low risk of bias and applicability of patient 
selection, reference standard, flow, and timing. However, one 
study was a high risk of bias in the index test and two studies in 
applicability 
Heterogeneity Considerable differences due to settings, participants, countries, 
index test and timing 
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INCLUDED STUDIES  
Author, year Amieva et al., 
2008 
Devier et al., 
2010 
Fox et al., 1998 Schmidt et al., 
2010 
Population and 
setting 
community 
setting in France 
memory clinic in 
the US 
secondary 
setting in the UK 
secondary 
setting in 
Germany 
Sample size 350 148 63 32 
Age (mean) 86.2 67.1 ± 9.9 44.7 ± 8.1 73 (median) 
Education 42% had no 
diploma, 40.6% 
with primary 
diploma, 17.4% 
with higher 
education 
15.1 ± 4.3 years not stated not stated 
Index test early signs and 
symptoms of AD 
early signs and 
symptoms of AD 
early symptoms 
of FAD 
symptoms 
reporting rapidly 
progressive AD 
to fatality stage 
Target condition AD dementia AD AD AD fatality 
Reference 
standard 
NINCDS-ADRDA NINCDS-ADRDA NINCDS-ADRDA Post-mortem 
examination 
Comparison 
group 
AD vs normal 
group 
a longitudinal 
follow-up with 
no control group 
longitudinal 
prospective case 
study with no 
control group 
AD vs rapidly 
progressive 
dementia 
 
4.13 Discussion 
4.13.1 Summary of findings 
The search to identify studies on the sequence and timing of AD at the early stage, how far back 
from diagnosis, symptoms and signs that will justify a diagnosis, yielded four studies with 
heterogeneous objectives and a total of 593 patients followed for conversion to AD. All studies 
assessed the timing of the signs and symptoms but with different time points. Only one study 
(Devier et al., 2010) had outcomes similar to those in this review. However, they only recruited MCI 
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patients without a control group and reported four domains (memory, personality changes, 
disorientation, behaviour) and four symptoms. The symptoms in the domains were not specified as 
there was no data provided. Due to the paucity of data and heterogeneity in all the studies, the 
researcher could only provide a description without a formal evaluation of the signs and symptoms 
nor factors such as follow-up time, sequence, threshold and types of AD. Furthermore, 
methodological differences and small sample sizes, only one study had 350 participants (Amieva et 
al., 2008), while the others (Devier et al., 2010; Fox et al., 1998; Scmidt et al., 2010) had 148, 63 and 
32 participants respectively, made statistical analysis impossible. 
Furthermore, there were few studies conducted on the review question. In a disease with high 
prevalence, high mortality and a high financial burden, all avenues should be explored to reduce the 
burden rather than channelling the energy in one direction. Research is needed to identify the 
timing and sequence from diagnosis, the first symptoms to justify a diagnosis, to complement the 
current diagnostic criteria. 
 
4.13.2 Strengths and weaknesses of the review 
One of the strengths of this review was its comprehensive search strategy and detailed protocol 
(appendices 12 and 16) to identify articles for review. In order not to overlook articles, the disease 
theatre was used as the main field, followed by the timing theatre, then basic theatres like the type 
of AD or onset, country of study and combinations before removing duplicates. Multiple databases 
were searched with a single-concept search without language restriction and reference list, as well 
as group registers to locate as broad a range of studies as possible. Studies were assessed 
methodologically with the QUADAS-2 tool and the process was overseen by the supervisors. 
Authors of original articles were contacted for more information regarding insufficient data. 
Furthermore, studies were assessed with the standard reference standard for the diagnosis of AD 
with the NINCDS-ADRDA and post-mortem examination, which is the gold standard. In this review, 
the NINCDS-ADRDA, the NIA-AA and the DSM tool were considered, as AD could be adequately 
diagnosed with these diagnostic tools. 
Regarding the signs and symptoms of AD, even though there were differences in timing, objectives 
and participants, the FAD study by Fox et al. (1998) identified a participant with a MMSE score of 
25/30, the lowest in the converters group that remained the same for two years, similar to family 
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members that remained well in this group. Furthermore, there was no difference between the 
converters and non-converters in terms of age, gender, handedness or MMSE at initial assessment. 
Memory disturbances remained the predominant predictor of early AD from normal ageing in all 
studies and verbal memory was more vulnerable than non-verbal in the EOFAD (Fox et al., 1998) as 
the memory test for words indicated significant differences in scores between 1–5 years before 
becoming symptomatic against the semantic memory vulnerability. 
Depressed symptoms appeared at the same time as cognitive symptoms and each of these was the 
first symptom to appear in some individuals with LOAD (Amieva et al., 2008; Devier et al., 2010). 
The rapidly progressive LOAD presented predominantly with myoclonus (75%), disturbed gait (66%) 
and rigidity; these were also early in presentation, even before apathy. This review is the first to 
identify the sequence and timing of the presentation of the early stage of AD; how far back from 
diagnosis the first symptom that will warrant a diagnosis. This is a period recognised as important 
for timely intervention, as the degenerative processes have not progressed to a severe cognitive 
and functional decline. 
The main limitation of this review is the dearth of data and heterogeneity in methodology and 
findings. Moreover, a pooled estimate was not possible with the differences in participants; 
sequence and timing, with fewer symptoms were reported in some studies. Several other potential 
sources of heterogeneity like the age of onset, gender and education could not be investigated with 
the paucity of data. Only one study (Amieva et al., 2008) reported the sequence and timing in line 
with the review question, with fewer symptoms than the review. Another limitation was the 
exclusion criteria. The researcher excluded studies on individual symptoms and signs, due to the aim 
of identifying sequence and timing, had these been included, the results may have been different. 
Studies on all types dementia were also excluded, which may have resulted in the paucity of data. 
Even though the researcher and the librarian independently identified articles at the title and 
abstract level without disagreement, the researcher reviewed the full articles independently. The 
identified full articles were then reviewed by my supervisor with an agreement on the four articles 
that were included. The review of full articles independently by the researcher might have 
introduced bias and could be a limitation; nonetheless, the search was undertaken rigorously with 
the librarian. 
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This review is useful to GPs, health policy makers and the public, especially if there was enough data 
to draw definite conclusions on the timing and sequence of the early presentations of AD, as the 
potential diagnostic value of the signs and symptoms are documented. 
4.13.3 Applicability of findings to the review question 
Based on the current diagnostic criteria, the absence and presence of two clinical features could aid 
the diagnosis of AD. There is also a distinction between the early and late presentations of the 
disease, but without a clear definition of the timing and sequence of these presentations. In 
addition, the presentation of these signs and symptoms varied according to the age of onset. 
Memory loss presents early and mostly in the LOAD (Amieva et al., 2008), while neurological and 
depressive behavioural presentations are an early occurrence in the EOAD (Devier et al., 2010). 
Another group of LOAD (rapidly progressive AD) presented early with myoclonus, rigidity, depressed 
mood and addition focal neurological symptoms consistent with CJD; the disease was diagnosed as 
CJD until the Schmidt et al. (2010) post-mortem study isolated AD as the cause of the presentations. 
The findings of this review may not be applicable to draw conclusions, as this is a single study with 
few subjects with bias in objectives. Further studies are required to identify the sequence and 
timing of the early signs and symptoms preceding the diagnosis to aid the early detection and 
subsequent diagnosis of AD. 
 
4.14 Conclusions 
4.14.1 Implications for practice 
There is a proposition of multiple definitions to capture the intermediate stage between ageing and 
mild cognitive changes, which is in line with the effort in diagnosing the disease early, by recognising 
the signs and symptoms as reliable predictive markers of the disease (Flicker et al., 1991; Stephan et 
al., 2010). There is currently insufficient published data on the sequence and timing of the early 
presentations to aid diagnosis of AD. The role of these presentations to aid diagnosis is not in 
dispute because they are incorporated in the current diagnostic criteria to indicate the possibility of 
the AD (Albert et al., 2011; Dubois et al., 2014). In this review, recommendations cannot be made 
on the sequence and timing of the early signs and symptoms of AD due to insufficient qualitative 
and quantitative data. The researcher is advocating for more research to identify the sequence and 
timing for the detection of the disease. 
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4.14.2 Implications for future research 
Due to the paucity of data in this area, further high quality and quantitative research are required to 
identify the sequence and timing of the early presentations to aid in the early detection of AD. Even 
though the information included in this research is insufficient, it is essential to note the differences 
and subsets in AD, as this information will help to confirm the particular type of AD based on the 
type of sequence and timing of the presentations. A detective model with the type, timing and 
sequence of the signs and symptoms preceding the clinical diagnosis of AD could be more useful to 
determine the therapeutic effect of interventions.  
 
4.15 Data 
All the data analysed in the tests (symptoms) used in this review are detailed in Table 4.3. It has 
been explained previously that all studies included in the review had different objectives to this 
review’s objectives except for one study. However, the majority of the symptoms and signs 
presented in this review are from a single study (Schmidt et al., 2010). The data presented from 
other studies were the cognitive, behavioural, personality and disorientation domains, without 
indicating the specific signs or symptoms of the domain. Other symptoms and signs of this review 
including olfactory disturbances, anosognosia, acalculia, alexia, anomia and irritability were not 
mentioned in all studies. 
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Table 4.3: Data for all the signs and symptoms in the study 
 
Test 
 
No of studies 
 
No of participants 
Memory loss  4 593 
Apathy 1 32 
Anxiety 1 32 
Depression 3 520 
Disinhibition 1 32 
Hallucination 2 32 
Weight loss 1 32 
Aberrant motor disturbance 1 32 
 
4.16 Differences between the protocol and review 
Initially, it was intended to review studies on the sequence and timing of presentation of the early 
signs and symptoms of AD to understand how far back from diagnosis the first symptom that will 
justify a diagnosis was reported. However, due to the paucity of studies of this kind, differences in 
study objectives, design and timing in the studies included, a comparison and meta-analysis were 
not possible, so a narrative review was undertaken instead. 
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CHAPTER FIVE: A retrospective medical record review study. 
5.1 Introduction The previous chapter systematically mapped the existing literature on the sequence and timing in early signs and symptoms of AD and paved the way for the retrospective record review in this chapter. The RMRRS   capture the patterns in the signs and symptoms as these were presented by the patients before the diagnosis of AD. Consequently, this the whole aim of identifying patterns in the presentations at the early stage of the disease. 
Substantial scientific discovery has been made about AD including the definition and manifestation 
of the phases of the disease (NIA-AA). The manifestation of AD includes the wide range of 
neuropsychiatric symptoms (NPS); the association of these symptoms and AD have widely been 
reported elsewhere (Jost et al., 1996; Cummings et al., 1998; Lyketsos et al., 2011; Zhao et al., 
2016). The type and association with the deficits in the structure of the brain mechanism have also 
been stated (Jeste et al., 2000; Rosenberg et al., 2015), hence their importance in discriminating AD 
from other diseases (Schmidt et al., 2010). However, there is no clear pattern of the timing and 
sequence of these signs and symptoms at the early stage that will support the early diagnosis of AD 
in the primary care. There is also very little evidence of what signs and symptoms occur at the 
preclinical stage, which needs clarification (Dubois et al., 2016). Until now, the evidence pertaining 
to the timing of these presentations is debatable.  
AD remains the highest cause of mortality and replaces ischaemic heart diseases as the number one 
cause of mortality. AD accounts for 11.6% of the registered death in 2015 (National Statistic, 2016) 
and part of its high associated morbidity can be accounted for because the disease is diagnosed late. 
Episodic memory loss, anxiety, olfactory disturbances, depressed mood, irritability and hallucination 
are all signs and symptoms seen in a variety of conditions including AD. The lack of a distinct and 
AD-specific pattern of signs and symptoms has resulted in late diagnosis and misdiagnosis of the 
disease leading to its’ confusion with other conditions. The current diagnostic criteria (Dubois et al., 
2015) emphasise the importance of the early signs and symptoms in aiding the correct diagnosis of 
AD. Results of several studies (Monto et al., 2000; Gordon et al., 2002; Zhang et al., 2014) have 
shown how important the pattern of signs and symptoms are in aiding the diagnosis of the disease. 
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Patterns in signs and symptoms have been used to develop predictive models in other diseases, 
enabling early detection and diagnosis of diseases (Ambrosy et al., 2013; Nijman et al., 2013; Van et 
al., 2013). Yet the studies on the early signs and symptoms of AD are limited in content and lack the 
ability to predict the early stage of AD, the stage at which clinical intervention would work best 
(Alzheimer’s Association, 2013; de Vugh & Verhey, 2013; Barnett et al., 2014). Given the rise in 
morbidity and mortality of AD and the devastating effect of worsening cognitive impairment, 
providing GPs with a predictive model for early detection could potentially improve the lives of 
patients and decrease the burden associated with late diagnosis of the disease.  
In this research, the focus is mainly on identifying the signs and symptoms and their patterns before 
the diagnosis of the disease, which will subsequently inform the suggestion of a predictive model. 
The model establishes the significant relationship and the strength of impact between the 
dependent variable (AD) and independent (s) (signs and symptoms). The predictive model assume 
the logistic regression model based on the fact that the dependent variable (AD) is binary 
(present/absent), takes the value of Y with a range of 0 to 1 and represented by the following 
equation: 
Odds= p/ (1-p) = probability of event occurrence / probability of event not occurrence 
In (odds) = ln (p/ (1-p)) 
Logit (p) = ln (p/ (1-p)) = b0+b1X1+b2X2+b3X3....+bkXk. 
P is the probability of the presence of AD. 
 
5.2 Purpose 
The study was undertaken to identify the patterns in signs and symptoms, as reported by patients 
ten years preceding the clinical diagnosis of AD.  
5.3 Methods 
5.3.1 Study participants, recruitment and logistics. 
This study is a retrospective pooled analysis of signs and symptoms that appear in patients notes in 
the ten year period preceding the clinical diagnosis of 109 adults patients (cases n=37 and control 
n=72). These patients were each diagnosed between the year 2006-2016 with LOAD (FOO.1*) in 
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three GP surgeries in Milton Keynes and Luton. These surgeries are integrated primary health care 
that served about 7,000- 30,000 patients. From these clinics, 109 patient records including 37 AD 
cases were selected and evaluated by the GPs with MMSE (a score of 4-29 was recorded) and 
subsequently diagnosed with AD in the memory clinics with the NINCDS-ARDRA diagnostic criteria, a 
validated diagnostic tool. Others included 72 controls, matched according to age (+ or – 1 year) and 
gender in the same GP surgeries without AD. 
To ensure concurrences and reliability, the files with the data collected were first reviewed and 
assessed by a professional in the GP surgeries before being handed over to the researcher. My 
supervisors subsequently assessed the data collected. The procedure for the study and anonymity 
of the records was approved by the NHS-REC, HRA, University of Bedfordshire and each GP surgery 
(Appendices 2, 3, 4). Even though there are conditions under which missing values can be ignored 
(Eff & Don, 2009; Stekhoven et al., 2012), which depend entirely on the relationship between the 
variable of interest missing and the available variable to help explain the missing value; in this study, 
which was missing completely at random was replaced by multiple imputations. The result of the 
logistic regression is provided for the original data and imputed data in Table 5.8. 
Tables 5.1 - 5.3 show the distribution of the cases and controls according to location, gender and 
ethnicity. The socioeconomic characteristics of the patients could not be established, as this 
information was not collected at baseline; 70.6% of the sample had no education or employment 
status, 8.3% were retirees and 21.1% were a mixture of professionals including consultant, 
pharmacist, engineers, nurses, carers and a dentist. The demography of participants was as follows: 
Luton had the highest prevalence of 77.1% and Milton Keynes 22.9% (Table 5.1). The ethnicity of 
participants indicated that majority of individuals were white (69%). However, the Asians, the 
Caribbean and the Middle Ease ethnic groups, were the least with 9% respectively. The 
demographic result of could be due to the fact that these towns are mainly Caucasians with a 
diverse ethnic minority. 
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Table 5.1 Demographic characteristics of participants. 
Frequency Cases Control Total % 
Milton Keynes 5 20 25 22.9 
Luton 32 52 84 77.1 
Total 37 72 109 100.0 
The frequency table indicates the number of samples in the two areas, with 77%  
of samples in Luton. 
 
Table 5.2 Gender characteristics of participants.  
Gender Cases (%) Control (%) Total (%) 
Male 
Female 
12 (32.4) 
25 (67.6) 
32 (44.4) 
40 (55.6) 
44 (40.4) 
65 (59.6) 
Total 37 (100) 72 (100) 109 (100) 
The majority (65) of the samples were females representing 59.6% of the total sample. 
 
 
5.3.2 Variables 
5.3.2a Signs and symptoms 
I initially set out to identify patterns in fourteen signs and symptoms previously identified as early 
presentations of the disease as described in chapter 2 (section 2.6.2) and to identify novel signs and 
symptoms not yet identified in the literature. These signs and symptoms were presented by the 
patients and confirmed by the GP during their consultations. A computation was made on the 
timing and sequence of the presentations, i.e. from the time of reporting to the official diagnosis of 
the disease. The analysis was undertaken on the frequency of four or more individual signs and 
symptoms. 
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Table 5.3 Ethnicity of participants 
Ethnicity Cases Control Total % 
White 25 44 69 63.3 
Mixed 11 14 25 22.9 
African 1 2 3 2.8 
Caribbean 0 1 1 .9 
Asian 0 1 1 .9 
Middle East 0 1 1 .9 
Undeclared 0 9 9 8.3 
Total 37 72 109 100.0 
The ethnicity table arranges the samples according to groups, with 63.3% among the white ethnic 
group, 22.9% mixed, 2.8% Africans, 9% Caribbean, Asian and the Middle East respectively. However, 
8.3% of the controls did not declare their ethnicity. 
 
5.3.2b Confounding factors 
The signs and symptoms might be influenced by other factors which might be associated with AD. 
The factors identified as confounders linked to AD include comorbidities, age and socio-economic 
factors such as poor diet, lack of education and physical activities (Katz et al., 1997; de Groot et al., 
2003). These factors were collected and comorbidities including hypertension, diabetes and other 
conditions were identified with the sample. The comorbidities were diagnosed separately from AD 
and met the standard measurement of ICED.  
5.3.2c Ethical consideration 
Ethics protocol was observed following the approval from NHS-REC, HRA, GP surgeries and the 
University (UREC), which stressed and ensured that non-identifiable data was collected and 
processed. The data protection Act of 1998 was observed, which ensured that the data was used for 
the academic purpose and destroyed immediately after the research was completed. Data was 
stored without passing it to anyone else, apart from the research team. 
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5.3.2d Data management 
I undertook the task of managing the data by collecting each variable into the data abstraction sheet 
and made sure the timing and sequence of presentation of the signs and symptoms were collected. I 
also specified the differences between classes of some symptoms such as episodic memory loss. 
These were undertaken to prepare the data for analysis. The data was collected with a validated 
case report form, a specialised document in clinical research and included the covariates used 
(gender, age at diagnosis, ethnicity, type of AD and education), comorbidity and medical history.  
5.3.3 Data analysis  
The main outcome measure was the patterns regarding the sequence and timing of signs and 
symptoms associated with AD, measured with the OR and associated 95% confidence intervals (CI). 
The researcher initially estimated the prevalence and distribution of these signs and symptoms in 
both groups (cases: patients with AD and controls: age and gender-matched individuals without AD) 
after the data was cleaned and variables checked for accuracy. The timing of presentations, up to 
ten years before diagnosis was established and followed by the sequence and timing of 
presentations in relation to the ultimate diagnosis of AD. This was followed by calculating the mean 
(x ̅“x-bar”) in timing in years between the reporting of the signs and symptoms and a diagnosis of 
AD, which is the average of set value in years of the presentations, calculated by adding the sum 
value in time and dividing by the number of the values or subjects. The data analysis was 
undertaken with SPSS and MedCalc software. The binary logistic regression was the standard of 
measurement, as it was the suitable measurement for my data with a dependent variable with two 
categories. This was against Poisson regression for counting and multinomial regression that could 
be used for dependent variables with more than two categories, to determine the OR in respect to 
the cases and controls. The OR and 95% CI determined the association of the signs and symptoms to 
AD, by coding 1 in association with cases, and 0 for the control respectably. The analysis was 
undertaken for gender, ethnicity and locality for all the samples, while reporting the OR and p 
values. However, the bivariate models analysis for the cases could not be established using the 
logistic regression, as the Hosmer and Lemeshow test indicated that the model was not a good fit 
(.032) for the small sample size in cases. The ideal score will be .05 and above in order to follow a 
chi square distribution with g-2 degrees of freedom (Hosmer Jr et al., 2013); a small p-value indicates 
a poor fit. The exact logistic regression would have been the perfect model; a valid analytical 
technique for a small, sparse, skewed or heavily tied data, which was unavailable for this analysis. 
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5.4 Results 
5.4.1 Descriptive analysis 
The overall prevalence of these symptoms and signs were higher in cases than control (Table 5.4), 
however, individually, there was heterogeneity in their prevalence. There was a higher prevalence 
of these symptoms among white women especially those between the ages of 70-75 and 80-85 
years (16.21% respectively). Episodic memory was the symptom with the highest prevalence in the 
entire sample (26.6%) and more frequent in the cases (75.6%) than controls (1.38%). This was 
followed by depression with 13.76% in the entire sample.   Symptoms that were identified in cases 
only included abdominal pain (8.1%), agoraphobia (2.7%), dehydration (2.7%), excessive sweating 
(2.7%), hallucinations (8.1%), poor appetite (2.7%) and tiredness (5.4%). The Chi-square test also 
written as χ2 test, which differentiates between the expected frequencies and observed frequencies in one or more independent variables, was inappropriate for my study as the 
frequencies in some signs and symptoms were less than 1. More than 20% of the frequencies in these signs and symptoms are less than 5, hence the Fisher’s Exact test (Pr <= P) was undertaken. The test was insignificant for all variables, i.e., the null hypothesis that there is no relationship between these variables and AD could be accepted, except episodic memory with a p-value of 0.00% (Table 5.4) 
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Table 5.4 Prevalence (%) of the signs and symptoms in cases and control 
Signs and symptoms Total 
N 
% Cases 
N 
% Controls 
N 
% Pr <=P 
 
Abdominal pains 3 2.75 3 8.10 0 0  
Agoraphobia 1 0.91 1 2.70 0 0  
Anxiety 5 4.58 2 5.40 3 4.16 .24 
Auditory disturbances 14 12.84 8 21.6 6 8.33 .21 
Backache 7 6.42 4 10.8 3 4.16 .17 
Constipation 4 3.66 2 5.40 2 2.77 .41 
Dehydration 1 0.91 1 2.70 0 0  
Depressed mood 15 13.7 7 18.9 8 11.1 .16 
Dizziness 3 2.75 1 2.70 2 2.77 .71 
Drowsiness 2 1.83 1 2.70 1 1.38 .71 
Episodic memory loss 29 26.6 28 75.6 1 1.38 .00 
Excessive sweating 1 0.91 1 2.70 0 0  
Flatulence 2 1.83 1 2.70 1 1.38 .71 
Hallucinations 3 2.75 3 8.10 0 0  
Headache 5 4.58 3 8.10 2 2.77 .21 
Indigestion 4 3.66 2 5.40 2 2.77 .21 
Irritability 2 1.83 1 2.70 1 1.38 .56 
Leg cramps 1 0.91 1 2.70 0 0  
Olfactory disturbances 1 0.91 0 0 1 1.38  
Poor appetite 1 0.91 1 2.70 0 0  
Tiredness 2 1.83 2 5.40 0 0  
Visual disturbances 1 0.91 1 2.70 0 0  
Weight loss 4 3.66 2 5.40 2 2.77 .11 
N = number; χ2= Fisher’s Exact test. 
 
Among the previously identified signs and symptoms of AD, only anxiety, depression, episodic 
memory loss, hallucinations, irritability and weight loss were identified in the study, out of which 
irritability was only identified in one sample of the control group. Other signs and symptoms 
identified with considerable frequency included backache, headache, constipation and indigestion. 
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However, agoraphobia, dehydration, dizziness, drowsiness, excessive sweating, flatulence, poor 
appetite and leg cramp were identified in single measures respectively. Out of the symptoms 
identified in the cases, episodic memory was presented as the first symptom in 16 (43.2%) of the 37 
cases, auditory disorders in eight (21.6%), depression in five (13.5%) and headache in one (2.7%). 
5.5 Individual symptoms and signs in cases 
The mean in the timing of the signs and symptoms as reported in cases is shown in Table 5.5. The 
table shows the means in years of the symptoms. Headache had the highest mean in cases 
(mean=26.8%) and was presented 68 years before diagnosis, followed by depression presented 60 
years before diagnosis (16.4%) and was not associated with medication or comorbidity. However, 
the symptom was presented in the control group 56 years before the pseudo-diagnosis with a high 
prevalence (53.3%) in this group than the cases (46.3%). 
Auditory disturbance that has not been fully identified with AD was the third symptom sequentially 
presented 30 years (mean=14.5%) before the diagnosis of AD with a prevalence of 21.6% in this 
group. Backache followed with a means of 9.2% and a prevalence of 10.5%.  
 
 
Table 5.5 Means of signs and symptoms in years before diagnosis in cases and controls 
Symptom Mean in years 
(SD) cases 
Mean in years (SD) 
controls 
p-value 
Anxiety 1      (0) 17.3 (15.5) 0.70 
Auditory 
disturbance 
14.5 (8.94) 4.8   (3.1) 0.05 
Backache 9.25 (10.7) 6      (2.6) 0.19 
Depression 16.4 (21.1) 12.5  (17.8) 0.20 
Episodic 
memory 
3.48  (3.42) 11     (4.3) 0.0001 
Headache 26.8 (36.1) 5.5    (4.9) 0.20 
Weight loss 0.5   (0.14) 3       (2.82) 0.0001 
 SD: standard deviation. 
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When analysing for the correlation (r) of the signs and symptoms, represented in a correlation 
matrix; the univariate analysis (Table 5.6) indicates a positive correlation at < 1% significant level 
between episodic memory and AD (0.475**). For auditory disturbance, there was a positive 
correlation with AD (0.587**) and episodic memory (p=0.586*); which means that individuals with 
auditory disturbances are likely to have episodic memory loss and AD. There was also a positive 
correlation but a weak one between the female gender and AD (.116**) at the two-tailed level. 
 
 
Table 5.6. Correlations Matrix of variants. 
 Group Gender Epi. Mem. Loss Audi. Dist. 
GROUP Pearson Correlation 1 .116** .475** .587** 
Sig. (2-tailed)  .003 .000 .000 
N 109 109 109 109 
GENDER Pearson Correlation .116** 1  .017 -.007 
Sig. (2-tailed) .003  .658 .949 
N 109 109 109 109 
EPISODIC_MEMORY_LOS
S_YEARS 
Pearson Correlation .475** .017 1 .586** 
Sig. (2-tailed) .000 .658  .000 
N 109 109 109 109 
AUDITORY_DISTURBANC
E 
Pearson Correlation .587** -.007 .586** 1 
Sig. (2-tailed) .000 .949 .000  
N 109 109 109 109 
**. Correlation is significant at the 0.01 level (2-tailed). 
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Episodic memory, which is the chief symptom linked with AD especially the late onset, was 
presented six years before diagnosis with a means of 3.4% and had the highest prevalence in this 
group. Hallucination was next and presented three years (mean = 1.8%) before the diagnosis of AD. 
Constipation and tiredness were presented five years respectively before diagnosis. However, 
tiredness was not associated with the control group. 46.4% of the prevalence of episodic memory 
was among the white females and 17.8% for white males (Table 5.7). The table further indicates 
that individuals with auditory disturbances, a symptom that has not been reported in AD, have 
threefold (3.03) increased odds for associating with AD, with a p-value of ≤ 0.050. Other signs and 
symptoms with increased odds but not significant are abdominal pain and hallucination, with p 
values of ≤ 0.07 respectively. The table also shows that individuals with backache had 88%, 
headache 58% and depression 19% increased odds of association with AD, however, with p values > 
than 0.1. 
 
Table 5.7 Odds ratio of symptoms reported by cases and control 
Variable Odds Ratio 95% CI 
Anxiety 1.31 0.20 - 8.20 
Auditory Disturbance 3.03 0.96 - 9.53 
Backache 2.70 0.58 - 1.31 
Depression 1.01 0.96 – 1.07 
Episodic memory 2.77 1.52 – 5.02 
Headache 3.08 0.49 - 14.4 
Weight Loss 1.31 0.20 - 8.20 
Ethnicity  1.18 0.56 - 4.20 
Gender 1.15 0.44 - 3.01 
The 95% CI indicates the lower and upper limit. 
 
Ethnicity and gender have an influence on the outcome of cases (Table 5.7). The Wald statistics and 
the all-important OR Exp (B), shows that the variables ethnicity and gender were not very significant 
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and positive in the overall effect. However, when controlling for gender, the OR indicates that the 
female gender has 61.8% increased odds more likely to be associated with AD compared with men 
(full report in Appendix XVII). Similarly, the OR shows that the mixed ethnic group had more than 
two-fold (0R = 2.1) increased odds of developing AD, followed by Caucasians with a 93%, increased 
odds. Even though the Wald statistic was significant for Luton locality, the OR was not significant 
and could be excused due to the limited samples. However, for the other ethnic groups, the result 
was insignificant. 
The majority of the signs and symptoms were diagnosed at age 70-80 in both the cases and controls, 
followed by those within 80-90 years. For the original data, Table 5.8 indicates that individuals with 
episodic memory loss had more than two fold (OR = 2.77) increased odds for developing the disease 
as indicated by the high prevalence in cases than controls (28 to 1). The table indicates the 
significance of gender for episodic memory loss and auditory disturbances; however, the CI was less 
than 1 for gender and auditory disturbance. When considering the sequence of the appearance of 
the signs and symptoms in years prior to diagnosis of AD, it was found that headache was the first 
symptom to be reported 68 years before diagnosis. This was reported as early as 14 years into the 
life of the patient. In comparison to the control group, however, the symptom was presented 11 
years before the pseudo (non-AD conditions) diagnosis. The symptom was followed by depression 
at 60 years, auditory disturbance 30 years, backache 25 years, hallucination 15 years and episodic 
memory six years before diagnosis (Table 5.9).   
The result of the imputed data was considerably the same as the original data for episodic memory; 
while the p-value remained p<0.001, the CI was slightly different for gender and ethnicity (Table 
5.7). When adjusted for gender and ethnicity, there was more than two fold increase in the odds for 
episodic memory. For auditory disturbance, however, the result was similar when adjusted for 
gender and almost the same for the crude model and the model adjusted for gender and ethnicity. 
For depression, the results were insignificant. The slight difference in the odds ratio results of 
episodic memory loss in the current and imputed data could be due to the fact that the symptom 
was presented in only one individual in the control group; the results are still significant. Generally, 
there were few differences across the imputed results. 
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Table 5.8: Adjusted odds ratio for gender and ethnicity. 
Original data 
Variable 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Audi. disturbance 3.03*** (0.96-9.53) 2.12*** (0.90-5.03) 1.71*** (0.76-3.86) 
Depression 1.01*** (0.96-1.07) 1.02*** (0.96-1.09) 1.07*** (0.95-1.07) 
Episodic memory 2.77*** (1.52-5.02) 2.71 ***(1.48-4.96) 2.54*** (1.41-4.57) 
Imputed data    
Audi. disturbance 1.68***(1.24-2.28) 2.12***(0.90-5.03) 2.11*** (0.90-4.98) 
Depression 1.01***(0.96-1.07) 1.02***(0.96-1.09) 1.01*** (0.9.5-1.07) 
Episodic memory 2.77***(1.52-5.02) 2.71***(2.07-3.55) 2.70***(1.47-4.94) 
Model 1: crude: model 2 adjusted for gender; and model 3 adjusted for gender and ethnicity*. The crude model 
considers how individual symptom/sign is associated with AD affects the outcome measure while ignoring other 
variables; model 2 adjusts to incorporate gender, while model 3 incorporates ethnicity as a covariate. **Significant 
difference at p<0.01.*Significant difference at p<0.05 
 
Table 5.9 Timing of signs and symptoms in patient notes prior to a diagnosis of AD 
Symptom/sign Cases 
Mean in Years 
(SD) 
Controls 
Mean in 
Years 
(SD) 
Mean 
Difference 
95% 
Confidence 
Interval (CI) 
Headache 26.8 (37.2) 5.5 (4.94) -21.3 -32.5 to -
10.0 
Depression 16.4 (21.1) 12.5 (17.8) -3.90 -25.5 to 17.7 
Auditory disturbance 14.5 (8.94) 4.83 (3.18) -9.67 -18.8 to -
1.28 
Backache 9.25 (10.7) 6.00 (2.64) -3.25 -19.9 to 13.4 
Episodic memory loss 6  (3.48) 0 0 0 
The table shows that headache was reported with a mean age of 26.8 years before diagnosis. Only 
one person reported the symptom of episodic memory in the control group. 
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When I considered episodic memory and gender, I found that 62% of those cases in which episodic 
memory loss was recorded was in the female gender (Table 5.10), with an overall prevalence of 26.6 
in the whole sample (Table 5.4). Only about 3.4% of the prevalence of the symptom was recorded in 
the control group. The 34 males representing 31.1% of the total sample and 46 females (42.2%) 
were symptom-free. 
The distribution of auditory disturbances in the sample was found to be 85.7% in the female, with 
75% in the cases, indicating a female predilection for developing the disease (Table 5.11; see Table 
5.4 for the prevalence). 
 
Table 5.10 Distribution in years of the reporting of episodic memory loss and its association 
with gender. 
 GENDER Prevalence---Years before the diagnosis of episodic 
memory loss 
Total 
Sample  N (%) 0.5 5-10 10 & Above 
Cases Male 3 (2.7) 7 (6.4) 3 (2.7) 0 (0) 13 (11.9) 
 Female 6 (5.5) 13 (11.9) 5 (4.6) 0 (0) 24 (22.0) 
Control Male 30 (27.5) 0 (0) 0 (0) 1 (0.9) 31 (28.4) 
 Female 41 (37.6) 0 (0) 0 (0) 0 (0) 41 (37.6) 
 Total 80 (73.3) 20 (18.3) 8 (7.3) 1 (0.9) 109 (100) 
 
N: number 
 
 
Table 5.11 Distribution in years of the reporting of auditory disturbance and its association with 
gender 
 GENDER Prevalence---Years before the diagnosis of auditory disturbances  Total 
Sample  N (%)  0.5 5-10 10 & Above 
Cases Male 11 (10.1)  0 (0) 0 (0) 1  (0.9) 12 (11) 
 Female 18 (16.5) 1 (0.9) 3 (2.7) 3  (2.7) 25 (23)  
Control Male 31 (28.4) 0 (0) 1 (0.9) 0 (0) 32 (29) 
 Female  35 (32.1) 3 (2.7) 2 (1.8) 0 (0) 40 (37) 
 Total 95 (87) 4 (3.7) 6 (5.6) 4 (3.7) 109 (100) 
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Of the 29 samples with the symptom of episodic memory loss, 75.8% were Caucasians and 75% in 
cases (Table 5.12). However, this symptom was not recorded in the Asians or the Caribbean, with 
only 3.4% being noted in the African community. This indicates that the Caucasian ethnic group with 
the symptom were three times more likely to be diagnosed with AD than any other ethnic groups. 
 
 
Table 5.12 Episodic memory and ethnicity in cases and controls Ethnicity Years (%) Cases N (%) 0-5 5-10 10 & Above Total White 4 (3.7) 15 (13.7) 6 (5.5) - 25 (22.9) Mixed 5 (4.5) 5 (4.5) - 1  (0.9) 11 (10.1) African - 1 (0.9) - - 1  (0.9) Control= White 43 (39.4) - - 1 (0.9) 44 (40.3) Mixed 14 (12.8) - - - 14 (12.8) African 2 (1.8) - - - 2 (1.8) Caribbean 1 (0.9) - - - 1 (0.9) Asian 1 (0.9) - - - 1 (0.9) Middle East 1 (0.9 - - - 1 (0.9) Undeclared 9 (8.3) - - - 9 (8.3) Total 80 (73) 21 (19.2) 6 (5.5) 2 (1.8) 109 (100) 
Data is the number of sample that presented with episodic memory years before diagnosis (percentage of population). 
 
 
Out of the 14 samples with the auditory disturbances, 57.1% were Caucasians, followed by a 35.7% 
for the mixed race (Table 5.13). However, the symptom was not recorded in the African, Asian or 
the Caribbean ethnic group. This shows that the white female ethnic group with auditory 
disturbance were twice likely to be diagnosed with AD than any other ethnic group. While the 
Africans, Asians and Caribbean were less likely to be diagnosed with AD despite having the 
symptom. 
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The Hosmer and Lemeshow Test suggested that the binary logistic regression was a good fit to the 
data with a p-value of 0.684 (>0.05), and could correctly classify the outcome of the cases in 68.6% 
of the time, indicating an improvement over the null model (Appendix XVII). The result indicates 
that the logistic regression is reliable and valid for this data, with a higher rate of correctly 
classifying the outcome. 
 
Table 5.13 Auditory symptom and ethnicity of cases and control. Ethnicity Years (%) Cases No 0-5 5-10 10 & above Total White 19(17.4) - 3 (2.7) 3 (2.7) 25 (22.9) Mixed 9 (8.3) - 1 (0.9) 1 (0.9) 11 (10.0) African 1 (0.9) - - - 1 (0.9) Control: White 41(37.6) 1 (0.9) 2 (1.8) - 44 (40.4) Mixed 11 (10.0) 1 (0.9) 2 (1.8) - 14 (12.8) African 2 (1.8) - - - 2 (1.8) Caribbean 1 (0.9) - - - 1 (0.9) Asian 1 (0.9) - - - 1 (0.9) Middle East 1 (0.9) - - - 1 (0.9) Undeclared 9 (8.3) - - - 9 (8.3) Total 95 (87.1) 2 (1.8) 8 (7.3) 4 (3.7) 109 (100) 
Data is the number of sample that presented with episodic memory years before diagnosis (percentage of population). 
 
 
5.6 Comorbidities 
Concomitants health conditions have been associated with AD, which can act as confounders or 
effect modifiers. In this study, multiple comorbid conditions were isolated with AD including 
hypertension with the highest prevalence and tremor with the least. The number of comorbidities 
per individual was between zero and nine (Table 5.14). 14 cases had one comorbid condition each, 
while the controls had 0-4, with seven controls having one each.  
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Table 5.14 Comorbidities identified in cases and controls  
N of  individuals N of comorbidities N of individuals N of comorbidities 
Cases Cases Control Control 
1 9 0 9 
4 4 3 4 
7 3 8 3 
6 2 7 2 
14 1 7 1 
5 0 47 0 
Total=37 Mean= 3.8 (3.1 SD) Total=72 Mean=2.5 (1.2 SD) 
  
 
The most frequently reported comorbid condition was hypertension, reported by 20 cases (40.5%), 
chronic kidney disease followed with 10.8%, high cholesterolemia and ischaemic heart attack with 
8.1% respectively (Table 5.15). Asthma, depression, biventricular heart disease and sciatica were 
reported by 5.4% of cases respectively, while others including osteoarthritis, gastritis, adnexia, 
tinnitus, paresthesia, gallstones, hyperthermia, ocular hypertension, cataract, cardiovascular 
accident, asthma, bilateral fine drusen, cerebral atrophy, diverticular disease and hypothyroidism 
were reported in one individual respectively. The frequently reported comorbidities had a mean of 
3.8 (3.1 SD). 
137 
 
Table 5.15 Numbers of comorbidities per individuals in cases and control 
 
 
Comorbidity Number of cases (%) Number of control (%) 
Hypertension/Essential 15/5   (40.5) 9 (12.5) 
Chronic kidney disease 4      (10.8) 1 (1.38) 
High cholesterolemia 3        (8.1) 0 
Ischaemic heart disease/ attack (TIA) 3       (8.1)    2 (2.8) 
Asthma    2           (5.4) 3 (4.2) 
Depression 2               “ 1 (1.38) 
Osteoarthritis 2                 “ 6 (8.3) 
Biventricular heart failure 2                 “ 1 (1.38) 
Sciatica 2                 “ 0 
Adnexa   1               (2.7) 0 
Atrial fibrillation 1                 “ 1 (1.38) 
Bilateral fine drusen 1                  “ 0 
Cardiovascular disease 1                  “ 2 (2.8) 
Cataract 1                  “ 1 (1.38) 
Cerebral atrophy 1                  “ 0 
Diabetes mellitus 1                  “ 7 (9.7) 
Diverticular disease 1                 “ 2 (2.8) 
Gallstones 1                 “ 0 
Gastritis 1                 “ 0 
Hyperthermia 1                 “ 0 
Hypothyroidism 1                 “ 3 (4.2) 
Macular degeneration 1                 “ 0 
Ocular hypertension 1                 “ 0 
Paraesthesia 1                 “ 1 (1.38) 
Tinnitus 1                 “ 1  “ 
Tremor 1                “ 0 
Chronic obstructive pulmonary 
disease (COPD) 
             0 8 (11.1) 
Otitis external              0 2 (2.8) 
Lacunar infarction             0 1 (1.38) 
Total number of Comorbidities 
reported 
          26 29 
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5.7 Discussion 
This study explored the possibility of identifying patterns in signs and symptoms preceding the 
clinical diagnosis of AD. The researcher discovered that individuals with AD have higher odds of 
auditory disturbances. This finding to my knowledge is novel and cannot be compared with other 
studies, as this is the first study that has reported auditory disturbance apart from auditory 
hallucination, which is considered to be frequent psychotic symptom of AD (El Haj et al., 2017). 
There could be biological plausibility that could be investigated with a large sample, as the result is a 
borderline significance due to small sample size. 
The three most distant presentations included headache, which was presented more than two 
decades before diagnosis, followed by depression and auditory disturbances before episodic 
memory loss. Weight loss, however, presented less than a year before diagnosis, closely tailed by 
anxiety and hallucinations. Opining and supporting literature stating that these presentations are 
late mechanisms and indicate the progression of the disease (Soto et al., 2012; Besser et al., 2014; El 
Haj et al., 2017). The result is contrary to literature stating that anxiety is an early presentation 
(Casselli et al., 2013; Li et al., 2014) and could be due to the small sample size. A bigger sample with 
these signs and symptoms in combination could help predict accurately the onset of AD. 
The symptoms and signs associated with AD were more striking in the white population than other 
ethnic group, supporting findings from previous study that AD is highly prevalence in the Caucasians 
than other ethnic groups (Farrer et al., 1997) and contrary to more recent research indicating a 
higher prevalence in the African Americans and the Asian groups (Whitmer et al., 2014). However, 
the prevalence in this research could be due to the high population of whites in the areas and 
chance, as it might be difficult for an ethnic minority to go for check-up regarding memory issues 
than their white counterparts, especially as the interviews indicate issues of language barriers and 
translation issues, which could confound the diagnosis. 
Furthermore, the study indicates that the female gender had a higher prevalence of the signs and 
symptoms in AD than their male counterpart with increased odds of having episodic memory and 
auditory disturbance respectively.  The female gender has been associated with the risk factor gene 
for AD A POE-E4 allele (Payami et al., 1996) with two of the most prominent non-modifiable risk 
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factors for AD identified as the female gender. However, episodic memory has only been associated 
with the female gender in measures and type, not the prevalence, even though the symptom 
correlates with high levels of amyloid deposition (Mortamais et al., 2016).  
Excessive sweating, dehydration, poor appetite, abdominal pains, weight loss and constipation were 
all identified with AD. However, even though weight loss has been identified as an early sign and 
significant in this research (p-value <0.0001), the gastrointestinal symptoms have been associated 
with adverse effects of AD medications (Matsunaga et al., 2015; Wischik et al., 2015; Zhao et al., 
2016) only, especially the clinical effects of memantine monotherapy.  Dehydration and excessive 
sweating could be risk factors rather than signs; this is because AD is associated with dietary 
deficiency including water even at the mild to moderate stage of the disease (Buffa et al., 2010). 
Depression was also associated with AD, which is consistent with Rosenberg et al. (2015) study, 
indicating the symptom as an AD mechanism. However, depression could be a reverse causality, as 
individuals reported the symptom as early as 60 years before diagnosis in this study, which could 
indicate the presence of depression with AD as a resulting factor. 
Irritability was not identified with the cases in this study, which also supports other findings (Zhao et 
al., 2016) indicating that it is a less prevalence mechanism in AD.  This is because the sign is related 
to functional connectivity alterations in the salience network (Balthazar et al., 2014); without the 
connectivity alterations, the sign could be a rare mechanism in AD. 
Among the comorbidities associated with AD in this study, hypertension had the highest prevalence 
and supports other studies indicating that the symptom is one of the predominant comorbid 
condition associated with AD (Poblador-Plou et al., 2014). In a Spanish study of 72,815 patients over 
64, hypertension had the highest prevalence of a comorbid condition with 38.6 for men and 44.9 for 
women (Poblador-plou et al., 2014). However, literature (Kruyer et al., 2015) suggests that it could 
be a modifiable risk factor rather than a comorbid factor, as hypertension accelerated cognitive 
deficits, microvascular deposits of β amyloid, vascular inflammation, and blood-brain barrier leakage 
and pericycle loss in mice and humans (Snyder et al., 2015). 
High cholesterolemia was also identified as comorbidity. Even though the Framingham study (Tan et 
al., 2003) showed that the condition is not a risk factor for developing AD, others have identified it 
as a causative factor (Papolla et al., 2003). However, this is still debatable (Wood et al., 2014) due to 
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the blood-brain barrier mechanism that restricts the entry of blood-derived products into the brain 
including cholesterol. 
The limitation of this study includes a sample size that will not allow the generalisation of the signs 
and symptoms preceding the clinical diagnosis of AD, even though sufficient data was obtained for a 
statistical analysis. The small sample size is not sufficiently representative of adults followed-up in 
primary care nor the overall adult population of Luton and Milton Keynes. Conversely, the controls 
were specifically selected and comorbidities and symptoms presented are similar to what is known 
of this population.  
5.8 Conclusion  
The research demonstrates that auditory disturbance, which was more striking in the Caucasian 
female gender, could predict the diagnosis of AD. While further research is advocated in a large 
scale, as the sample in this research is insufficient to initiate subgroup analysis, the result supports 
future plans to improve the early diagnosis of AD. The symptom could support the specific 
prediction of AD. There was no recall bias, as data collected was written at the point of collection. 
Other symptoms identified with cases including headache and backache and depression, had higher 
odds of identifying individuals with AD, but with insignificant p-values in discriminating these 
individuals. While depression has previously been associated with AD, headache and backache were 
associated only as side effects of medications and a baseline that may vary with comorbidities and 
geographical location. Similar studies in large scale could indicate if the symptoms are associated 
with the disease. The success of the study could not be assessed as confusion remains around 
whether a symptom arises from another condition and can still present in the same manner, as 
there was no data to indicate previous patterns of the signs and symptoms preceding the clinical 
diagnosis of AD. 
The study acknowledges that GPs have the potential to improve the diagnosis. Thus, such potential 
was considered in the context of available evidence through a semi-structured interview carried out 
in the next chapter; even though the GPs are not determinative of the cause of the delayed 
diagnosis, they will help guide the outcome of the studies.  
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CHAPTER SIX: General practitioners’ perspectives of the early signs and symptoms of AD: 
A Qualitative interview 
6.1 Introduction 
Chapter 5 described the quantitative phase of my research. It is an innovative work as it identifies a 
symptom that could potentially help discriminate individuals with AD early. However, the low 
prevalence of AD led to a small sample population in these areas and will thus not allow for 
generalisation. 
This chapter presents the findings from the qualitative interviews of GPs in Milton Keynes and Luton 
CCGs; to achieve objective 3 of this thesis, which is to explore the perspectives of the GPs regarding 
the early signs and symptoms of AD, issues of late diagnosis and recommendation to circumvent 
factors that delay an early diagnosis of the disease. These findings are part of a mixed method 
research with the data obtained from the systematic scoping review and RMRRS described in 
chapters 4 & 5 respectively, for the identification of patterns in signs and symptoms preceding the 
clinical diagnosis of AD. 
Participants in this qualitative phase of the study included GPs (n=4) from Milton Keynes (three 
males and one female) and Luton (three females) general practices. Eligibility was based on their 
professional duties as GPs, including (predominantly) experience in the diagnosis and management 
of AD patients in primary care within the last ten years. There was no distinction between the ages 
of male or female participants, as the experience of managing AD individuals was the main inclusion 
criterion (Figures 6.1 & 6.2). The sampling technique was purposeful sampling, which was 
undertaken in light of the GPs experience and consent to be involved with the research. An 
extensive process of recruitment was followed painstakingly, which included emails to all the GPs 
and practice managers, personal recruitment, i.e. personally going to the GP practices to speak with 
individual GPs or their managers and recruitment through colleagues or medical pair recruitment 
that yielded few responses. The emails to the 27 GP surgeries yielded only one response, personal 
recruitment yielded four responses, while the medical pair yielded an additional two responses; this 
is further explained below. Had there been a substantial number of positive responses, I would have 
used the quota sampling to include some subgroups like gender and locality.  
Favourable research ethics opinion was received from the Office of the Research Ethics Committee, 
North of Scotland and the Institute for Health Research Ethics Committee in the University of 
Bedfordshire. The protocol for the study, study materials and interview guide were all approved by 
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both the aforementioned ethics committees (Appendix I, II, III, IV and Table 6.1). Informed consent 
was sought from all participants before commencing the interviews.  
The interviews, which were performed face-to-face, were semi-structured and conducted using the 
interview guide (Appendix VI) as an overarching framework that explored the commonalities of 
experience to allow the flexible exploration of the GPs perspectives on AD. The interview guide and 
questions were developed after reviewing the relevant literature (HSCIS, 2014; NHS, 2014; Jones et 
al., 2015) and after consulting with my academic supervisors. The questions were based on the need 
to identify patterns in the signs and symptoms preceding the clinical diagnosis of AD, issues 
surrounding the late diagnosis and recommendations to early detection of the disease; this was 
undertaken to allow the flexible exploration of GPs perspectives regarding the early diagnosis of the 
disease. The interview guide was piloted with three GPs prior to data collection to assess its 
practicability, comprehensiveness and acceptability. The questionnaires were returned with positive 
comments without the request for alteration (Appendix XX) and identified the same themes that 
were identified in the general interviews; hence, I proceeded for the general interviews.  
The questionnaire covered the early signs and symptoms (Q3), issues with the late diagnosis of AD 
(Q4), benefits of early intervention (Q5) and recommendations against factors that delay early 
detection of the disease (Table 6.1). Interviews were undertaken in the GPs workplace and began 
with a brief introduction of the study, a description of its aim and objectives, ethics approval and 
the process of the interview (Appendix VIII). Participants signed the informed consent form 
(Appendix V) and recruitment continued until a point of thematic saturation was reached, which 
could be achieved with as little as six interviews (Guest et al., 2006), depending on the individual 
study topic and the depth of collected data. I initially planned to interview 16 GPS. I sent emails to 
24 general practices introducing the research and requesting for their participation, visited 18 
practices once (two practices kept making promises and were visited four times, five practices three 
times) and made frequent calls to the GP practices in MK. My supervisors and I then visited the CCG 
contact to solicit her support for the recruitment as a gatekeeper. The CCG contact sent emails to all 
the GPs in MK which did not result in further recruitment. However, after a series of personal visits, 
the researcher was able to recruit five GPs through the consent of the surgeries managers’ and only 
one could not be interviewed as his manager declined his participation. For Luton CCG, the research 
was advertised in the GP bulletin. However, none of these yielded any engagement, except for the 
medical pair recruitment (recruitment through colleagues) that yielded three more interviews.  
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Figure 6.1: Participant age: Indicating the highest number of GPs within the 50-60 age groups. 
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Table 6.1: Interview guide: Questions structured around six themes. 
 
LATE DIAGNOSIS OF ALZHEIMER’S DISEASE: RECOMMENDATION TO 
OVERCOME BARRIERS IN THE UK. 
SEMI-STRUCTURED INTERVIEW GUIDE, FOR GENERAL PRACTITIONERS (GP) IN 
MILTON KEYNES. 
Previous research indicates that the late diagnosis of Alzheimer’s disease (AD) is 
a major challenge to public health.  One in four individuals in the U.K. has 
received an official AD diagnosis. It sometimes takes two to three years from the 
symptoms presentation of the disease before a diagnosis is confirmed (HSCIS, 
2014). Late diagnosis can result in accelerating the progression of the disease to 
a state of cognitive and functional decline, leading to extended hospital stays, an 
increase in health care costs and subsequent mortality. There is also a burden on 
the caregivers and a financial impact on health and social care institutions.   
This interview guide was developed after the review of the relevant literature 
and consultations with my supervisors. This is a semi-structured interview guide, 
structured around six themes namely: 
             1. INTRODUCTION/ DEMOGRAPHIC QUESTIONS 
 How long have you been practicing as a medical practitioner? 
 How long have you been a partner/associate in this practice? 
 Can I ask how old you are? (A) 28-38, (B) 38-48 (C) 48-58 (D) 58+ 
 
Specific Questions 
2. EARLY SIGNS AND SYMPTOMS OF AD 
 What are the signs and symptoms you notice in patients before their official 
diagnosis with AD?  
 How long before the diagnosis do you start to notice these signs? 
 Which sign or symptom appears first among those you have mentioned? 
 Have these signs and symptoms subsequently aided with the diagnosis?  
 
3. DIAGNOSTIC CRITERIA 
 What are your GP surgery diagnostic criteria for AD? 
 
4. LATE DIAGNOSIS OF AD 
 Are there issues that delay an earlier diagnosis of AD? 
 What are the issues you have observed with the late diagnosis? 
Follow –up 
You mentioned _______do you mean? 
Could you expand on that, please? 
5. BENEFITS OF EARLY DIAGNOSIS OF AD 
 Let's talk about the early diagnosis, how do you feel about early detection and 
diagnosis of AD? 
 Could you please explain that further? 
145 
 
 Are there benefits or challenges with the early diagnosis? 
 Can you elaborate more on the challenges of the early diagnosis? 
 How has this impacted on your practice? 
 You mentioned the benefits to the patient, carers, and society; can you elaborate 
and be specific on this, please? 
    6.  DIAGNOSING AD IN GP PRACTICES 
 
 How easy is it to diagnose an individual with AD in practice? 
 Are there specific challenges to diagnosing AD in your practice? 
 Are there specific challenges for you as a GP? 
 On a scale of 1-10, how would you assess the diagnosis of AD in terms of the 
early signs and symptoms in your practice? 
 
Indirect Questions 
 Have you discussed this issue of late diagnosis of AD with your colleagues? How 
do they feel about it? 
Probes 
 Do you mean that? 
  Is it correct to say that you____? 
Follow up questions  
 Could you expand on that, please? 
 Do you have a further explanation or examples of this? 
 Is there anything you’d like to say that you haven’t had the chance to say? If you 
think of anything else, please do email or call me. 
Thank you for taking part in this study; as mentioned in the information sheet, 
the result of this interview will be anonymised and the data made available to 
you on request. You will be offered a chance to be an author in the form of 
Milton Keynes and Luton GP consortium, on any paper which emanates from the 
study. Thank you once more 
 
6.2 Data analysis 
The audio recorded interviews were analysed using framework analysis. My data included cases and 
codes and as framework analysis is flexible and a form of a content analysis that can be used to 
analyse data with numbers in qualitative studies (Ritchie & Lewis, 2013), it was identified as the 
ideal choice. Furthermore, its flexibility nature enabled me to summarise the output in a matrix of 
rows and columns as its methodical processes and ‘spreadsheet’ approach, aligned more closely to 
quantitative paradigm (Pope & Mays, 2009). The analysis involved familiarisation with data, 
identification of themes (nodes and codes) and interpretation of findings (Silverman, 2006; Bazeley 
& Jackson, 2013).  
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The first part of the analysis involved familiarisation with the data that had been collected, a process 
of immersing oneself in the data to get an understanding of the data as a whole. This process 
involved listening to the tape, transcribing and reading the transcripts (Appendix III). The transcripts 
were further checked for accuracy against the recording and reread several times line by line before 
sorting and transferring the data into Nvivo 11 for analysis.   
Nvivo 11 software (QSR International (UK) Ltd, Cheshire, UK) facilitates the analysis of qualitative 
data with features such as characters-based coding, rich text capabilities and multimedia functions 
crucial for qualitative data management (Zamawe et al., 2015). In this research, I had the 
opportunity to learn and experience the use of the software for future use.  The disadvantages of 
using Nvivo include the fact that the software does not accept all data files except with a converter; 
an individual could also force the package to fit the design in the proposal stage; and using 
synonyms to isolate themes could lead to partial retrieval of information, which forms part of Nvivo 
program (Zamawe et al., 2015). This study was devoid of using synonyms as I went through the 
transcripts in details more than once to create the themes from the data itself, hence my 
confidence in the value of the software. Nvivo is software that hastens the process of qualitative 
analysis as the process of converting printed data to softcopy as well as identifying themes and 
codes depends on the individual undertaking the process. 
Emerging themes and patterns that constantly occurred in the data were defined and labeled with 
codes, which were refined as themes/nodes and redefined to produce themes and sub-themes 
while gaining an overview of the depth, richness and diversity of the data. An illustration of key 
themes was drawn from quotations of interview transcripts and themes were compared with the 
systematic scoping review and RMRRS to identify patterns in signs and symptoms preceding the 
clinical diagnosis of AD and extracts are presented below. 
Eight main themes were identified from the transcripts following the interviews with GPs which 
included the early presentation of AD prior to a clinical diagnosis; diagnostic criteria used in GP 
practices; early diagnosis in terms of the early signs and symptoms of AD; ease of diagnosis with the 
S/S; discussion with other colleagues; issues with memory clinics; issues with the NHS and 
treatment of the ageing population. Further sub-themes from the analysis are presented solely on 
participants’ narratives. These narratives are reproduced verbatim to explore the GPs perspectives 
on the early diagnosis of AD.   Interviews were transcribed with software (transcribe.wreally). A 
discussion section follows the presentation of extracts of interviews in line with some policies in 
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health service delivery and empirical evidence. Also, the demography of the participants, especially 
the age and age of services are coded to further enlighten the reader on another theme emerging in 
the discussion section, which is the aging professional. 
6.2.1 Findings 
The primary themes in these interviews were the interplay of the early signs and symptoms, early 
diagnosis and factors surrounding the late diagnosis. However, the emphasis was mainly on issues 
surrounding the late diagnosis with most explanations on consultations and individual patients; 
“where is the time” was a phrase reflected across the interviews. In this regard, the concepts 
portray the challenge faced with the ten minutes appointment time. 
The findings of this study echo the literature that describes the diagnosis of AD as challenging. The 
notable difference with the literature was the lack of emphasis on biomarkers which were never 
discussed. Echoing a similar research in Amsterdam where the GPs indicated that they would only 
pursue a diagnosis (biomarkers examinations) when patients’ cognition began causing problems in 
their overall functioning (Prins et al., 2016) the GPs felt that a diagnosis was necessary only if it had 
consequences for treatment and care. 
  
Figure 6.2: The participants’ gender:  Four females and three males. 
 
Gender 
Females
Males
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Demographically, the participants’ ages ranged from 32-66 years with a mean age of 51.7 years. The 
length of experience that the GPs had as post-qualification practitioners ranged from 8-41 years 
with a mean age of 23.2 years. Participants were associates in their various practices over a range of 
periods from 6 months to 31 years with a mean period of 13.6 years (n=7). The framework analysis 
afforded the researcher the flexibility to analyse codes and cases simultaneously, while assuming a 
content analysis. The eight themes are presented as follows: 
 The presentation 
 Diagnostic criteria 
 Early diagnosis 
 Ease of diagnosis with the early signs and symptoms 
 Discussion with other colleagues 
 Issues with the memory clinic 
 Issues with the National Health Service (NHS) 
 Treatment of the aging population 
 
6.2.1 Presentations 
In relation to the presentations, three sub-themes emerged (Figure 6.3) including early 
presentation; the timing of presentations and signs and symptoms aiding with the diagnosis.   
 
Figure 6.3: Sub-themes of presentation. The theme includes the signs and symptoms aiding with 
the diagnosis. 
 
These sub-themes will be discussed individually. 
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 6.2.1.1 Early signs and symptoms 
The early signs noticed by the GPs and the symptoms reported by the patients included:  memory 
loss; lack of understanding; depressive symptoms and psychiatric symptoms. Interestingly, 75% of 
the participants (Figure 6.4) indicated that memory loss was the first symptom to be noticed and 
reported, as the ten-minute appointment made it impossible to notice other signs; therefore, it 
became so much of concern about their memory loss than looking for other signs.  
‘But often these days in general practice where continuity of care practices is not the way 
many GPs would like it; it becomes so much of concern about their memory; it will 
exacerbate any anxiety (GP2).’ 
One of the GPs s opined that it is either the memory loss or depressive symptoms with subsequent 
psychiatric symptoms.  
‘So either they are forgetting things or their mood has changed, so for no reason, they have started 
to become aggressive (GP1).’ However, the depressive symptoms were uncommon, which could 
probably be a reverse causality for AD. 
‘They are usually noticing changes in their memory, so the memory changes are 
mentioned first, they are more common, the changes in mood change is not common but 
noticed by them (GP2).’ 
The analysis further indicated that some patients, however, presented with arthritis and high blood 
pressure. This is because AD is a multi-faceted disease and could assume the nature of other 
illnesses, while other chronic illnesses of the blood and endocrine system could lead to memory 
loss, which further complicates and confuse the diagnosis. 
 ‘A lot of patients don't present with memory loss, but with at least arthritis, high blood 
pressure, mood changes, heart attack, diabetes, there are a lot of other chronic diseases, 
but then you think, is AD also a consideration? (GP3).’ 
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Figure 6.4: Participants matrix. Each colour of the matrix represents a participant and the numbers 
in the row represent the comments made by each participant regarding the early signs and 
symptoms. 
 
6.2.1.2 Timing of presentations 
As indicated by the participants (Figure 6.5), the timing between the manifestation of the signs and 
symptoms to the clinical diagnosis of the disease ranged from four months to one to two years. The 
lack of continuity of care was seen by the GPs as a hindrance to isolating the signs and symptoms 
early due to the fact that the individual was seen by different GPs, which hinder the ability to detect 
subtle changes in the individual. They further stated that the signs may not be noticeable because 
the patients may seem alright. However, if the patient has caring relatives or family, symptoms 
reporting might be early and presentation time could be short, say three months.  
‘But often these days in general practice where continuity of care practices is not the way 
many GPs would like it; it becomes so much of concern about their memory; recently I 
had a patient who had early dementia, but she waited nearly four months for the clinic 
appointment (GP4).’ 
‘It could be months or even year or two (GP6)’ 
I think we are talking months, probably maybe between 6 and 12 months, but are very 
variable. You got somebody who's got very caring relatives or very close friends or 
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spouse, it may be the short amount it could be 3 months but I think in most cases of 
people I see, is over a period of somewhere between maybe  4 to 12 months, it's quite 
variable (GP4).’ 
When explaining about the difficulties of ascertaining the timing in presentation and isolating the 
signs and symptoms early, participants stressed the fact that the high turnover of staff and the ten-
minute appointment delayed the ability to engage fully with the patient and likely impacted their 
ability to detect the early signs and symptoms of AD. The ten-minute appointment was by far the 
most raised issue among the GPs. It was a real concern due to the inability to strike a balance 
between meeting the current needs of the patient and trying to detect subtle changes of AD. Some 
of the GPs described the stake in taking a decision as follows:  
‘You have ten-minute appointments, you're looking at other physical diseases, multiple 
pathologies,  morbidities and other things, so diagnosis is not an instance but is 
something that develops because of its family doctor. There are other things in general 
practice now; because there's a high turnover of staff (GP2).’ 
‘General Practice has ten-minute appointment like it convey about, remember because 
we look after seven thousand patients; two doctors at the moment, we are short of 
doctors, so I am not proactive, most GP are not proactive in making the diagnosis, unless 
it's so obvious, then is not an issue (GP3).’ 
‘Yeah, yeah, remember how the NHS works, a GP practitioner works ten minute 
appointments so I have ten minutes to see one patient for one problem, now so the way 
you diagnose is within the resources you have and a time limit you have; you might see 
the patient probably 6 or 7 times, before you start thinking that this is a firm diagnosis of 
AD (GP 6).’ 
The high turnover of staff contributed to the recruitment of locum, which in turn prevented an 
extended relationship that will foster the ability to detect changes in the Dr/patient relationship. 
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Figure 6.5: Matrix of presentation. The colours in this matrix represent the topic of discussion; 85% 
of participants that spoke more about the early presentations, 57% about aiding of the 
presentations with the diagnosis, while only 42% commented on the timing of signs and symptoms. 
 
Another defining issue was the lack of continuity of care; this was caused by inconsistency in the 
same patient seeing different GPs at each visit, which made it impossible to know which signs and 
symptoms were presenting first and therefore, the focus was often based on a concern about the 
memory loss rather than a progressive decline in other presentations. In view of the lack of 
continuity of care, one of the GPs summed it up as ‘continuity of care brings a diagnosis (GP2).’   
Yeah if it is a patient known to you and you have multiple contacts with a patient you will 
pick things up, and then you will introduce that as something you need to be screened for 
that condition; there are other things in general practice now; you never see the same 
doctor you must see a locum company that diagnoses there and then because there is 
not a lot I can do at the moment (GP3). 
Still, on the timing of presentations, GPs recognised that lack of cooperation was a challenge faced 
by patients as this impacted on the ability to detect the early signs. The lack of cooperation was 
seen to be brought about by the fear of stigma. Even though stigmatisation is not an extensive issue 
with AD, it still elicits fear among individuals and family, as the mechanism of coping with the 
diagnosis is challenging in the midst of trying to deal with the demands of the diagnosis and 
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emotional turmoil it brings. The extracts further illustrate that the patient will sometimes use the 
excuse that forgetfulness is normal, which can confound a diagnosis. Perhaps, if other signs were 
considered, this might not be the case. GP2 reveals that in this GPs experience it is often the patient 
who is reluctant to seek a diagnosis of AD, as it is seen as a label that carries social connotations and 
possible stigmatisation. Some patients may not realise that there are benefits to having an earlier 
diagnosis. So more patient information should be available, that indicates the signs and symptoms 
patients and their family members/carers should look for and the options available to them.  
Definitely, like the challenges are it’s a big diagnosis; and say for instance the patient is 
relatively young or even if the patient is old but they have had a couple of or the patients 
themselves have had good quality of life, then, although they have noticed the memory 
problem, they were still coping, once they have got the label of AD, a lot of things 
changed. It happens suddenly because of the diagnosis (GP5).  
I think that the delay is not on our side; sometimes patients themselves try and normalise 
the concerns.  I have patients who have frequently come to me and say well everyone 
gets forgetful a bit as they get older and also relatives. I think less so, you know, when I 
am thinking about fifteen years ago when I was a GP, there was a huge stigma about 
being diagnosed with AD or dementia and a real reluctance to consult a consultant 
psychiatrist to discuss treatment options; but even the diagnosis was considered a shame 
and I have had many spouses/patients who really refuse to accept that their 
wives/husbands its becoming more and more muddled (GP2). 
On the professionals’ side, the lack of proactive investigations that would facilitate an early 
diagnosis by the GPs and inadequate training specifically with regards to the early signs and 
symptoms of AD, was another driver of the late diagnosis of the disease. The lack of sufficient 
knowledge of the disease pathology made it impossible to notice the timing of the first notable 
presentation as one of the GPs noted and attributed the diagnosis of the disease to the psychiatric 
team. Perhaps, with a suitable tool in the primary care, the diagnosis will not be the sole derogation 
of the secondary care. 
GPs are not really trained adequately to assess people for AD, that's really the job of a 
psychiatrist and the psychiatric team. So what we tend to do is send people for memory 
test in various instances and then if the memory test is suggestive of Alzheimer's or 
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dementia, at that end, it is the secondary care who make the diagnosis rather than GPs 
(GP1). 
None of the participants mentioned finances as a hindrance to the early detection only the lack of 
resources in the NHS. However, they were optimistic that the development of a suitable tool for the 
early diagnosis could be beneficial.  
6.2.1.3 Ease of diagnosis with the signs and symptoms 
The role of the signs and symptoms in aiding with the diagnosis was emphasised as a factor in the 
early diagnosis of the disease. Although most of the GPs were not keen to isolate other early signs 
and symptoms apart from the memory loss, participants all stated that the signs and symptoms 
mentioned, aided with the diagnosis of the disease especially when the disease was at the advanced 
stage of dementia. The notion is that the family members would have noticed these presentations 
months or years before the diagnosis and waited to be sure that the symptoms were consistent and 
the changes pronounced, before seeking the attention of the physician; hence the ease of diagnosis. 
So again it’s like, obviously when they come to us with these specific presentations, the 
assumptions is that these symptoms would have started months or years prior to their 
coming to us, because they would have noticed the change probably  for about a good 
six months, so the changes would be that they would lose keys in the house and not find 
them, they would probably be watching a soap probably on a regular basis and then 
when they ask them what it meant, probably they would not remember what happened 
previously. So these are the sort of signs and symptoms of their daily living, which the 
spouse notices because they are changes that are quite noticeable, because they were 
not there before and they are quite obvious and they do give it like I said, a fairly long 
time to see if there is consistency in their symptoms. So once they are convinced that 
there is something wrong, they come to us (GP1). 
6.2.2 Diagnostic criteria used 
In terms of the diagnostic criteria used, the majority of the participants indicated the preference for 
memory clinic as a way of making a diagnosis as there were no specific criteria for the primary care 
except the MMSE. While GPs used “GP code” (with six questions), “six sets test” and MMSE with full 
physical examinations, where possible, the GPs relied on the secondary care to make the final 
diagnosis. The GPs initiated the diagnosis after a full physical examination has been conducted to 
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exclude other diseases or conditions, with series of blood tests and electrocardiograph (ECG) to rule 
out other causes and establish a healthy heart before finally sending the patient to the memory 
clinic to establish the diagnosis; GP group echoed the series of test done before the diagnosis was 
established. 
 I don’t think there are any specific diagnostic criteria to be followed, but it is the mini-
mental test (MMSE) that we do on these patients. So once we are told that definitely 
there is a certain change they have noticed, then we bring the patient back for a 20-
minute appointment and then we do the mini-mental test. I think that is a real gold 
standard for diagnosing memory problem (GP5). 
We would use the six sets test, but obviously, we would do a full physical examination to 
ensure that, because physical problems can mimic this, like hyperthyroidism, interaction 
with other medications. So we do a full physical examination first and take a full history, 
hopefully from somebody who knew the patient well and then with the patient 
themselves, we would do the six set test (GP4). 
We have quite strict criteria because we would always insist on referring to the memory 
clinic, so we have a certain number of routine blood tests that we need to organise first, 
for us to exclude certain conditions. We also do an ECG more because thinking about….if 
they are going to need treatment… lots of medications can have an effect on the way the 
electro-conducting mechanism of the heart works. So it’s important to know they have a 
normal ECG before you start, then refer them to the memory service and nearly always, 
they would actually get a CT diagnosis as well….although, that is not absolutely 
mandatory to make the diagnosis. We don’t ourselves just make the diagnosis without 
referring to the memory service (GP7). 
6.2.3 Early diagnosis 
I have split the issues that impact early diagnosis into four sub-themes including (1) the issues that 
delay early diagnosis; (2) the burden of late diagnosis; (3) the benefits of early diagnosis and (4) the 
challenges associated with early diagnosis, and these are considered below:- 
6.2.3.1 Issues that delay early diagnosis 
When asked about the issues that lead to delays in early diagnosis, participants indicated the lack of 
patients’ insight into their early signs of dementia; they worried that the fear of losing their 
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independence prevented them seeking help at the early stage as well as the fear of being labeled 
with the disease. A GP sums it up as follows:  
I suspect, there is a lot some of our patients who for…  they won’t want to have a 
diagnosis because they would have their fear; if it is working-age patients, they would  
fear loss of  ability to  drive, loss of ability to work  and then I suspect probably a small 
proportion of patients don’t want to be diagnosed with dementia, perhaps they are not 
presenting and perhaps they are having a hard time at home and  well they are; yes I 
remember one of my patient,  I think she did have dementia, but she was …and she did 
have a certain degree of insight but she was refusing……; she was so…….she didn’t want 
that diagnosis. She was doing everything possible not be….. Laughed at …… labels by 
family or by professionals and she was so angry that we are talking in those terms, but 
then, unfortunately, she did decline over the years (GP3).  
‘Well, often the Patients have no insight, if they live alone, they might not appreciate 
that they are slowly dementing (memory loss) (GP4).’ 
Social isolation was also an issue that was attributed to the late diagnosis of the disease. Individuals 
staying alone were often forgotten and their being isolated prevented others from noticing the early 
changes in their wellbeing. As one of the GPs put it  ‘I think people who are more socially isolated… 
maybe don't have family around or a lot of friends…they might not come to anybody else’s attention 
because they manage somehow to function even though they have quite a level of disability in terms 
of committing public functions (GP7).’Another supported this view by indicating that the delay is 
usually from the patients’ side, especially when the individual is without relatives and friends. 
The delay is usually either the patient is on his own. That’s one of the areas probably 
where the diagnosis can be delayed because the patient either is been independent, they 
have not needed any carers, or the family probably is not around. They are in s situation 
perfectly where they were managing before and then their memory goes off… Because 
they are on their own and nobody else notices it, it does then get delayed because 
nobody is picking that up and bringing that patient to us about their concerns (GP3). 
Additionally, logistical problems alongside delays in getting an appointment with the memory clinic 
contributed immensely to the delay in diagnosis.   
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The GPs are aware of the benefits of early detection; however, they were skeptical about the 
support to the patient after diagnosis. They were worried that the patient would not have the 
desired support or therapy needed especially with the limited resources and time as well as high 
turnover of staff in the NHS. Therefore, making a diagnosis would be difficult for the patient without 
therapy. Some of the GPs sum it up as: 
That's the issue, in the NHS, where is the support? What do I do when I make this 
diagnosis?  Is there a consultant out there who, is there enough of them to say I can see 
them or support them, or to introduce any therapy, psychological therapies, physical 
therapies, anything that can get this diagnosis well supported, finding it  is extremely 
difficult...pause.... very difficult, because the NHS resources are limited (GP1). 
If I had thirty minutes with a patient, it’s easier, but I cannot afford thirty minutes per 
patient because we are looking after 7000 patients; one doctor looking after well over 
three thousand patients, plus there is a high turnover of medical staff, so yeah, if we had 
more time and more resources, it gets easier and easier to diagnose some of these  our 
patients and say, we've  got time, let’s do some a longer chat, a longer discussion  your 
problem and then it makes it easier to put that diagnosis into perspectives (GP3). 
6.2.3.2 Burden of late diagnosis 
Conversely, all the participants indicated that the burden to the individual is high, including 
cognitive and functional decline, resistance to treatment and poor support from family, friends, 
health and social care. The main burden to the family highlighted by the participants was stress and 
anxiety around obtaining a formal diagnosis as well as poor support from the NHS on how to cope. 
However, there was no mentioned of the burden on the healthcare system or healthcare personnel, 
which could be due to the fact that the GPs were more concerned about the issues facing the PC 
and how they contribute to the diagnosis of AD. 
‘So if the diagnosis is delayed considerably, then I think there is more resistance to 
treatment (GP5).’ 
‘I think is the patient and the partner or the family that is struggling, I think that is the 
major issue and not only the other thing the late diagnosis a sort of traumatises them. 
Hmmm, it’s a sort of it is Idolism. Is there anything else that can be done to make life 
easy? (GP1).’ 
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Well I think if you get a late diagnosis, it is inevitable that your patient probably gonna 
deteriorate and any intervention probably gonna be unsuccessful; so there is no point in 
given patients with a late diagnosis, well  I won't say there is no point but, I would expect 
that there would be relatively little gain, because if they have a late diagnosis, they 
would probably have  quite a severe  degree of dementia and I suspect they are probably 
gonna have considerable cerebral atrophy and may well not respond to treatment  which 
is available  (GP2). 
6.2.3.3 Benefits of early diagnosis 
In terms of the benefits of early diagnosis, one of the participants stated that there was no negative 
aspect to an early diagnosis. Others (Figure 6.6) supported this view by stating that the early 
diagnosis was beneficial in terms of planning ahead, power of attorney and anticipatory care.  
Furthermore, it was beneficial to employers as they could support the patients and place them in 
suitable positions within the workplace. 
I think it is really… really good; if we’ve got the resources and a good system available to 
us which can diagnose AD early, obviously the triaging area is us, so once we have 
identified and signpost and they are seen promptly, then it’s very… very beneficial for the 
patient and for the family, because then, they can adjust to that real diagnosis and then 
manage it better. So I think all around, it’s much more beneficial for the diagnosis to be 
made as early as possible (GP5). 
There are undoubtedly benefits; I can’t think of any negative aspect of early diagnosis, to 
be honest. I think for example if a person is at work and is struggling, I think it would be 
worthwhile for both for the patient and the employer, patients ‘employer to know, so it 
will be helpful and whether they are able to accommodate the person you know, in 
position in which they could still work. I am not sure how much for the patient and the 
employer to have; yes I think it will be possible (GP4). 
‘There are lots of positives…because simple things like forward planning, anticipatory 
care and power of attorney over financial and health needs…obviously all those things 
are really important (GP7).’ 
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6.2.3.4 Challenges associated with early diagnosis 
The challenges reported by the participants that were associated with the early diagnosis included: 
denial by the patients as they were afraid to be associated with the disease due to the fear of losing 
their independence. Not only were they afraid of losing their independence, they were afraid of 
stigmatisation from the society, even though AD is not associated with much stigmatisation.  
I suspect that some of our patients..… they won’t want to have a diagnosis because they 
would have their fear; if it is working-age patients, they would  fear about loss of  ability 
to  drive, loss of ability to work  and then the stigma, being label dementia probably  is 
going to be on themselves, I suspect probably a small proportion of patients don’t want 
to be diagnosed with dementia, perhaps they are not presenting and perhaps they are 
having a hard time at home and  well they are; yes I remember one of my patients …I 
think she did have dementia, but she was or and she did have a certain degree of insight 
but she was refusing… she was so…….she didn’t want that diagnosis. She was doing 
everything possible not be… Laughter … labels by family or by professionals and she was 
so angry that we are talking in those terms, but then, unfortunately, she did decline over 
the years (GP2) 
 
Figure 6.6: Benefit matrix.  The participants in this matrix all spoke about the benefits of 
early diagnosis of the disease; 71% commented respectively on the challenges, burden and 
impact on the GPs. 
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The call for the early diagnosis was well supported by the GPs; raising the awareness of the disease 
especially through the media, has enabled individuals to seek help and the GPs were more 
sympathetic and considerate when treating the elderly. The GPs were far more able to have an 
open discussion of the disease with their patients and families on the diagnosis and interventions 
available.  With consideration of the racial diversity of patients, the GPs were hopeful of a suitable 
tool for the diagnosis that could be used in a racially diverse population with language difficulties 
and comorbidities. 
Oh certainly we are far more aware to consider it in an elderly person and there is more 
acceptable to discuss it early with patients and families and also as a GP, you get a query 
from relatives. So I think generally, which is good news, I think the media relations 
certainly raised lots of awareness for people on getting treatment early (GP6). 
 
Also, issues of racial and cultural diversity proposed a challenge with early diagnosis of AD, 
especially the ethnic groups at risk of vascular dementia due to high vascular and metabolic 
disorders. The language barriers mean that there is the need to develop a tool that could be 
applicable to these ethnic groups. 
We do have a very ethnically diverse population; we have a lot of southern Indians and 
people from Bangladesh, who are… certainly, have a higher risk of multi-infarct 
dementia, because they’ve got a higher incidence of hypertension, diabetes, metabolic 
syndrome already. But obviously, for some of those individuals again, the conventional 
testing isn’t that friendly…  I have to say I don’t know whether there are tools that we 
could use with that population (GP7). 
6.2.4 Ease of diagnosing with the signs and symptoms presented 
The responses by the participants regarding the ease of diagnosing with the presence of the signs 
and symptoms are split into three sub-themes namely (1) ease of diagnosing the signs and 
symptoms in GP practices, (2) ease of diagnosing as individual GPs and (3) scale of diagnosis or 
points given with regards to how easy it is to diagnose the signs and symptoms presented (Figure 
6.7). 
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Figure 6.7: Sub-themes of ease of diagnosis. 
 
6.2.4.1 Ease of diagnosing with signs and symptoms in the GP practice 
The ease of diagnosing AD in the GP practice was regarded as challenging. Respondents all indicated 
that AD was difficult to diagnose except when the disease was at an advanced stage. Apart from the 
fact that some patients might insist on specialist confirmation, the GPs felt that further assessment 
was not required at an advanced stage of the disease. 
‘Practically it is difficult except that I think there are expectations I supposed, that the 
patients would want specialist confirmation, even though clinically it is feasible to 
diagnose them especially if they advanced, more of us can say they don’t need to go 
through the assessment (GP1).’ 
The ease of diagnosing AD also depended on individual practitioner; the enthusiasm by the GP to 
examine the patient in-depth, especially if the patient had an inclination that something was wrong, 
all contributed to the ease of diagnosis. The evidence indicates that some of the GPs were 
sometimes less concerned about obtaining a diagnosis especially when there were no complaints 
from the patients. This is demonstrated best by the following quote (GP2). 
 I have worked with a number of different doctors and some doctors I worked with have 
very little interest in examining patients or doing anything for them, they just want them 
out of the door. So, it depends on your approach to life, I think it can be difficult diagnosis 
because it presents in very subtle ways, so if you have somebody who maybe doesn’t 
think quite right but doesn’t make a lot of fuss about it, you obviously won’t say; or you 
will be fine, go away, goodbye and I am not bothered and that’s what a lot of my 
Ease of diagnosing 
with the signs and 
symptoms 
Ease of diagnosing 
in the GP practice 
Ease of diagnosing 
as individuals Scale of diagnosis 
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colleagues do or have done and still do, I have seen lots of evidence of that. So you know, 
it depends on your approach, but my approach has always been, what will I like a doctor 
to do for me if I was that person, or that person was my relative (GP2). 
 Furthermore, it takes years before the signs and symptoms manifest while the degenerative 
processes continue. This could make the diagnosis challenging at the early stage when the signs and 
symptoms are subtle and could be mistaken for old age or other conditions. .  
I think in itself, it can be difficult to recognise in the early stages… because, memory 
changes and age happen together anyway…and to a certain degree, change of 
personality…so it can be very challenging at the early stages, not so much towards the 
end of the spectrum…it’s a bit in the middle which is a kind of useful, but can be hard 
(GP5). 
Time and lack of resources were also mentioned as the contributors to the challenges faced in 
diagnosing the disease early. According to some of the GPs, there are no trained personnel or 
facilities that will make the process easy and a GP is torn between the choice of concentrating on 
current complaints or fully assessing the patient when it comes to the issue of time. One of the 
comments is as follows: 
Yeah, exactly, it is challenging, general practice is very challenging, so your part is 
changing every day, your part is more towards your time limit, your works load, what 
you can diagnose, what you can't, whether there are resources to do that and work 
properly; there is tremendous challenge in the NHS. Those are the challenges, have you 
got time with your patients? Have you got more resources? Have you got mental health 
practitioners working in your practice? You have none of that, do have any other trained 
staff to help you with a diagnosis like this, no we don't. Do you have time? Are you under 
tremendous time constraining? Yes, absolutely challenging, very challenging; the time 
constraints etc (GP3). 
6.2.4.2 Ease of diagnosing AD as individual GPs 
As individual GPs, the achievement of a diagnosis was not challenging as long as they could listen to 
the patients’ complaints and refer them to specialist clinics; ‘The challenge will be not listening; as 
long as we are listening to the spouse and referring them further on, I don’t think there is a challenge 
there (GP2).’ However, most of the GPs indicated that AD is not a common disease; one in twenty of 
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those 65 years and below with the prevalence variable in localities. Without a disposition, the signs 
and symptoms were sometimes mistaken for other conditions as they are not frequently 
encountered in the PC. 
‘You don’t use to seeing it and so you may miss it, so you have to have a higher end 
suspicion and I have to say that I may miss things, I think everybody does, but it depends 
also on your approach to life (GP3).’ 
Additionally, the disease presents as other conditions like normal aging or diseases like CJD, which 
can delay the diagnosis as other conditions have to be excluded to establish a diagnosis of AD. 
 Well, lots of people often complain of similar illnesses or similar symptoms and they 
don’t have dementia, they could be a little bit forgetful sometimes, or they may be going 
through stress. So you can’t just say everybody who says I keep forgetting things or my 
memory is not so great, you can’t assume that they are all demented, there may be 
many reasons for that, if they are physically unwell, they could be stressed to reasons. So 
physical illness makes you unwell, it affects your mental function and stresses you to do 
that. So it’s quite difficult to tease out who is physically ill, who are just suffering from 
the stresses of life and who is got dementia (GP1). 
 Also, practitioners felt that time constraints due to the ten minutes appointment system enforced 
by NHS did not allow them to investigate the symptoms more thoroughly as the GPs were more 
concerned about the present complaints than looking for hidden ones.  
‘Generally speaking, it is not easy, smiles... for the reasons of, we are so busy; going 
backward, ten-minute appointment, conveying about medicine, so you can say it’s not 
easy (GP4).’ 
Finally, the lack of a suitable tool for an ethnically diverse population, which could enhance the 
communication between the GP and the patient, was limited in terms of the availability of 
interpreters:  
  ‘ Well, yes…that’s a challenge to me because I don’t necessarily have the 
communication skills to pick out those things because if you are going through an 
interpreter, you really can’t go do a memory state examination successfully with 
someone else interpreting for you…..(GP7).’ 
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6.2.4.3 Scale of diagnosis or points that are given with regards to how easy it is to diagnose 
with the signs and symptoms presented 
When asked to rate the ease of diagnosing the signs and symptoms of AD on a scale of one to ten; 
one being the least easy and ten being the easiest to diagnose the presentations, participants 
opined that the diagnosis was difficult, with a range from 2-5 for each sign and symptom.   
‘Well, I think it’s difficult, well I will say it’s probably well there 2, 3, and 4. It’s a difficult 
diagnosis to make and get right (GP2).’ 
One of the GPs stated ‘I will give it a five’ (GP5). Additionally, they indicated that the diagnosis 
would be easy with familiarity with individual patients over time, as continuity of care and follow-up 
were necessary to make a successful diagnosis, which was a challenge within the NHS. 
It could be ten out of ten if you have the time and the resources, yes; but in certain 
situations, if you don't have that, it may delay the diagnosis and is follow-up, and its 
management, not just making a diagnosis; because follow-up and management is part 
of the diagnosis and then you can say, where can I send you? And it’s becoming 
increasingly difficult within the NHS to support your diagnosis (GP1). 
Moreover, the screening tool in the PC was MMSE, which was considered unsuitable for highly 
educated individuals as they could manipulate the procedure and to individuals with Down 
syndrome due to limited intelligence; therefore, it was entirely dependent on the GP’s relationship 
and knowledge of the patient. 
I think we have to be specific…… Again the screening tool which we used, that is slightly 
subjective to the patient, if the patient has the intelligence, they can manipulate it either 
way; depending on the persons or patients with moderate or severe dementia cannot be 
able to do that. So early, I think it depends on I suppose clinician who knows the patient 
very well to be able to say they are manipulating it or not, by experience and by the 
knowledge of the patient. But why would they do it? Probably I do not know. So I will say 
five. (GP3). 
6.2.5 Discussing the early diagnosis of AD with other colleagues 
Findings from the study indicate that the low prevalence makes it impossible to discuss the disease 
with other colleagues, as some of the GPs indicated that low prevalence and patients’ unwillingness 
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to undergo further testing hinder a proper discussion. However, some participants discussed the 
disease with other colleagues and felt that the AD patients needed more assessment and support, 
which could point to the issue of limited consultation time and professionals. They were happy with 
the considerable benefits of early diagnosis even when the patients were seen less regularly. 
‘Yeah, we have certainly discussed it in meetings and we all hear considerable benefits of 
early diagnosis (GP4).’ 
‘They are of the same opinion as me; I guess as a GP, there are the challenges to really 
ensure that you are assessing all your patients adequately, because often we, these days 
we don’t see patients as regularly perhaps as we used to (GP2).’ 
 We don’t have a huge (number of) patients in that cohort of elderly aged patients and 
therefore we don’t have that many patients actually and being here ten years, my load of 
assignment since 2003 and the patients also; I have two patients at the moment with 
dementia and I don’t have many willing and the patients who are nurtured earlier are 
not keen on going into any medicine or even assessment etc (GP1). 
6.2.6 Issues with memory clinics 
The result of this study suggests that the main issues with the memory clinics are logistical, as AD is 
underdiagnosed by these services; hence there is a backlog of patients waiting to be diagnosed. 
Perhaps, if there was a standard tool to be used in the PC, the backlog would not exist and certainly 
not to the same extent, as other conditions are excluded and a firm conviction of AD made before 
referring the patient to these specialist clinics. The GPs further stated that the waiting lists of 
patients in these centres were occupied by those who did not need this service. 
‘I think is just a logistical problem …I think in the memory clinic, for example, the patient I 
referred that has the advanced disease or typical case of dementia, I don’t think she has 
yet had an appointment (GP4).’ 
‘So I think that is a deficiency and I suspect partly the problem is that the waiting list is 
occupied by patients who perhaps who don’t need to be there (GP2).’ 
6.2.7 Issues with the National Health Service (NHS) 
In terms of issues with the NHS, the ten-minute appointment was the dominant concern as 
participants all indicated that the consultation time was not enough for a GP to have a proper 
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conversation and assessment of the patient (Figure 6.8). It has meant that a proper history taking or 
mental assessment is not possible within the consultation time, especially with comorbidities, 
except if the patient comes in with memory issues or dementia.  The GPs felt that trained 
professionals within the PC should be carrying out the assessment (ie nurse practitioners) to provide 
a subsequent diagnosis of individuals with the disease. 
 
Figure 6.8: Ten-minute appointments. 57% of the participants spoke about the issues with the ten-
minute appointment and one participant, in particular, spoke about this issue four times more than 
others. The issue was discussed due to its’ impact on the time spent with the patient, to make a 
definite diagnosis. 
 
The extracts suggest that the NHS needs more human and material resources to help in the early 
diagnosis of AD, especially with a population that is racially diverse, as it is increasingly the case in 
the UK. 
‘I guess it’s the time; most GPs have ten-minute consultations and I must admit I often 
need longer than that (GP3).’ 
The reality is that we have a ten minute appointments to see patients, and that means 
you see the patient, you take a history, you do an exam, you keep detail accurate records 
and to do that for one problem, is very difficult, and to do it for more than one problem, 
is impossible, you will not do it well; and to do a mental health assessment, we don’t 
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have the time to do that, you need a lot of time to do that properly. And I cannot do it in 
a ten-minute consultation, so somebody else should be doing that, somebody who is 
trained adequately to assess somebody mentally should be doing that, and that’s the 
only way you can figure out an early diagnosis in the majority of people that got 
dementia (GP2). 
Not only is the NHS in need of more resources, participants felt that the service could organise itself 
and encourage individuals to go for an early assessment. Furthermore, the extract indicates the 
need to develop a system where those individuals who are 65 years and over are mentally assessed 
on an annual/regular basis possibly in their homes, as this was a strategy adopted in other 
developed countries to isolate the disease and other chronic diseases early. The GPs were also of 
the opinion that the public could be encouraged to contribute to their health care rather than 
believing that healthcare is meant to be free. The contributions could help ease the financial 
pressure or cut back faced in health care delivery.    
Well, I think the main challenge is actually getting people to come to see us because a lot 
of people don’t. So there isn’t a mechanism in society at the moment to review people to 
get an assessment of their general health and their mental health. With the situation 
being as it is, where the NHS is in debts, that’s highly unlikely, but if you go to France, 
France spends a lot more money in their NHS in France than they do here; well they don’t 
have an NHS but they have an equivalence system and until public beliefs, stop believing 
that everything should be free, and start contributing, all successful governments double 
or triple or quadruple the amount of money going into NHS which is never gonna happen 
probably. The service that we get for everything, will not improve. So in an ideal world, 
you have somebody who is dedicated to go and see every single person age 65 and over, 
once a year to do a mental health assessment and I mean everybody, and that is never 
gonna happen, whether you go in to see somebody who is in their home or you have 
centres where people go to, if people don’t turn up, then you go chasing them and go 
and see them. And you can have some of these systems whether they are in-depth, but 
this isn’t in an ideal world (GP3). 
Other challenges included the role and responsibilities of locum; the GPs related the high turnover 
of staff and the employment of the services of locums to the lack of continuity of care, as according 
to them, ‘continuity of care gives a diagnosis (GP2)’. Perhaps, recruiting more GPs or mental health 
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nurses to undertake the screening of individuals and sustaining the continuity of care could be of 
benefit in the initiative for early diagnosis of the disease.  
 ‘in the general practice now; you never see the same doctor you must see a locum 
company and because there's a high turnover of staff, patients don't get continuity of 
care and continuity of care gives a diagnosis. We could have at least trained mental 
health nurses that would come and screened the population, because they know the GPs 
do not have the resources to it themselves, either too busy doing other things, but they 
came, I think when it was a government drive to make this diagnosis, there was a drive 
and all of a sudden it is falling apart because of the cuts back in the NHS. I believe there 
must have been a cut back to them, they disappeared (GP2). 
6.2.8 Treatment of the aging population  
With regards to the treatment of the aging population, participants noted that the aged were 
discriminated upon by the public and there was lack of enthusiasm from healthcare providers and 
the NHS in treating them as aggressively as younger generations. This discrimination and perhaps at 
best, unconscious bias, meant that the views of older patients were not addressed as thoroughly as 
those of the younger generation.    
Well I think is very important, to me I think there is creeping ageism in our society and a 
lot of people now have very strong views  about not treating people  who get older with 
the same enthusiasm as you would treat young people; In fact, my wife had a hairdresser 
and she said the hairdresser and her friends have been talking and they thought that 
people over 65 years of age shouldn’t  be allowed to vote, because they didn’t know 
what they were doing, and I mean that’s a dreadful thought, dreadful opinion; I am 66, I 
am fully complimentist (work position), I am working full time, I work five days a week, I 
have five site commitment, I have a  judicial appointee to the lord chancellor, so I have 
significant responsibilities, I have a heavy workload and I could  pretty well do it and to 
suggest that somebody my age shouldn’t vote is insulting and disreputable and I think 
the same approach goes in medicine (GP3). 
The GPs lamented that aged individuals have not been treated fairly in the NHS and felt that these 
individuals should be treated equally whether they were newborn babies or aged. The GPs explain 
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that patient-centered care should be tailored to meet the needs of individuals in all circumstances. 
One of the GPs summarised it as follows: 
The number of relatives who have been treated in the NHS, who are elderly, have not 
been treated well, have not been treated the same aggressive approach as you should 
approach any patient well. So I feel very strongly that you should treat everybody the 
same, irrespectful of their age and you should only not provide care if it is in the patient’s 
best interest that that should happen. As far as making a diagnosis and treating a 
patient with AD or any other disease is concerned, I feel extremely strongly that you 
should get on and do it just as much as you will treat a baby who’s got a head cold or an 
infected lung (GP6). 
6.3 Discussion 
This study is the first exploration of GPs’ perceptions of the use of early signs and symptoms for the 
diagnosis of AD.  It also examined issues surrounding the late diagnosis as well as GP 
recommendations against the delays which may hinder an early diagnosis of AD. The GPs 
interviewed in this study, provided insights into the issues preventing the early diagnosis of AD. 
Individuals with AD diagnosed at an early stage have the potential to live longer, as the disease 
responds to treatment at this stage. The participants’ mean age was 51.7 years and their length of 
practice ranged from 8-41 years indicating their experience and ability to comment on the issues at 
hand.  
The gold standard for diagnosing AD is the advanced testing (Viola & Klein, 2015; Olsson et al., 2016) 
which is unavailable in the primary care setting and the MMSE available in the clinical practice is not 
sensitive enough due to communication barriers in autistic individuals and issues with literacy in 
highly intelligent people (Prins et al., 2016). Findings from this study indicate that the patients’ 
concerns, physician observations and history from family, friends and other health professionals are 
essential to enable the early detection of the disease. However, it was widely acknowledged by the 
participants that these signs and symptoms are sometimes overlooked due to the current limitation 
on consultation times. This finding is supported by recent research that indicates the challenges 
with the current consultation time (Lewis et al., 2016; Mercer et al., 2016; Gove et al., 2016). Other 
challenges in healthcare mentioned include the ageing population, expectations from patients and 
shrinking budgets, which have interfered with the effective delivery of health care and the 
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subsequent late diagnosis of AD.  Moreover, a valid instrument for early diagnosis in the PC might 
lead to fewer referrals to the memory clinic. 
The NHS is the national body saddled with the responsibility of providing health care for its citizenry, 
which was borne in 1948. Recently, this body has been burdened with a rising tide of demand which 
conflicts with its lack of adequate financial and human resources (Filochowski, 2015). The situation 
has been tagged, the biggest crisis in NHS history (Alderwick & Ham, 2016), with deficits in hospital 
budgets, missed targets for patients ‘care’ and inadequate professionals resulting from, most 
recently, the Great Recession of 2008-9. All the participants reiterated that the NHS has deficits in 
finance, which made the resources unavailable, inadequate funding of enough professionals and 
huge demands of their time. All of these factors have contributed to the late diagnosis of AD 
individuals.  
Supporting this is the crisis in general practice (Roland & Everington, 2016) which includes a breach 
of waiting time for consultations, increasing workload and overwhelming budget regulations. It is 
unsurprisingly common for a GP to have appointments and see 60 patients in a day (Roland & 
Everington, 2016) due to the increasing workload. GP participants confirmed that the current 
situation in the NHS afforded insufficient time compared to that required to engage fully and 
comprehensively with the patient. Some GPs however, are against the qualitative assessment and 
increased duration of the consultation, as they perceive this will increase workload (Croxson et al., 
2017).  The complexity of the ageing population, chronic or long-term conditions, as well as multi-
morbidity, requires more complex and longer consultation to deliver quality care; this is a rising tide 
of workload that will require additional expertise (Thompson et al., 2016). A suitable tool might help 
reduce the workload and the need to increase the consultation time. 
Furthermore, the funding crisis has seen the NHS employing the services of locums to sustain the 
services of doctors and plug the gaps created by a high turnover of staff. However, the use of 
locums in the NHS (Rimmer, 2016) has contributed to the lack of continuity of care, flouting the 
need for an integrated care approach for those in need of health care services, as patients are made 
to see different doctors on several consecutive occasions. This could affect the ability to establish a 
doctor-patient relationship that will enable patients to talk openly about their concerns and 
facilitate an early detection of AD. Additionally, the NHS spends nearly 25 times as much on locum 
agency fees as they spend on recruiting doctors for permanent positions (Lacobucci, 2016). If the 
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reverse was the case, it would be reasonable to believe that there would be less service gap, with 
adequate continuity of care for patients, and a subsequent early detection of AD.  
Central to the study is the finding that memory loss is considered to be the primary indicator for 
further investigations to determine whether a diagnosis of AD is appropriate. The result is 
supportive of the literature (Cumming et al., 2013; Jahn, 2013; Tramutola et al., 2015; Viola et al., 
2015) where memory loss was identified as the early sign of the disease. However, other symptoms 
including apathy and odour deficits have been identified, which are superior to memory loss in 
discriminating individuals at the early stage of the disease (Devanand et al., 2015; Ringman et al., 
2015). The use of the PC data has also enabled us to identify other symptoms that presented earlier 
than memory loss, previously not investigated in AD (Bature et al., 2018). The knowledge of the 
early presentations and timing could help initiate patterns that could inform a predictive model for 
early detection to be used in PC, as the GPs acknowledged that they do not always recognise the 
disease in patients early. 
Aside from the issues faced in the healthcare sectors, some of the reasons for the late diagnosis as 
opined by the GP participants, included a lack of insight of patients and their relatives into the early 
signs and symptoms of AD. The lack of insight (anosognosia) has been identified as one of the signs 
and symptoms of AD, as an early mechanism of the disease and part of a neuropsychological 
syndrome of AD (Migliorelli et al., 1995). The sign, which initially was not affiliated with the disease 
duration and severity (Reed et al., 1993), is however severe when patients are at the stage of severe 
cognitive decline (Conde-Sala et al., 2014) and it is associated with episodic memory loss (Senturk et 
al., 2016). Anosognosia predicts the progression of the disease (Munro et al., 2016) and could be an 
early mechanism and not a factor of delay, or vice visa.  
My study also highlighted the role of the fear of stigmatisation which can delay an early diagnosis of 
the disease. This is in line with other studies (Gautier et al., 2013; Dubois et al., 2016) who have 
opined that AD diagnosis is associated with labeling or stigmatisation. Ironically, AD label is not 
associated with a significant level of stigmatisation in the society in general (Johnson et al., 2015; 
Gove et al., 2016). 
One of the qualities of professionalism in the healthcare setting is the ability to seek and share 
advice on issues regarding health, including AD. When asked about discussing the issue of early 
diagnosis with professional colleagues, even though some GPs stated that they had fewer AD 
patients to initiate discussion, GPs that engaged with others felt strongly that the support on early 
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screening was inadequate in this regard. The GPs were of the opinion that mentoring, training and 
adequate resources were essential to empower the primary care medics to deliver effective 
diagnosis and management of AD. The findings of this study provide an insight into the needs of 
professionals to be trained in this area and corroborate the findings of other researchers (Simon et 
al., 2014; Blom et al., 2016; Curran & Wattis, 2016; Maresova et al., 2016) indicating the need for 
specialist training of healthcare professionals in the primary care setting. This is to ensure that GPs 
can manage multiple comorbidities simultaneously and provide high-quality health care to meet the 
public expectations and the standards set by the Care Quality Commission (CQC). Moreover, the 
fewer prevalence of the disease could be a yardstick to trigger a debate as to how the services could 
attract individuals with the disease. 
Information sharing stretched beyond the professionals in the healthcare settings to as far as the 
patients’ families and friends. Arguably, the majority of the participants spoke about the fact that 
reliable information about the signs and symptoms of AD were often collected from trusted families 
and friends and sometimes the healthcare receptionist. The result of this study supports the 
findings of other studies (El Haj, 2016) that indicate the challenges of retrieving information from AD 
individuals and echo those that reports that trusted information can reliably be received from 
informants (Rueda et al., 2015; Amariglio et al., 2015).  The result further emphasises the need for 
effective communication and collaboration between professionals and patient’s families and friends 
for effective healthcare delivery. On the contrary, genuine report of symptoms by AD individuals has 
closely been linked to social, cognitive and functional symptoms of AD (Jacova et al., 2013), 
indicating that information derived from the patients themselves is beneficial (Morris et al., 2014). 
Hence, there is a need for early diagnosis before the stage of AD dementia with irreversible memory 
loss. 
AD is a disease that was initially associated with ageism due to the high prevalence in the elderly 
population; however, it is a known that the disease also affects the young, in a less frequent but 
often more dramatic way (Klimkowilz et al., 2014).  Due to the fact that the prevalence increases 
with age, findings in this study indicate that the elderly population is not treated with the same 
enthusiasm as the younger generation. The findings further imply that the mistreatment of the aged 
is applicable to health care professionals and the society at large. A recent report by Tullo et al. 
(2015) on medical professionals indicates there is a lack of sympathy by this group towards the 
aged. Concern around this finding has led experts and policymakers to call for more training for the 
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medical students on geriatric medicine (Gordon et al., 2013; Masud et al., 2014; Cullinan et al., 
2015). The call by the GPs for an annual check-up for those 65 years and above could also help 
diagnose AD earlier in this group. 
6.4 Conclusion 
The study highlights important changes that would facilitate the earlier diagnosis of AD, which 
would enable the effective use of healthcare professionals' time and financial resources available to 
the NHS. The identification of early signs and symptoms of AD may be beneficial to GPs and PC 
patients - providing a timely therapeutic intervention and support to all involved. 
6.4.1 Implication for research, policy and practice 
The interviews were held with a relatively small group of GP participants and cannot necessarily be 
generalised. Although the responses from most of the participants were broadly similar, the 
restriction of participants to only two CCGs may reflect perspectives within a narrow geography 
rather than at national level.  While other researchers (Iacobucci et al., 2016; Lewis et al., 2016) 
have identified challenges faced in the primary care including the timing of consultation, the need 
for training of GPs, memory loss as a determinant to initiate an AD diagnosis and issues of 
stigmatisation in dementia awareness, this study goes further. The research highlights the views of 
the GPs regarding the early signs and symptoms of the disease, issues surrounding the late diagnosis 
and their recommendations to early detection of AD.  Additionally, issues including isolation and 
lack of continuity of care as a hindrance to early detection of AD are discussed. Research is 
advocated in this regard to know if these views can be generalised with regards to the early 
diagnosis of the disease. 
The limitation of the sample size means that conclusion cannot be drawn from the results of the 
interviews; policy implementation cannot be solicited at the moment until a wider audience within 
a wider geographical area that is a representation of all GPs is interviewed. However, the result has 
implications for practice, as GPs could consider issues of training and more awareness of the early 
signs and symptoms that could limit the emphasis on memory loss as a determinant to initiate a 
diagnosis in concerned areas. This could be beneficial even before the issues in the primary care are 
considered for policy implementation. 
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6.4.2 Study strength and Limitations 
This study provides a summary of the perceptions of a representative/number of GPs regarding the 
constraints of ten minute consultation times, and the inability to provide continuity of care as the 
main contributors to late diagnosis of AD. Furthermore, they acknowledged that they do not always 
recognise the early signs and symptoms of AD in patients, hence the need to develop a predictive 
model which can be used within the PC setting. To the best of our knowledge, this is the first 
interview of GPs perspective on the early signs and symptoms of AD, issues surrounding the late 
diagnosis and their recommendations to factors against the delay in early diagnosis.  
A limitation of the study is that the interviews were held with a relatively small group of GP 
participants and cannot necessarily be generalised. Although the responses from most of the 
participants were broadly similar, the restriction of participants to only two CCGs prevents its 
generalisation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
175 
 
CHAPTER SEVEN: Final discussion and conclusion 
7.1 Overview 
This chapter describes and discusses the findings of the mixed method approach used in this thesis. 
The methods used were: a systematic scoping review of literature undertaken to map, synthesise 
and appraise the quality of existing evidence on the timing and sequence of signs and symptoms 
that justify the clinical diagnosis of AD; a retrospective medical record review using a case-control 
design to identify patterns in signs and symptoms preceding the clinical diagnosis of AD in general 
practice notes and patients’ records, as these were presented by the AD patients before their 
clinical diagnosis; and semi-structured qualitative interviews that explored the perspectives of GPs 
regarding factors that may contribute to a late diagnosis and recommendations for overcoming 
barriers to timely diagnose AD.  
 
7.2 Summary of results and broad implications 
The early signs and symptoms of typical AD include memory loss with or without cognitive and 
behavioural changes, while the atypical presents without memory loss. Of the already known signs 
and symptoms, there are no patterns to distinguish the timing and sequence of these presentations 
from other diseases, as previous research has focused on identifying the symptoms without 
emphasising patterns, which is paramount to early diagnosis. Other researchers (Chen et al., 2001; 
Craig et al., 2005; Vos et al., 2013) have identified the advanced symptoms of the disease at the 
stage of dementia or after the disease establishment. So far, the diagnosis of AD according to the 
current diagnostic criteria (Dubois et al., 2014), is weighted on biomarkers without specificity of the 
pattern in signs and symptoms (Molin et al., 2016).  
This study sought to investigate and offer the opportunity to establish patterns in signs and 
symptoms of the disease ten years’ pre-diagnosis to suggest the development of a predictive model 
for early diagnosis of the disease, as the degenerative process takes between 10–30 years before 
the symptoms are reported. Furthermore, issues surrounding the late diagnosis of AD and 
recommendation to early diagnosis are presented from the GPs’ point of view. 
In relation to the identification of signs and symptoms, of the established fourteen signs and 
symptoms of AD, only anxiety, episodic memory loss, weight loss, depression, hallucination, 
irritability and appetite disorders were significantly associated with AD, with sleeplessness being 
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present in only one case. These could be due to the sample size, as there were few studies on the 
timing and sequence of AD and issues in the primary care. Other signs and symptoms that emerged 
from the RMRRS and interviews indicated headache, backache, dizziness, drowsiness, flatulence, 
loss of appetite and dehydration. However, gastrointestinal disturbances (flatulence, loss of 
appetite and constipation) were reported as side effects of medications (Matsunaga et al., 2015; 
Wischik et al., 2015).  
The findings in this study, presented in chapters four, five and six, support previous studies 
indicating memory loss as an early mechanism and in the predementia stage (Arshavsky et al., 2010; 
Bateman et al., 2012; Mortamais et al., 2016). For example, memory loss was indicated as the first 
symptom in the EAOD and LOAD in the systematic scoping review and the interviews. The interview 
findings could be associated with the fact that AD is suspected if memory deficits are exhibited 
during the medical and physiological examinations. This was also noted in previous research 
(Santacruz & Swagerty, 2001), therefore could be considered as the first presenting symptom. Other 
signs and symptoms mentioned in the interviews as presenting first included anxiety and 
depression. Indeed, patients sometimes presented early with mood changes, supporting the 
hypothesis that depression is an early mechanism of AD (Rosenberg et al, 2015). However, 
depression could be a reverse causality, as it has been suggested as a risk factor for AD, with an 
overlap between the symptom and AD (Novais & Starkstein, 2015).  
In the RMRRS, findings indicated that auditory disturbances in the form of tinnitus presented way 
beyond memory loss, especially in white females. This supports findings of other studies that 
memory loss is not the earliest presenting symptom (Oppenheim, 1994; Petersen et al, 2014), 
highlighting the fact that individuals with AD have higher odds of auditory disturbances in the early 
stage. Individuals presented with the disturbance 30 years before the diagnosis, indicating that it is 
an early symptom of the disease process. However, the symptom has not fully been investigated in 
AD, except auditory hallucinations and could also be a reverse causality or a confounder. To the best 
of my knowledge, there is no study that has investigated the relationship of auditory disturbances 
and the onset of AD, apart from studies looking into auditory hallucinations in psychosis in AD (Jeste 
et al., 2000) and psychiatric symptoms of AD (Arnold et al., 1998; Ballard et al., 1999; Murray et al., 
2014; El Haj et al., 2017). Although we found that auditory disturbances may be associated with AD, 
this may be the case for other diseases too, so it will be interesting to look for associations with 
other dementia conditions. 
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Participants included in the study were diagnosed according to the NINCDS-ADRDA diagnostic 
criteria, with a MMSE score of 15 and above. Findings in the systematic scoping review indicate that 
the memory score of 25 in individuals at risk of the autosomal dominant AD could discriminate 
those at risk of conversion to AD. Even though there is no evidence supporting MMSE as a 
standalone test, the score could help identify individuals with autosomal AD for the more 
sophisticated diagnostic tool.   
In addition, the systematic scoping review of the literature revealed 35 additional focal symptoms 
identified in individuals with RPAD. The focal symptoms and signs were consistent with a form of 
prion disease (CJD), including myoclonus and rigidity. A third of RPAD experienced rapid weight loss 
and had sleep disturbances, indicating their significance in discriminating the disease from other 
dementias. The rapid weight loss supports other findings indicating weight loss as an early sign. 
Ironically, other studies indicate that weight loss could be a sign of severe cognitive impairment, 
therefore not an early sign (Soto et al., 2012; Besser et al., 2014). 
A longitudinal study (Tyas et al., 2001) and a case-control (Breteler et al., 1991) implicated 
headache/migraine as a risk factor for AD, with Matsunaga et al. (2015) suggesting it as a side effect 
of AD medications. In my RMRRS, AD individuals exhibited the symptoms with a mean age of 26.8 
years before clinical diagnosis of the disease. The symptom was more common in the white males 
and mixed-race females as an early upstream mechanism. However, the symptom could be a risk 
factor, supporting previous literature indicating that the symptom is a risk factor for AD (Breteler et 
al., 1991; Tyas et al., 2001). There is a misconception that a chronic headache is not a serious 
problem and primary headache disorders are rarely professionally diagnosed (Olesen, 2013; Luna, 
2016). Yet, it is estimated that a chronic headache for at least 15 days affects 2.4% and migraine 
10% of individuals at some point in their lives. This is an indication that more research is required to 
establish the true relationship of this symptom to AD. 
Lower backache was another symptom experienced by the AD groups and consistent with white 
females in the RMRRS. Individuals with the symptoms were 58% odds of being associated with AD. 
Lower backache has not been investigated in AD, except for lumbar puncture in AD (Peskind et al., 
2009) and AD caregivers ‘burden’ (Shaji et al., 2003). This report calls for more research to 
understand whether backache is an early symptom in AD or not. 
Additionally, the semi-structured interviews of GPs highlights and feeds into our understanding of 
GPs’ perceptions on issues in general practice that contribute to the late diagnosis of the disease. 
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The GPs reported the constraints of ten minute consultation times and the inability to provide 
continuity of care as the main contributors to late diagnosis of AD. Furthermore, they acknowledged 
that they do not always recognise the early signs and symptoms of AD in patients, hence the need 
to develop a predictive model which can be used within the PC setting. These perceptions are also 
consistent with recent literature (Dubois et al., 2016) indicating the constraints of the consultation 
time and lack of resources in the primary care and the NHS. These findings could be replicated by 
researchers and noted by policymakers to facilitate the provision of quality, evidence-based and 
person-centred care to individuals, especially the elderly, which will support an early diagnosis for 
better care outcomes. 
The treatment of the ageing population was also a core theme in the semi-structured GP interviews, 
which was seen as unsatisfactory and bias. The interviews with GPs revealed that the elderly 
population is not treated with the same enthusiasm as younger generations by medical 
professionals. A recent report by Tullo, Khoo and Teodorczuk (2015) on medical professionals 
indicates there is a lack of sympathy of GPs towards the aged. Concern around this finding has led 
experts and policymakers to call for more training for medical students in geriatric medicine 
(Cullinan et al., 2015; Gordon et al., 2013; Masud et al., 2014). The call by the GPs for an annual 
check-up for those 65 years and above could also help diagnose AD earlier. AD is a disease that was 
initially associated with age due to the high prevalence in the elderly population, however, it is a 
known that the disease also affects the young, in a less frequent but often more dramatic way 
(Klimkowilz et al., 2014); it is pertinent to provide patient centred care irrespective of age. This will 
also reduce the burden of the disease on the health care system, as the burden arises more from 
disability than mortality (Prince et al., 2015). 
The GPs’ interviews also indicated that some individuals suspected of having AD and their families 
felt early diagnosis was irrelevant simply because they felt they were going to die anyway and there 
was no treatment to cure the disease. Such views are supportive of the critics of early diagnosis on 
the basis of identifying a disease without the options of treatment (Mattson et al., 2010; Gauthier et 
al., 2013). However, there are interventions that could slow the disease process, giving individuals 
more time with their families or the opportunity to make informed choices about their care and 
other issues. More information and awareness will help to educate patients on the importance of an 
early diagnosis and the interventions available. 
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7.3 Strengths and limitations of the study 
The major strength of this study is the use of mixed methods to collect the information needed for 
this research, as the study had a robust and diverse collection of data to achieve the aim of the 
research. The study also benefitted from the use of general practice data, which is the primary data 
collected at the first point of contact with patients and gives first class/reliable information on the 
presentations at an early stage of AD. The general practice data used for the RMRRS afforded the 
researcher with the opportunity to ascertain the length of time from the presentation of the first 
symptom/sign to the clinical diagnosis of AD. This accorded the study the title of a retrospective 
longitudinal study. 
Additionally, the research utilised a broad range of statistical analyses to identify the patterns in 
presentations; the systematic scoping review adopted the descriptive analysis, while the RMRRS 
utilised logistic regression and the semi-structured interviews used a framework analysis. An expert 
in the field of statistics, who is also one of my supervisors (Dr Pang), was involved to ensure that the 
process was reliable and valid. The researcher underwent a series of statistical training including 
STATA, MedCalc, SPSS and training on the Clinical Practice Research Database (CPRD) for technical 
expertise on statistical analysis, even though STATA and the CPRD data were not available for this 
analysis. 
Furthermore, this study presents the first analysis of the sequence and timing of patterns of the 
signs and symptoms using primary care data and GP interviews, which adopted a sound 
methodological approach with varied samples and appropriate protocol for each study. The semi-
structured interviews gave the GPs the freedom to explore wider issues and experiences in a 
conducive environment, thereby providing a broader understanding of the research topic in primary 
care that could confound the identification of the early signs.  
Unlike other studies that derive information of the presentations of AD from informants, this study 
is free of confounding effects of misinformation, as these signs and symptoms were presented by 
the patients personally and timely. Hence, appropriate for identifying the sequence and timing of 
the disease. A longitudinal study would have been better to collect the early signs and symptoms of 
a disease with a long latency period as this, but impracticable in PhD research. However, the 
research involved a systematic scoping of studies that included a longitudinal study, while the 
RMRRS took the place of a longitudinal retrospective study, as primary care data is considered an 
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excellent choice in assessing conditions with a long latency period and rare occurrence of diseases 
including AD (Wu & Aston, 1997; Ickowicz, 2006). 
The research also gathered information from the perceptions of professionals (GPs) dealing with 
individuals with AD as the first point of contact, thereby making the data reliable and valid. This is 
because GPs are in a unique position to assess the signs and symptoms as well as issues surrounding 
the late diagnosis of the disease. Even though each diagnostic criterion has its own merits and 
demerits, the RMRRS samples were diagnosed by the NINCDS-ADRDA, successful and reliable 
diagnostic criteria for the diagnosis of probable late onset AD with a sensitivity of 81% and 
specificity of 70% (McKhann et al., 1984; Knopman et al., 2001), and widely used in clinical trials and 
research. Although there has been a refinement of the criteria, it is still widely used and acceptable 
in research.  
There are limitations that need to be acknowledged, as the data collected was insufficient to 
generalise the results in the RMRRS. A random sampling was not possible, which might have 
introduced a sampling bias. Nonetheless, the next best available sampling method, consecutive 
sampling that includes all prevalence available, was used. Moreover, the patterns could only be 
drawn for LOAD for the RMRRS, as cases of the disease diagnosed in the GP surgeries, which were 
included in the RMRRS, were above 65 years and typical indicating late onset typical AD. 
Consequently, there is the need for future studies to ascertain the patterns in subgroups of AD. 
 
7.4 Implications for future research 
At this stage, it is imperative to address implications for future research, policy and practice. 
7.4.1 Research implications 
The RMRRS findings indicate that individuals with AD have higher odds of auditory disturbances at 
the early stage of the disease, which could potentially help identify individual with the disease early. 
Headache and backache were reported in some individuals in the RMRRS, even though headache 
has only been reported as a risk factor and backache as a side effect of medication. Future research 
could explore more precisely the relationship between AD and these symptoms, especially at the 
early stage of the disease, as these findings highlight the need for further research in this area and 
the early detection of AD. Further research is advocated with sufficient data that is diversified and 
can be generalised, to draw explicit patterns on the different types and stages of AD regarding their 
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sequence and timing for the development of a predictive model for early detection. Researchers are 
encouraged to utilise the CPRD database that is diversified, reliable and valid for this purpose as 
patient-level data collected by professionals in general practice is up to standard with additional 
resources for a variety of purposes, including one such as this (William et al., 2012). Moreover, a 
new model for early diagnosis will be criteria that incorporate a topographic pattern of trajectory 
while supporting the pathology of the disease, as new validated criteria are essential to detect 
changes at the earliest stage of the disease. 
7.4.2 Policy implications 
This research highlights the issues in the primary care regarding the early signs and symptoms, early 
diagnosis and recommendations to timely diagnosis of the disease. The NHS and policymakers 
should consider these and aim to reduce the inequalities in health care, especially with the care of 
the elderly, as the prevalence of AD is high in this group. Policy should be reviewed by allocating 
more time for consultations and adequate material and manpower resources, as this will provide an 
opportunity to detect signs and symptoms at the earliest possible time, not just for AD, but for 
other diseases with a long latency period. This would allow the timely intervention to reduce the 
progression and burden of the disease. Late diagnosis of AD is not only detrimental to the 
individual’s life but impacts on the health, emotions and economy of family members and 
healthcare institutions in general (Albers et al., 2014; Takizawa et al., 2015). Positive outcomes in 
patients will reduce the resources spent in health care, especially the institutionalisation of AD 
dementia patients. This is because the results presented in this study align with other studies 
indicating the issues in primary care and the NHS in general and the effect this has on the diagnosis 
of AD in the early stages. Early diagnosis is considerably beneficial (Sperling et al., 2011; Dubois et 
al., 2015; Dubois et al., 2016) not just to the patient, but to the general populace and health care. 
7.4.3 Public health implications 
The findings in this study also indicate issues of isolation in the elderly and not treating them with 
the same enthusiasm as the younger generations, which delays the ability to notice the signs early. 
These findings have significant public health implications as they could be barriers to early detection 
of the disease. Therefore, there is the need for greater awareness of issues surrounding the elderly. 
Public health should aim to distinguish barriers for easy access to health care, by providing adequate 
information to the general public and taking steps to improve the welfare of the elderly, which will, 
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in turn, reduce the cases of self-isolation and late diagnosis of the disease by identifying cases at the 
early stage. 
 
7.5 Contributions to knowledge 
Findings from previous studies on the AD have isolated and highlighted the early signs and 
symptoms of AD, especially at the MCI level to dementia, however, little is known about the 
sequence and timing of these presentations before the clinical diagnosis of the disease. This study 
contributes to three main areas in AD. Firstly, it extends the existing knowledge on the signs and 
symptoms, presenting the sequence and timing of the early signs and symptoms previously 
identified as well as new, as these were presented by patients before the clinical diagnosis in the 
primary care, that is, even before the MCI stage. These symptoms included headache with a mean 
time of 26.8 years before diagnosis, depression at 16.4 years, auditory disturbance at 14.5 years, 
backache at 9.2 years, episodic memory at 3.4 years and hallucination at 3.8 years. Furthermore, the 
study adds knowledge to the field of diagnosis by providing information to help identify patterns in 
early signs and symptoms in a large cohort, which could be used to develop a model in primary care 
as the only non-invasive cost-effective tool for early detection of AD. Secondly, the research adds 
knowledge as it is the first to collect clinical data to identify patterns in signs and symptoms of AD 
before diagnosis. Thirdly, the research provides useful information regarding the views of experts in 
primary care on early signs and symptoms, issues surrounding late diagnosis and recommendations 
to early detection of the disease. In general, the study provides evidence for the early presentation 
of AD to be investigated further with a large sample in primary care. 
 
7.6 Future research 
There is the need to replicate the findings of this study, which identified patterns in the sequence 
and timing of early presentations of AD and isolated new ones, using a larger scale sample. This is to 
further validate and confirm if the result is the same in other groups or cohorts. In particular, it 
would be beneficial to establish the relationship between auditory disturbances and AD in a large 
cohort as well as subgroups, which may provide the information needed to isolate the different 
subgroups of AD and other dementias, discriminating individuals at risk of conversion to the AD in 
general.   
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7.7 Conclusions 
The heterogeneity concerning the three main determinants of preclinical AD, including normal 
cognition, cognitive decline and pathophysiological syndrome, due to the dearth of data (Epelbaum 
et al., 2017) has contributed to the late diagnosis of the disease, so this study sought to identify 
patterns in the signs and symptoms preceding the clinical diagnosis of AD. Even though the data was 
insufficient for generalisation, a statistical analysis was undertaken, which reported the sequence 
and timing of signs and symptoms preceding the clinical diagnosis of AD from primary care data. In 
particular, auditory symptoms were identified in individuals with AD and headache was reported as 
an early sign, but whether headache is a risk factor or a symptom remains to be established. The 
researcher is advocating for further research, using a large diverse sample that is sufficient to detect 
changes for generalisation of the results. 
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APPENDIX V: Letter of request for support sent to GP surgeries. 
 
 
My name is Fidelia Bature, a 2nd year Ph.D. student at the University of Bedfordshire. I am undertaking a 
research on signs and symptoms preceding the diagnosis of Alzheimer's disease, to identify patterns in 
presentations and develop a predictive model for early detection.  
The rationale is that early detection of AD delays the progression and enables individuals to live independently 
and there is a need for a non-invasive, inexpensive and observable detective measures that can be used in the 
primary care settings, to complement the biomarkers examination. 
I will be looking into the anonymous and coded patient data in the GP surgeries and interview GPs in Milton 
Keynes. The review will be carried out within a period of six months to a year while the GP interview takes 
between half to an hour. My supervisors and I are delighted to have the full support of the Clinical 
Commissioning Group (CCG) and on board already are some GPs and their surgeries. GPs who engage with the 
study will be offered Membership to the Milton Keynes General Practice consortium, which will be cited in any 
publications generated from this study. 
I will be grateful to discuss the project proposal with you at your convenience and have you engage with the 
study, as it has the potential to improve outcomes for patients with Alzheimer’s disease. I am currently 
applying for ethics approval for the review study through IRAS (NHS, REC), which is the health regulatory 
authority that is an exception to the ethical and legal requirement of an informed consent. My supervisors (Dr. 
Dong Pang, Dr. Barbara Guinn & Dr. Yannis Pappas) and I are keen to know who might be interested in 
engaging with the study to ensure the application is appropriately worded. The ethics for the interview was 
sought and approved by the Research Ethics Committee, which is available on request. 
Kindest regards, 
Fidelia Bature. 
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Appendix VII: Participants information sheet (interviews). 
  
PARTICIPANTS’ INFORMATION SHEET. 
This participants’ information sheet is for the general practitioners in Milton Keynes and Luton who are invited 
to participate in research, titled “Identifying Pattern in Signs and Symptoms Preceding the Clinical Diagnosis of 
Alzheimer’s Disease”. 
Fidelia Bature 
University of Bedfordshire 
Alzheimer’s Research 
 
Introduction 
My name is Fidelia Bature, a student researcher with the Institute for Health Research, University of 
Bedfordshire. I am undertaking research on Alzheimer’s disease (AD), the most prevalent type of dementia and 
the current leading cause of death in those 65 years and above in this country. I am informing and inviting you 
to be part of this research and you are under no obligation to decide today whether or not you will participate 
in the research. Before you decide, you can talk to anyone you feel comfortable with about the research. 
What is the study about? Research indicates that there are cases of late diagnosis of patients with Alzheimer’s 
disease. These patients have a greater cognitive impairment and faster progression that leads to an extended 
period of institutionalisation and increases mortality than those identified earlier in the disease process. We 
want to find ways of identifying the disease earlier for timely interventions.  We want to know your 
perspective regarding the issue of late diagnosis of AD and your recommendations for improving early 
diagnosis rates. We also want to know your experience on the early symptoms of the disease because this 
knowledge might help us to learn how the disease presents itself at an early stage. 
Why have I been invited? You are being invited to take part in the research because we feel that your 
experience as a general practitioner can contribute much to our understanding and knowledge of Alzheimer’s 
disease and it's early detection.  
Do I have to take part? Your participation in this research is entirely voluntary. The choice that you make will 
have no bearing on your job or any work-related evaluations or reports. You might change your mind later and 
stop participating even if you had agreed earlier.  
What will happen if I take part? If you accept, you will be asked to participate in an interview with me. If you 
do not wish to answer a question during the interview, which will take place in your surgery, you may say so 
and I will move on to the next question. No one else but the interviewer will be present unless you would like 
someone else to be there. The information recorded is confidential, and no one else except my University 
supervisors will have access to the information documented during the interview. The entire interview will be 
audio-recorded and transcribed, but no-one will be identified by name. All transcripts will be anonymised, 
using a number instead of your name. Only the researcher will know what this number is and the information 
will be kept securely under lock and key. The information recorded is confidential, and no one else except my 
academic supervisors will have access to the transcripts of the interview. The audio-recordings will be 
destroyed one year after the interviews have been transcribed. 
What will I have to do? The research takes place over a two year period. During this time, I will interview you 
once, which will take about half an hour. 
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Your participation is likely to help us find out more about how to enable the early diagnosis of AD. 
Will my participation be kept confidential and what happens to the information? Nothing that you tell us will 
be shared with anybody outside the research team, and all information will be kept confidential as required by 
data protection law. Nothing will be attributed to you by name. Rather, pseudonyms or codes will be used for 
easy collection and analysis of data.  
Quotes from this interview which might be published or used for presentations or training will be anonymised 
with pseudonyms or codes, without a personal identifier. A consent form is attached for this purpose. 
How will the data be linked back to participants? 
The data from this study will not be linked back to participants and if at any point clarification is needed, this 
will be undertaken by the researcher confidentially; otherwise, all data will be anonymised. 
What will happen in the case of professional misconduct? 
The aim of the study is to identify patterns in the presentation of early signs and symptoms of AD. The 
researcher will not be in a position to identify professional misconduct or make a judgement on whether 
professional misconduct occurred. This is because I do not possess the necessary specialist medical knowledge, 
that is required to make such judgement or observation, and secondly because the data that I will receive will 
be anonymised for the purposes of the study. For all other cases of professional misconduct, including 
unacceptable behaviour or poor communication by the health practitioner, I will follow the established 
protocol which is to inform the Preliminary Proceedings Committee, based in part 144, section B of the Health  
Practitioners Act 2009. 
 What will happen to the findings of this study? The knowledge that we will gain from this research will 
inform a thesis for the partial fulfilment of a postgraduate research degree. Findings can be shared with you on 
your request. The findings will become available to the public through national and international academic 
journals and conferences.  
Contact for further information: Thank you for your interest in the study. If you would like further information 
or wish to ask questions later, you may contact any of the following: 
Fidelia Bature 
Institute for Health Research, 
University of Bedfordshire 
The United Kingdom. 
Email-fidelia.bature@study.beds.ac.uk 
OR                                                                   
Dr. Dong Pang 
Director of Study 
Institute of Health Research, 
University of Bedfordshire 
United Kingdom 
 
OR 
Professor Gurch Randhawa, 
Professor of Diversity in Public Health and Director, Institute for Health Research,  
University of Bedfordshire. 
 Who has reviewed the study?  This proposal has been reviewed and approved by the University of 
Bedfordshire Research Ethics Committee, which is a committee whose task it is to make sure that research 
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participants are protected from harm. Also, ‘The North East-Newcastle & North Tyneside 2 Research Ethics 
Committee’ has reviewed the study. 
The study is being supervised by Dr. Dong Pang and Dr. Yannis Pappas, all of the University of Bedfordshire; Dr. 
Barbara Guinn of the School of Life Science, University of Hull. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix VIII: Consent form for GPs. 
 
Study Number: 195174. 
GP SURGERIES CONSENT FORM 
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TITLE OF PROJECT: Identifying Pattern in Signs and Symptoms Preceding the Clinical Diagnosis of 
Alzheimer’s Disease:  
Name of Researcher: FIDELIA BATURE. 
          Please initial box 
 I confirm that I have read and understand the information sheet 
dated............................  (Version ............) for the above study.  I have 
had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
 
 
 I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my duties or legal rights 
being affected. 
 I give permission to publish direct quotes from this interview                                              
 
 
 
  
 I agree with Anonymised quotes from this interview to be used in this 
research for publication and training purpose.    
 
 
 
 I agree to be audio/video recorded and I understand that the recordings will 
be kept secure and destroyed one year after the interviews have been 
transcribed.   
 
 
 I agree to take part in the above study.    
  
 
________________________ ________________ ____________________ 
Name of Participant Signature  Date  
 
_________________________ ________________ ____________________ 
Researcher Signature  Date  
 
 
Appendix IX: Information sheet for GP surgeries. 
  
IRAS ID:  212908.  
INFORMATION SHEET FOR GP SURGERIES 
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This information sheet is for the GP surgeries in Milton Keynes and Luton, who are invited to participate in 
research, titled “Identifying Patterns in Signs and Symptoms Preceding the Clinical Diagnosis of Alzheimer’s 
Disease”: A retrospective medical record review study. 
Fidelia Bature 
University of Bedfordshire 
Alzheimer’s Research 
 
Information sheet 
Introduction 
My name is Fidelia Bature, a student researcher with the Institute for Health Research, University of 
Bedfordshire. I am undertaking a research on Alzheimer’s disease (AD), the most prevalent type of dementia 
and the 5th leading cause of death in this country. I am informing and inviting you to be part of this research. 
You are under no obligation to decide today whether or not you will participate in the research. Before you 
decide, you can talk to anyone you feel comfortable with about the research. 
What is the study about? Research indicates that there are cases of late diagnosis of Patients with Alzheimer’s 
disease. These patients have greater cognitive impairment and faster progression that leads to an extended 
period of institutionalisation and increases mortality than those early identified. We want to find ways to 
identify the disease early and administer the right intervention at the right time. This will be undertaking by 
identifying the early signs and symptoms of the disease through the medical records of patients with AD and 
those without AD but with the signs and symptoms of the disease, because this knowledge might help us to 
learn how the disease presents itself at an early stage. 
Why has the GP surgery been invited? You are being invited to take part in the research because we feel that 
as a primary care provider, you are the first point of contact with the patient and therefore, might have data 
about the patient that could be of importance and contribute to identifying the early signs and symptoms and 
develop a predictive model for early detection of Alzheimer’s disease. 
Does the GP surgery have to take part? Your participation in this research is entirely voluntary. The choice 
that you make will have no bearing on the GP surgery or any work-related evaluations or reports. You might 
change your mind later and stop participating even if you agreed earlier.  
What will happen if the GP surgery takes part? We are asking you to help us learn more about Alzheimer’s 
disease in Milton Keynes and if you accept, we would be delighted to have access to your patients’ anonymous 
data.  The information recorded is confidential, and no one else except my supervisors will have access to the 
information documented from the data. Any information about your patients will have a number on it instead 
of your patient’s names. Only the researcher will have access to this information which will be kept privately 
under lock and key. The information recorded is confidential, and no one else except my supervisors will have 
access to the anonymous data. The data will be destroyed after the information has been coded. 
What will the GP surgery have to do? Provide data that has been anonymised. The researcher has already 
developed a data abstraction form for this purpose.  
HOW WILL THE PATIENTS SELECTION BE UNDERTAKING? 
The design of this study is a case-control study, that is, case notes of individuals diagnosed with the disease 
and those without the disease, but within the same age group, sex and locality; the researcher will select case 
notes of those with the disease and the controls base on their age, sex and who have attended the same GP 
practice. The design has been chosen to help us discriminate the disease from other dementias or neurological 
conditions. 
 
Will the patients’ data be kept confidential and what happens to the information? All information will be 
anonymised by the GP surgery before receipt by the investigator. Anonymised data will be stored in a 
computer with a password only known by the researcher and the computer kept secured always. 
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What will happen to the findings of this study? The knowledge that we will gain from this research will inform 
thesis for the partial fulfilment of a research degree. Findings can be shared with you on your request. Findings 
will become available to the public through the national and international academic journals, and conferences.  
How will the data be linked back to participants? 
The data from this study will not be linked back to participants and if at any point clarification is needed, this 
will be undertaken anonymously. 
What will happen in the case of professional misconduct? 
The aim of the study is to identify patterns in the presentation of early signs and symptoms of AD. The 
researcher will not be in a position to identify professional misconduct or make a judgement on whether 
professional misconduct occurred. This is because I do not possess the necessary specialist medical knowledge, 
that is required to make such judgement or observation, and secondly because the data that I will receive will 
be anonymised for the purposes of the study. For all other cases of professional misconduct, including 
unacceptable behaviour or poor communication by the health practitioner, I will follow the established 
protocol which is to inform the Preliminary Proceedings Committee, based in part 144, section B of the Health  
Practitioners Act 2009. 
What will happen to the findings of this study? The knowledge that we will gain from this research will inform 
a thesis for the partial fulfilment of a postgraduate research degree. Findings can be shared with you on your 
request. The findings will become available to the public through national and international academic journals 
and conferences.  
Contact for further information: Thank you for your interest in the study. If you would like further information 
or wish to ask questions later, you may contact any of the following: 
Fidelia Bature 
Institute for Health Research, 
University of Bedfordshire 
The United Kingdom. 
OR 
Dr Dong Pang 
Director of Study 
Institute of Health Research, 
University of Bedfordshire 
United Kingdom 
OR 
Professor Gurch Randhawa, 
Professor of Diversity in Public Health and Director, Institute for Health Research,  
University of Bedfordshire. 
 Who has reviewed the study?  This proposal has been reviewed and approved by the University of 
Bedfordshire Research Ethics Committee, which is a committee whose task it is to make sure that research 
participants are protected from harm. Also, ‘The North East-Newcastle & North Tyneside 2 Research Ethics 
Committee’ has reviewed the study. 
The study is being supervised by Dr Dong Pang and Dr Yannis Pappas of the University of Bedfordshire; Dr 
Barbara Guinn of the University of Hull. 
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Appendix X: Informed consent for practice managers. 
 
 
 
INFORMED CONSENT FORM. 
 
I have been invited to participate in research about Alzheimer’s disease. 
I have read the foregoing information, or it has been read to me. I have had the opportunity to ask questions 
about it and any questions I have asked have been answered to my satisfaction. I consent voluntarily that the 
anonymous data from this study be used for the purpose of this study only. 
 
Print Name participant _________________________ 
Signature participant______________________ 
Date______________________________________ 
          Day/Month/Year___/___/____/ 
 
Statement by the researcher / person taking the consent: 
I have accurately read out the information sheet to the potential participant and to the best of my ability made 
sure that the participant understands that the following will be done. 
1. Anonymous patients ‘data will be extracted to identify the early signs and symptoms of AD disease. 
2. Other factors related to the early presentation of the disease will also be collected. 
I confirm that the participant was given an opportunity to ask questions about the study, and all the questions 
asked have been answered correctly and to the best of my ability. I confirm that the individual has not been 
coerced into giving consent, and the consent has been given freely and voluntarily. 
A copy of this ICF has been provided to the participants. 
Print Name of Researcher ___Fidelia Bature_________   
Signature of Researcher__________________________ 
Date__________________________________________ 
              Date/Month/Year___/____/_____/ 
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Appendix XI: Interview script for GPs (General). 
 
Interviewer:  It’s a pleasure to have you today; as I explained in the participant’s 
information sheet, the research is about identifying patterns in signs and symptoms 
preceding the clinical diagnosis of Alzheimer’s disease (AD). This is to develop a predictive 
model for early detection of the disease, and your being interviewed today is to get your 
personal experience regarding the early signs and symptoms, issues surrounding the late 
diagnosis of Alzheimer’s disease, as well as your recommendation to barriers against early 
detection of the disease. 
Participant: Ok 
Interviewer: The interview should not last more than 30 minutes and I still need to check 
out some few things with you before we get started. 
Participant: Laughter, make it 15, I got to go and see a patient. 
Interviewer: Thank you so much 
Participant: Well try and shorten it a little bit, alright? Smile 
Interviewer: Well I still need to check out some few things with you before we get started. 
Participant: Ok 
Interviewer:  I know you have agreed by signing to take part in this interview, is this still the 
same? 
Participant-: Yea that is perfectly fine. 
Interviewer- It is also important to let you know that at any point, if you want to stop or you 
want a pause, you just let me know and that will be fine. Again, if you do not want to 
answer any question that will be absolutely fine. 
Participant: Interrupted and completed the sentence -say so, that is fine, general laughter 
Interviewer: Thank you. Well, as we agree earlier, the interview is part of research and 
quotes from this interview might be used for teaching purpose; I hope this is still fine with 
you? 
Participant: That is perfectly fine. 
Interviewer: Do you have any question before we begin? 
Participant: Interruption- No, not really. 
Interviewer: That is fine; I will go to the first question….. 
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Appendix XII: Systematic scoping review protocol.  
This is a protocol for systematic scoping review to collect and synthesise evidence on frequency and timing of 
the signs and symptoms to draw patterns for the detection of AD. The reviewer will investigate and identify 
how far back from diagnosis the first symptoms reporting that will warrant diagnosis. Gaps in the evidence will 
be identified for further research. 
 
BACKGROUND 
AD is the most common type of dementia and unlike other dementias, it is characterised by the deposition of 
intracellular amyloid and extracellular tau proteins in the nerve cells, which cause degeneration of the nerve 
cells. The disease is an insidious disease with a long latency period, which was initially thought to be the 
disease of old age, as the signs and symptoms are easily mistaken for old age.  
In 2015, there was a prevalence of 520,000 in the UK (Alzheimer’s Statistics, UK, 2015), with 60,000 mortality 
directly attributed to dementia yearly. AD is the fifth leading cause of death among the elderly in the UK 
(Alzheimer’s Society, 2014). The high mortality rate is largely attributed to diagnosing the disease at the 
advanced stage in the majority of cases.  Approximately 75% of AD is diagnosed in the advanced stage. 
Delaying onset of the disease by five years through  early diagnosis nd intervention could reduce the mortality 
rate of dementia (advanced stage of AD) by 30,000 yearly (Dementia 2014 Report Statistics).The late diagnosis 
could be due to due to diagnostic uncertainties including limited awareness and recognition of symptoms by 
patients and physicians (Shim et al 2013) and lack of understanding of the transitional point of the 
asymptomatic  and the symptomatic phase (Cassell et al, 2013; Lowe et al, 2014; Alz.Org, 2015). The variable 
presentation and non-specific  signs and symptoms is a challenge to diagnosing the disease early. 
Advances in AD research have led to the identification of appropriate biomarkers including amyloid protein 
and phosphorylated tau that aid the diagnosis of the disease (McKhann et al, 2011, Dubois et al, 2007 & 2014). 
The diagnosis is supported with two clinical phenotypes. However, the most accurate pattern of the signs and 
symptoms is yet to be determined. Other markers including the signs and symptoms are not clearly specified in 
the clinical settings, as studies indicate heterogeneity in the early presentation of the disease. AD can have a 
significant impact on the cognitive and functional ability in individuals, especially if it is diagnosed late. This 
affects the quality of life leading to loss of dignity, independence and subsequent institutionalisation of 
individuals.  
 
DESCRIPTION OF THE CONDITION 
The diagnosis of AD is difficult and often late, largely because the disease shares similar symptoms with other 
conditions including other types of dementia and other neurological conditions like dementia with Lewy 
bodies, korsakoff syndrome and old age. 
AD is a progressive and irreversible brain disease characterised by the depositions of amyloid protein plaques 
and tau protein tangles in the  brain cells. More than 62% of cases of dementia are AD (Alzheimer’s 
Association, 2015). The disease is most common in adults 65 years and above and the prevalence increases as 
the age progresses. The current understanding of AD suggests that the disease is heterogeneous in the 
presentation. Advances in AD research  have greatly enhanced our understanding of the disease. The early-
onset AD (EOAD)which begins at age 60 and below is attributed to rare genes which are inherited by the 
individual and present frequently with atypical presentations with fewer memory presentations (Klimkowilz et 
al ,2014). The late-onset AD (LOAD) is attributed to genetic and  environmental factors with typical memory 
presentations, which begins at age 65 and above (Imitiaz et al 2014). The  EOAD and LOAD display distinct 
genetic patterns and different presentations (Casseli et al 2013, Lowe et al 2014, Shoemark et al 2015).  
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Reviews existing are mostly on neuropsychological predictors of mild cognitive impairment (MCI), the accuracy 
of these predictors and individual symptoms (Drago et al 2011, Gainotti et al 2014). This review will include the 
sequence and timing of  early presentations of all types of AD. 
 
SYMPTOMS 
The progression and the degenerative processes of AD sometimes take between ten to thirty years before the 
manifestation of the signs and symptoms. Literature (Bateman et al, 2012) indicates that significant changes 
are yet evidence in the pre-clinical stage which is often asymptomatic with changes in the brain and the risk of 
progression unknown. Sometimes, an individual might be aware that something is wrong but unable to know 
what that is unless if this is detected by biomarkers. The pre-clinical stage is closely followed by mild cognitive 
impairment (MCI) stage with mild symptoms and elevated level biomarkers (Albert et al, 2012). The symptoms 
frequently reported at this stage include apathy, agitation, anxiety, anosognosia, aberrant motor behaviour, 
acalculia, alexia, anomia, disinhibition, dysphoria, irritability, hallucination and olfactory disturbances and 
weight loss. The sequence and timing of these symptoms are, however, not clearly defined and sometimes 
mimic other neurological and psychological conditions making the early detection and diagnosis challenging. 
 
CLINICAL PATHWAY 
The first point of contact of symptomatic individuals is the primary care settings, where they undergo series of 
tests and investigations and memory test, before being referred to the secondary settings for the more 
advanced diagnostic procedure. The International Working Group (IWG) and the National Institute on Aging-
Alzheimer's Association (NIA-AA) have suggested a diagnostic pathway where the disease is diagnosed using 
the combination of cerebrospinal fluid (CSF) examination for biomarkers and PET scan in combination with two 
clinical phenotypes for typical and atypical AD (Dubois et al 2015). Dumurgier et al (2013) and a recent 
multicentre study in the US opined that there is variability in CSF collection methods with intra-subject 
variability in CSF levels (Lucey et al 2015). The variability also in the signs and symptoms (Casseli et al 2013) 
and lack of patterns of the signs and symptoms preceding the clinical diagnosis of the disease are major 
concerns.  
 
RATIONALE  
The evidence is suggestive that AD pathology can accumulate decades before the onset of clinical 
manifestation of the signs and symptoms (Bateman et al 2002, Price et al 2009). Even with the advances in 
research and diagnostic criteria for AD, the disease continues to be diagnosed late.  
In line with the current diagnostic criteria for AD (Dubois et al 2015), the combination of the biomarkers 
examinations and clear patterns of the signs and symptoms allow better diagnostic outcomes. Accurate and 
early diagnosis of AD is important to ensure timely therapeutic interventions that are effective mostly at the 
preclinical stage, to reduce the degenerative process and enable individuals to live independent lives. 
Therefore, knowing the sequence and timing in the presentation of the signs and symptoms at the early stage 
of AD is important. 
 
AIM 
To map, appraise and synthesise the quality of existing evidence on the signs and symptoms of AD. 
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OBJECTIVES 
1. To identify the sequence and timing of the presentation of signs and symptoms at the early stage of AD, to 
inform a primary study.  
2. To understand how far back from diagnosis the first symptoms that will justify a diagnosis was reported. 
 
METHODS 
Criteria for considering evidence for this review include: 
 
INCLUSION CRITERIA 
TYPES OF STUDIES 
Qualitative and quantitative empirical evidence relating to the impact of the early signs and symptoms on the 
early detection and diagnosis of AD will be synthesised in the systematic review of studies in developed 
countries.  
 
PARTICIPANTS 
Individuals aged 30-85 years of age, diagnosed with AD, will be reviewed. The age restriction is because the 
pathophysiology takes between 10-30 years. The incidence of the disease among those 30-40 years is rising 
(12.7% in 2009) (Harvey et al 2003, Alzheimer’s Association Europe 2009) hence the inclusion of these group. 
The early-onset begins at age 60 and below while the late onset begins at age 65 and above. Studies of 
individuals with the mixed diagnosis will be considered as long as the outcomes have been reported 
separately.  
 
INDEX SYMPTOMS 
The majority of individuals with AD present with multiple signs and symptoms that begins years before the 
diagnosis of the disease. Studies have been carried out on the early signs and symptoms but few undertaken 
on the sensitivity and specificity, as well as the sequence and timing of these presentations. At the early stage, 
the early symptoms recorded so far include apathy, agitation, anxiety, anosognosia, aberrant motor behaviour, 
acalculia, alexia, anomia, disinhibition, dysphoria, irritability, hallucination and olfactory disturbances and 
weight loss with a sensitivity and specificity of 14% & 19%; 30% & 99%; 15% & 99%; 16% & 100%;16% & 96% 
and  47% & 92% respectively (Igbal et al 2013). 
The index symptoms as anticipated would be utilised as a tool to develop a predictive model for early 
detection of AD in the primary care centres to complement the biomarkers examinations. 
The review will include combinations of signs and symptoms alone. Studies restricted on single signs and 
symptoms will be excluded. 
 
TARGET CONDITIONS 
All types and stages of AD will be included in the review. 
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REFERENCE STANDARDS 
The potential reference standard for the diagnosis of AD is included which is the standard clinical diagnostic 
criteria commonly used for AD; the National Institute of Neurological and Communicative Disorders, Stroke 
and AD and Related Disorders Association (NINCDS-ADRDA) the criteria for probable or possible AD (McKhann 
et al 2011). Individuals followed-up for less than a year before diagnosis might incorrectly classify the early 
stage of AD. Judgement will depend on whether the disease can be separated into early stage and late stage of 
AD. The more recent clinical diagnostic criteria for AD that uses biomarkers to support diagnosis; the National 
Institute on Aging-Alzheimer’s Association (NIA-AA)(Jack et al 2012) will also be considered for the more recent 
studies that might have used the new criteria. Diagnostic and statistical Manual of the American Psychiatric 
Association (DSM-IV (American Psychiatric Association, 1994), DSM-5 will also be considered. 
Individuals followed-up for less than a year before diagnosis might incorrectly classify the early stage of AD. 
Judgement will depend on whether the disease can be separated into early stage and late stage of AD. 
 
 
OUTCOMES  
1. The sequence and timing of presentation. 
2. The timing between diagnosis and first symptom reporting that justify a diagnosis. 
 
LANGUAGE OF PUBLICATION 
No language restriction will be applied to the search 
 
EXCLUSION CRITERIA 
Studies focusing on developing countries, other neurological conditions, and non-empirical studies will be 
excluded. Also, studies on other dementias and late stages of AD where it is not possible to separate data on 
early stage of AD will be excluded. 
 
SEARCH STRATEGY 
This implies the specific terms to use in searching the database and the global approach to searching including 
the specific database to search.  
 
RESEARCH EVIDENCE 
REFWORKS will be used as the referencing software. 
The databases to use will include: 
• Specialist literature databases: Ovid MEDLINE (1946), PUBMED (1996), CINAHL (1937) (Ebsco), Psych 
INFO (1967), Web of Science, Scopus, Nursing Index (1994) and Health Technology Assessment Database 
(HTA). We would search each database from early inception in other to capture all evidence on the early signs 
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and symptoms of AD. Hand searching of the reference list of systematic review for signs and symptoms, 
conference proceedings from Alzheimer’s Association and Dissertations Express. 
• Specialist systematic review databases:  Cochrane register of diagnostic test accuracy studies. 
Other literature sources will include Google and Google scholar. Hopefully, this approach should uncover 
literature to use in the review. There will be a different search term for each database as their parameters 
could be different (Jefferson et al 2011). 
 
PUBLICATION STATUS 
Published articles from a bibliographic database, specialists journals and reference lists from articles will be 
considered. Unpublished (grey or fugitive literature) or informally reported studies as full papers, including 
theses, reports, book chapters and conference abstracts, will be included as long as the full study details are 
available (Song et al, 2000). The studies would have been conducted from primary care centres, memory 
clinics, hospitals and community populations to capture and established a diagnosis of AD. 
 
COUNTRY OF FOCUS 
Countries classified as developed countries due to a high human development index (HDI) by the World Bank, 
will be included. This is to ensure that the population from the review studies are the same as the study 
population in terms of economic status, standard of living, infrastructures availability, provision of amenities 
and locality. 
 
KEYWORDS INCLUDE 
In this research, AD includes the two types of AD (EOAD and LOAD). Early detection or diagnosis is different 
from early-onset AD. The definition is based on the timing of the disease process when the neurodegenerative 
process has not or slightly began. The early theatre is used rather than the late theatre to allow the reviewer 
to find studies undertaken at the early stage of AD and report signs and symptoms before the full 
manifestation of the disease or dementia (the final stage of AD). These studies should have been done 
retrospective or prospectively within a period of 2-10 years before diagnosis, as the neurodegenerative 
process takes between 10-30 years before the manifestation of signs and symptoms (Bateman et al 2012), 
while the early stage is approximated to be six years  before diagnosis.  
 
Search one: 
AD AND Early detection OR early assessment OR early diagnosis OR early signs OR early symptoms OR early 
intervention OR dementia OR cognitive imbalance OR mild cognitive impairment OR subjective cognitive 
decline OR biomarkers OR biological markers OR brain pathology OR neuropsychological tests OR 
neuropsychological index OR tomography OR cerebrospinal fluid analysis OR mini-mental state examination 
OR screening OR magnetic resonance imaging OR MRI. 
Search two: 
AD  AND  (Early detection OR early assessment OR early diagnosis OR early signs OR early symptoms OR early 
intervention OR dementia OR cognitive imbalance OR mild cognitive impairment OR subjective cognitive 
decline OR behavioural symptoms OR psychiatric symptoms OR clinical presentations OR clinical features OR 
preclinical manifestations OR clinical presentations OR early manifestations OR early presentations OR early 
detection OR biomarkers OR biological markers OR brain pathology OR neuropsychological tests OR 
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neuropsychological index OR tomography OR cerebrospinal fluid analysis OR mini-mental state examination 
OR screening OR magnetic resonance imaging OR MRI) AND (Andorra OR Argentina OR Australia OR Austria OR 
Bahrain OR Belgium OR Bermuda OR  Brunei OR Canada OR Chile OR Croatia OR Cyprus OR Czech Republic OR 
Denmark OR Estonia OR Faroe Islands OR Finland OR France OR Germany OR Greece OR Holy See (Vatican)OR 
Hong Kong OR Iceland OR Ireland OR Israel OR Italy OR Japan OR Korea South OR Kuwait  OR Latvia OR 
Liechtenstein OR Lithuania OR Luxembourg OR Malta OR Monaco OR Montenegro OR Netherlands OR New 
Zealand OR Norway OR Poland OR Portugal OR  Qatar OR SanMarino OR Saudi Arabia OR Singapore OR 
Slovakia OR Slovenia OR South Africa OR Spain OR Sweden OR Switzerland OR Turkey OR United Arab Emirates 
OR United Kingdom OR United States). 
 
DATA COLLECTION AND ANALYSIS 
QUALITY ASSESSMENT 
The criteria to assess the  data quality includes the Quality Assessment Diagnostic Accuracy Studies (QUADAS-
2), which contains assessment domain  with signalling questions  to select patients, index symptoms and 
timing (Whiting 2011). The risk of bias will be assessed with the QUADAS standard risk of bias template   that 
rates studies based on good quality paper, poor quality paper, or uncertain for bias (selection). The result will 
be summarised in the summary tables and graphs. 
  
MISSING DATA 
The researcher understands that missing data could be pervasive. Statistical analysis based only on complete 
case subsamples could introduce biased estimates and standard error while the impact of the missing value 
will reduce the sample size and concomitant loss of statistical power based on comparative datasets. However, 
there are conditions under which missing data can be ignored (Eff and Don 2009, Stekhoven et al 2012), which 
depend entirely on the relationship between the variable of interest missing and the available variable to help 
explain the missing value. 
 Authors of empirical studies with missing data will be contacted for the full study reports while being clear as 
to the nature of data required (mean, median or standard deviation value). The data extraction forms might be 
sent to the authors to complete and authors will be re-contacted again if there is no answer the first time and 
all correspondents would be logged in as part of the review. 
Before then, the researcher will make sure that there are no publications that have been missed from the 
search that contains the data missing; perhaps a study has been published after the search was completed, 
without limiting the language of publication, to avoid language bias. If the full data cannot be retrieved after all 
these, the papers will be excluded. Whatever approach taken will be stated as part of the challenges faced 
while undertaking the study.  
 
STUDY SELECTION 
The screening process will include title screening, abstract screening of primary studies on AD against the 
inclusion criteria to identify relevant articles and reduce waste of time and resources in reviewing articles that 
do not meet the necessary inclusion criteria. A title and abstract screening forms have been developed (see 
Appendix1) and will be pretested before the scoping review. 
The second level of review will include the review of the full articles deemed relevant. Articles that are only 
available in an abstracts format and meet the inclusive criteria will be included at the second level of review 
while acknowledging their inclusion limitations, to avoid missing out on recently reported studies available 
only in abstract format (Boland, 2014). All other articles that do not meet the eligibility criteria will be 
excluded. 
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EXTRACTION OF DATA 
The data extraction forms and tables have been devised and will be piloted from the first five to ten studies 
using the data-charting form, to know if the data extraction approach is consistent with purpose and 
questions. Data in a PDF format will be copied and pasted to avoid input errors 
The researcher and her three supervisors would extract the data from each source (each supervisor will extract 
20% of the data while the 40% will be extracted from the researcher) record and tabulate using Endnote (EN) 
as a standardised extraction template. Data will be extracted including copies of tables and figures and quality 
assessed to include objectives and statement, methods, participants, sample size, statistical methods of 
comparison, analysis and results including outcomes. 
 
DATA SYNTHESIS 
Although data synthesis (collating, summarising and reporting) is minimal in a scoping review, an attempt is 
made to include quality assessment, to apply meaning to the results (Armstrong et al 2011). Additionally, this 
is to consider the implications of the findings within the broader research, policy and practice, as the 
researcher intends to publish the result for use by a wider audience and reduction of duplication of effort to 
guide in future research.  
For the quantitative data, estimates of sensitivity and specificity will be plotted in (i) forest plots and (ii) ROC 
plots with sufficient data. The synthesis will be undertaken using the weighted meta-analysis estimates where 
there are compatible designs and heterogeneity is considered reasonably (data quality as evidenced by CASP 
tools used across different designs including CASP cohort study checklist and CASP diagnostic checklist). 
Heterogeneity among the study results will be examined using the sub-group analysis (Pham et al, 2014). The 
analysis will be performed using Stata version 14 (StataCorp LP 2015).  
Where meta-analysis is not possible due to insufficient quantitative data and incompatible studies, qualitative 
weighing of evidence through a narrative synthesis will be carried out with a summary of each study under the 
themes provided.  Reporting the results of the study will assume a two dimension 1) descriptively on study 
characteristics and 2) analytical on outcomes of the study (Boland, 2014). 
 
ASSESSMENT OF REPORTING BIAS 
Formal assessment will be reported based on symptoms interpretation with or without biomarkers 
examinations and PET scans. 
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Appendix XIII: Titles and abstract form 
 
TITLES AND ABSTRACT FORMS 
N
O 
DATE REFERENCE INCLUDED AT 
SCREENING? 
OBTAINED 
PAPER/ELECTRONIC 
VERSION 
DOES THE 
ARTICLE MEETS 
THE INCLUSION 
CRITERIA 
INCLUDED 
AT 
SELECTION? 
REASONS FOR EXCLUSION 
1 09/05/2016 Amieva et al 2014 Yes Electronic No No Excludes discussion on reliability in timing of presentation from 
diagnosis 
2 08/05/2016 Beards et al, 2013 Yes Electronic No No This is an interview 
3 13/05/2016 Benoit et al, 2003 Yes Electronic yes No Looking at the most common Symptoms 
4 09/05/2016 Burke el al, 2016 Yes Electronic No No Establish diagnosis 
5 10/05/2016 Chan et al, 2008 Yes Electronic No No Comparing  VAS and AD 
6 09/05/2016 Chiba et al, 2012 Yes Electronic No No Retrospective survey of symptoms  between AD and dementia 
7 09/05/2016 Chui et al, 1994 Yes Electronic No No Prediction of extra pyramidal signs 
8 13/05/2016 Eustace et al, 2002 Yes Electronic Yes No No information on timing of symptoms and patients not 
confirmed pathologically as AD 
9 10/05/2016 Fristoni et al, 1999 Yes Paper No No Behavioural syndrome study 
10 13/05/2016 Gabelle  et al,2016 Yes Electronic Yes No Looking at a single sign-palmomental reflex 
11 09/05/2016 Hodgson et al, 2003 Yes Electronic No No Symptom seeking behaviour 
12 13/05/2016 Igbal et al 2013 Yes Electronic No No Looking at sensitivity and specificity of symptoms 
13 11/05/2016 Meyers et al, 2006  Yes Electronic No No Clinical clips 
14 10/05/2016 Palmqvist et al 2012 Yes Electronic No No Association between sub cortical lesions and behavioural and 
psychological symptoms in patients with AD 
15 13/05/2016 Park et al, 2015 Yes Electronic Yes No Looking at commonality of symptoms in cognitive profile 
16 09/05/2016 Patterson et al, 1990 Yes Electronic No No Assessment of the present of signs and symptoms 
17 10/05/2016 Perquine et al, 2012 Yes Paper No No A survey interview for the prospect of a prospective. cohort 
study 
18 13/06/2016 Picco et al, 2011 Yes Electronic Yes No Based on a single symptom 
19 13/06/2016 Pognet et al, 2013 Yes Electronic Yes No Changes in BPS 
20 11/05/2016 Reeves et al, 2015 Yes Electronic Yes No The outcome is to establish whether the cognitive phenotype or 
psychological symptoms in AD could localise discrete pathology 
and target symptoms treatment 
21 13/05/2016 Ringman et al, 2015 Yes Electronic No No Common symptoms in Familiar AD 
22 09/05/2016 Seidl et al, 2009 Yes Electronic No No Association of neurological soft signs with cognitive deficits 
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23 11/05/2016 Shimizu et al, 2011 Yes Electronic Yes No Comparing the clinical profile of AD and Semantic dementia 
24 13/05/2016 Suh et al, 2004 Yes Electronic Yes No Longitudinal association 
25 13/05/2016 Toyota et al, 2007 Yes Electronic Yes No Difference in cognitive profile with sequence or timing 
26 13/05/2016 Tsolaki et al, 2001 Yes Electronic Yes No Prevalence and correlate of extra pyramidal symptoms 
27 11/05/2016 Urbanowitsch et al, 
2015 
Yes Electronic Yes No Establish the frequency of Neurological softs signs in AD 
28 10/05/2016 Van der Mussele, 
2016 
Yes Electronic Yes No Data research dissertation 
29 10/05/2016 Wilsosz et al, 2010 Yes Paper No No Trajectory of cognitive decline 
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Appendix XIV: Data extraction form. 
DATA EXTRACTION FORM 
 
AUTHOURS & YEAR OF 
PUBLICATION 
Amieva et al,2008 Devier et al, 2010 Fox et al1998 Schmidt et al, 2010 
TITLE OF STUDY 
 
 
Prodromal Alzheimer’s disease: 
Successive emergence of the 
clinical symptoms. 
Predictive utility of type 
and duration of symptoms 
at initial presentation in 
patients with MCI. 
Pre-symptomatic cognitive deficits 
in individuals at risk of familiar 
Alzheimer’s disease. 
Clinical feature of rapidly 
progressive Alzheimer’s 
disease. 
TYPE OF STUDY Case-control from the PAQUID 
study cohort 
Longitudinal follow-up Longitudinal prospective study Retrospective case analysis 
FULL STUDY OR ABSTRACT PAPER Full study Full study Full study Full 
STUDY LOCATION France New York, USA London, UK Germany 
STUDY POPULATION Cohort subjects that experienced 
developing AD 
MCI Participants Asymptomatic individuals at risk of 
autosomal dominant familiar AD 
Rapidly progressive AD 
EXPOSURE AD MCI-AD AD AD 
STUDY AIM/OBJECTIVES To examine the emergence of the 
first clinical symptoms over a 14-
year period of follow-up before 
dementia 
To assess 1) the duration 
and symptoms 2) impact of 
the symptoms on 
predicting conversion to 
AD. 
To assess the earliest clinical and 
neuropsychological features of the 
disease 
To examine the clinical 
features in terms of 
symptoms frequency, time 
span until onset and time 
point of onset relative to 
disease. 
OVERVIEW OF METHODS A longitudinal  nested case-
control study 
Longitudinal assessment 
interviewing reliable 
informants to collect data. 
Case selection of asymptomatic at-
risk members of early-onset familiar 
AD 
Retrospective case analysis. 
STATEMENTS The first symptom to appear is 
memory loss, followed by 
cognitive decline, depression 
visual disturbance and verbal 
memory loss. ADL scores followed 
two years later. MMSE scores 
slightly declined (0.05% 
Memory loss was reported 
as the first symptom in 
80% of cases, depression 
in9%, language deficit 4%, 
cognitive changes 2%, 
behavioural and 
personality changes 1%.  
Seven of the subjects were left 
handed, 55 right handed and one 
ambidextrous. 
Of the 63 subjects, 10 converted to 
AD with no difference in gender, 
age or left handedness. 
 
35 neurological, psychiatric 
and autonomic symptoms 
were identified in a rapid 
progressive AD, with 
median time of survival 
being 26.4 months. 
Neurological symptoms 
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point/year) from the 11 year. reported in the study are 
not considered in the 
Mckhann (2014) diagnostic 
criteria. However, there is  
no control in the study 
FOLLOW-UP 14 years 1-9 years 1-6 years 11 years 
STUDY SPONSORSHIP This research has been supported 
by ARMA (Bordeaux), Caisse 
Nationale d’ Assurance Maladie 
des Travailleur salaries 
(CNAMTS),Conseil General de la 
Dordogne, Conseil General de la 
Gironde, Conseil Regional 
d’Aquitaine, Foundation de 
France 
Supported in part by the 
National Institute on Aging. 
This research has been supported 
by the Medical Research Council, 
the Alzheimer’s Disease Society, the 
David and Frederick Barclay 
Foundation and the Charles Wolfson 
Charitable Trust. 
Supported by grants from 
the Federal Ministry of 
Education and Research, 
Federal Ministry of Health 
and Robert Koch Institute. 
PARTCIPANTS CHARACTERISTICS     
Number of participants 350 148 63 32 
Age (Mean) 86.2 years  67.1 ±9.9 years 44.7±8.1 73 (median) 
Gender 36.6 males 55% females 32 females 53% females 
Signs and Symptoms Memory (verbal) loss, depression, 
cognitive decline, visual 
disturbance and ADL. 
Memory loss, language 
deficit, psychosis or 
depression, cognitive 
changes, disorientation 
and personality changes. 
Memory loss-episodic and verbal, 
cognitive changes. 
35 neurological symptoms 
and signs. 
Diagnostic criteria NINCDS-ADRDA NINCDS-ADRDA NINCDS-ADRDA Post-mortem examination 
of the brain 
Level of education 42% had no diploma, 40.6% with 
primary diploma, 17.4% with 
higher education 
15.1±4.3 years Not stated Not stated 
MMSE Score 
 
27.2 vs 27.2 27.5 ±2.2. 29.2 ± 1.2 Not stated 
OUTCOME/ RESULT ONE 
(Sequence and timing of 
presentation 
Activities of daily living scores 
were the least to appear at 13-14 
year of the study, MMSE scores 
remained the same till the 12 
year, memory decline 12 year 
Heterogeneity in first 
symptom to appear with 
sequence and timing 
(average time in months) 
as follows: 
Partly; initial first symptom only The most common 
symptoms reported were 
myoclonus (75%), disturbed 
gait (66%) and rigidity 
(50%). The sequence in 
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before diagnosis, closely followed 
by cognitive decline and 
depressive symptoms, visual 
disturbance in the last 5-6 years 
and Verbal 4 years into the study.  
Memory loss 38.5, 
depressed mood 37.4, 
performance 36.8, 
personality 32.5, behaviour 
31.1, language 29.2, 
disorientation 29.1 and 
psychosis 14.0. For the 
converters, the average 
time from the onset of first 
symptom to AD diagnosis 
was 62 months (a range 
from 19-176 months). 
appearance of symptoms 
were disorientation, 
depression, impaired 
concentration, anxiety, 
disturbed gait, seizures, 
myoclonus and 
hallucination consecutively, 
rigidity, sleep disturbance, 
apathy, weight loss and 
disinhibition 
OUTCOME TWO (period between 
diagnosis and first symptom 
reporting).  
As above  Average time from first 
symptom presentation to 
AD diagnosis was 62 
months. 
Timing from initial assessment to 
first symptom presentation. 
The symptoms median time 
span from clinical onset of 
the disease to the fatal end 
point was reported (in 
months); disinhibit ion 51.1,  
apathy 17.0, sleep disorder 
16.0, delusions 15.0, 
myoclonus, hallucinations, 
seizures 13.0, impaired 
concentration 4.5, 
depression 4.0 and 
disorientation 2.0. 
STRENGTH Nested case control of 14 years 
period, contributing to evidence 
on the long duration of the 
predementia phase. 
The provision of new 
information about the 
relationship of early 
symptoms in person 
presenting with cognitive 
decline. 
The study demonstrate that 
cognitive deficits predate symptoms 
in familiar AD by several years 
Reported the symptom 
frequency, time span until 
onset and time point of 
onset relative to disease 
end point. 
LIMITATIONS Absence of an accurate measure 
for episodic memory. The 
composition of the study sample 
was heterogeneous. 
A small number of 
converters within a group 
of EOAD. No detailed 
reports on the timing from 
first symptoms report to 
AD diagnosis. 
No comparison group. It was not 
possible to determine the exact 
point at which AD became clinically 
diagnosable within the three year 
follow-up. 
Fast declining AD cases 
without control and few 
numbers of subjects, which 
could limit generalisation. 
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LIMITATIONS The composition of the study 
sample which was 
heterogeneous 
There was no detailed reports on the 
timing from first symptoms report to 
AD diagnosis 
It was not possible to determine the exact point at 
which AD became clinically diagnosable within the 
three year follow-up. 
Fast declining AD 
cases without 
control. 
 
 
 
 
 
 
Appendix XV: Table of summary of studies. 
 
AUTHOR (S) & YEAR TITLE OF STUDY STUDY OBJECTIVE  SAMPLE SIZE OVERVIEW OF 
METHODS 
KEY FINDINGS STRENGTH LIMITATION STATEMENTS 
Amieva et al, 20o8. Prodromal 
Alzheimer’s disease: 
the Successful 
emergence of 
clinical symptoms. 
To examine the 
emergence of the 
first clinical 
symptoms over a 
14-year period of 
follow-up before 
dementia. 
350 A longitudinal 
nested case-control 
study. 
Activities of daily 
living scores were 
the least to appear 
at 13-14 year of the 
study, MMSE scores 
remained the same 
till the 12 year, 
memory decline was 
reported 2years into 
the study, closely 
followed the same 
year by cognitive 
Nested case control 
of 14 years period, 
contributing to 
evidence on the long 
duration of the pre-
dementia phase. 
The absence of an 
accurate measure of 
episodic memory. 
The composition of 
the study sample 
was heterogeneous. 
The first symptom 
to appear was 
memory loss, 
followed by a 
cognitive decline, 
depression visual 
disturbance and 
verbal memory loss. 
(0.05% point/year) 
from the 11 years. 
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AUTHOR (S) & YEAR TITLE OF STUDY STUDY OBJECTIVE  SAMPLE SIZE OVERVIEW OF 
METHODS 
KEY FINDINGS STRENGTH LIMITATION STATEMENTS 
decline and 
depressive 
symptoms, verbal 
decline in the 4th 
year and visual 
disturbance in the 
last 5-6 years into 
the study.  
Devier et al, 2010. Predictive utility of 
type and duration of 
symptoms at initial 
presentation in 
patients with MCI. 
To assess 1) the 
duration and 
symptoms; 2) the 
impact of the 
symptoms on 
predicting 
conversion to AD. 
148 Longitudinal 
assessment, 
interviewing reliable 
informants to collect 
data. 
Heterogeneity in the 
first symptom to 
appear with 
sequence and timing 
(average time in 
months) as follows: 
Memory loss 38.5, 
depressed mood 
37.4, performance 
36.8, personality 
32.5, behaviour 
31.1, language 29.2, 
disorientation 29.1 
and psychosis 14.0. 
For the converters, 
the average time 
from the onset of 
the first symptom to 
AD diagnosis was 62 
months (a range 
from 19-176 
months). Average 
time in the 
presentation was 
62months. 
The provision of 
new information 
about the 
relationship of early 
symptoms in person 
presenting with 
cognitive decline. 
A small number of 
converters within a 
group of EOAD. No 
detailed reports on 
the timing from first 
symptoms report to 
AD diagnosis. 
Memory loss was 
reported as the first 
symptom in 80% of 
cases, depression 
in9%, language 
deficit 4%, cognitive 
changes 2%, 
behavioural and 
personality changes 
1%. 
Fox et al, 1998. Presymptomatic 
cognitive deficits in 
individuals at risk of 
familial AD. 
To assess the 
earliest clinical and 
neuropsychological 
features of familial 
AD. 
63 Case selection of 
asymptomatic at-
risk members of 
early-onset familial 
AD. 
The study suggests 
that memory decline 
is one of the earliest 
measurable 
cognitive deficits in 
AD, with the verbal 
memory more 
discriminating than 
the non-verbal. 
Cognitive decline 
The study 
demonstrates that 
cognitive deficits 
predate symptoms 
in familiar AD by 
several years. 
No comparison 
group. It was not 
possible to 
determine the exact 
point at which AD 
became clinically 
diagnosable within 
the three-year 
follow-up. 
Seven of the 
subjects were left 
handed, 55 right 
handed and one 
ambidextrous. 
Of the 63 subjects, 
10 converted to AD 
with no difference in 
gender, age or left-
handedness. 
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AUTHOR (S) & YEAR TITLE OF STUDY STUDY OBJECTIVE  SAMPLE SIZE OVERVIEW OF 
METHODS 
KEY FINDINGS STRENGTH LIMITATION STATEMENTS 
was present 2-3 
years before 
symptoms 
manifestation and 4-
5 years before 
fulfilling the criteria 
for probably AD. 
 
Schmidt et al, 2010. Clinical features of 
rapidly progressive 
AD. 
To examine the 
clinical features in 
terms of symptoms 
frequency, time 
span until onset and 
time point of onset 
relative to disease. 
32 Retrospective case 
analysis. 
35 neurological, 
psychiatric and 
autonomic 
symptoms were 
identified in a rapid 
progressive AD, with 
a median time to 
survival being 26.4 
months. 
 
The study reported 
the symptom 
frequency, time 
span until onset and 
time point of onset 
relative to disease 
end point. 
Fast declining AD 
cases without 
control and few 
numbers of subjects, 
which could limit 
generalisation. 
The most common 
symptoms reported 
were myoclonus 
(75%), disturbed 
gait (66%) and 
rigidity (50%). The 
sequence in the 
appearance of 
symptoms was 
disorientation, 
depression, 
impaired 
concentration, 
anxiety, disturbed 
gait, seizures, 
myoclonus and 
hallucination 
consecutively, 
rigidity, sleep 
disturbance, apathy, 
weight loss and 
disinhibition. 
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Appendix XVI: Search terms for systematic scoping review. 
A. MEDLINE search strategy 
  
1. Alzheimer’s/ 
2. Alzheimer’s disease/ 
3. Cognitive disease/ 
4. Cognitive impairment*.tw. 
5. Cognitive decline*. tw. 
6. Cognitive changes*.tw. 
7. Mild cognitive impairment*.tw. 
8. Brain pathology *.tw. 
9. Memory Imbalance *.tw. 
10. Or /1-9 
11. Early signs and symptoms/ 
12. Early symptoms *.tw. 
13. Early signs *.tw. 
14. Early presentations *.tw. 
15. Early manifestations *.tw. 
16. Early detection *.tw. 
17. Clinical presentations/ preclinical *.tw. 
18. Characteristics *.tw. 
19. Clinical features*.tw. 
20. Brain pathology/ 
21 .Behavioural symptoms and signs/ 
22. Psychological symptoms and signs/ 
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23. Neuropsychological symptoms and signs/ 
24. Neuropsychiatric inventory/ 
25. Extrapyramidal symptoms/ 
26. Pyramidal symptoms/ 
27. Or /11-26 
28. 25 or 27 
29. Early onset Alzheimer’s disease/ 
30. Early onset AD *.tw. 
31. Early onset familial AD*.tw. 
32. Early onset sporadic AD*.tw. 
33. Early genetic AD*.tw. 
34. Or /29-33 
35. 28 or 34 
35. Late onset Alzheimer’s disease/ 
36. Late degenerative disease *.tw. 
37. Late onset AD*.tw. 
38. Late onset sporadic AD*.tw. 
39. Late onset familial AD *.tw. 
40. Or / 35-39 
41.  34 or 40 
42. Dementia*.tw. 
42. Markers/ 
43. Computed tomography*.tw. 
44. Cerebrospinal fluid analysis*.tw. 
45. CSF*.tw. 
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46. Mini-mental state examination*.tw. 
47. MMSE *.tw. 
48. Screening *.tw. 
49. Cognitive examination*.tw. 
50. Magnetic resonance imaging *.tw. 
51. MRI *.tw. 
52. PET scan *.tw. 
53. SPECT scan *.tw. 
54. Or/42-53 
55. 41 or 54 
56. Developed countries/ 
57. Andorra *.tw. 
58. Argentina *.tw. 
59. Australia *.tw. 
60. Austria *.tw. 
61. Bahrain *.tw. 
62. Belgium *.tw. 
63. Bermuda *.tw. 
64. Brunei *.tw. 
65. Canada *.tw. 
66. Chile *.tw. 
67. Croatia *.tw. 
68. Cyprus *.tw. 
69. The Czech Republic *.tw. 
70. Denmark *.tw. 
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71. Estonia *.tw. 
72. Faroe Island *.tw. 
73. Finland *.tw. 
74. France*.tw. 
75. Germany*.tw. 
76. Greece*.tw. 
77. Holy see (Vatican) *.tw. 
78. Hong Kong *.tw. 
79. Iceland *.tw 
80. Ireland*.tw. 
81. Israel *.tw. 
82. Italy*.tw. 
83. Japan*.tw. 
84. Korea South*.tw. 
85. Kuwait*.tw. 
86. Latvia*.tw. 
87. Liechtenstein *.tw. 
88. Lithuania*.tw. 
89. Luxembourg*.tw. 
90. Malta*.tw. 
91. Monaco*.tw. 
92. Montenegro*.tw. 
93. Netherlands*.tw. 
94. New Zealand*.tw. 
95. Norway*.tw. 
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96. Poland*.tw. 
97. Portugal*.tw. 
98. Qatar*.tw. 
99. San Marino *.tw. 
100. Saudi Arabia *.tw. 
101. Singapore *.tw. 
102. Slovakia*.tw. 
103. Slovenia *.tw. 
104. South Africa *.tw. 
105. Spain*.tw. 
106. Sweden*.tw. 
107. Switzerland*.tw. 
108. Turley*.tw. 
109. United Arab Emirate*.tw. 
110. United Kingdom*.tw. 
111. United States*.tw. 
112. OR/ 56-111. 
B. Other databases 
PSYCINFO (1806-9th May 2016) - Same MeSH, keywords, limits and study types used in 
MEDLINE search with appropriate syntax. 
Cochrane Library (CMR last update 2012) - Same MeSH, keywords, and date limits used as 
per MEDLINE search. The adjusted syntax for Cochrane based search. 
CINAHL (1937-7th May 2016)-Same MeSH, keywords, and study types as used in MEDLINE 
with appropriate syntax. 
Nursing Index (1994-7th May 2016) - Same MeSH, keywords and study types as per MEDLINE 
search with suitable syntax. 
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C. Grey Literatures 
Dates for search; 9th May 2016.  Included terms were AD, terms for cognitive impairment 
and limit same as databases limits.  
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Appendix XVII: Logistic regression result; Syntaxes (Imputation and 
Original DATASET). 
 
1.  LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=FSTEP(COND) EPISODIC_MEMORY_LOSS_YEARS 
  /CLASSPLOT 
  /PRINT=GOODFIT CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
2. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER EPISODIC_MEMORY_LOSS_YEARS GENDER  
  /CONTRAST (EPISODIC_MEMORY_LOSS_YEARS)=Indicator 
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
3. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER EPISODIC_MEMORY_LOSS_YEARS GENDER ETHNICITY  
  /CONTRAST (EPISODIC_MEMORY_LOSS_YEARS)=Indicator 
  /CONTRAST (ETHNICITY)=Indicator 
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
4. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER AUDITORY_DISTURBANCE  
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
5. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER AUDITORY_DISTURBANCE GENDER  
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
6. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER AUDITORY_DISTURBANCE GENDER ETHNICITY  
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  /CONTRAST (ETHNICITY)=Indicator 
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
7. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER DEPRESSION  
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
8. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER DEPRESSION GENDER  
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
9. CORRELATIONS 
  /VARIABLES=GROUP GENDER EPISODIC_MEMORY_LOSS_YEARS AUDITORY_DISTURBANCE 
  /PRINT=TWOTAIL NOSIG 
  /MISSING=PAIRWISE. 
 
ORIGINAL DATA:  
10. LOGISTIC REGRESSION VARIABLES GROUP 
  /METHOD=ENTER EPISODIC_MEMORY_LOSS_YEARS GENDER  
  /CONTRAST (GENDER)=Indicator(1) 
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
11. METHOD=ENTER GENDER AUDITORY_DISTURBANCE  
  /CONTRAST (GENDER)=Indicator(1) 
  /CLASSPLOT 
  /PRINT=GOODFIT SUMMARY CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
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Appendix XVIII: BMJ Open email regarding the reviewers’ judgement. 
More 
BMJ Open - Decision on Manuscript ID bmjopen-2016-015746.R1 
BMJ Open  
24-May-2017 
Dear BATURE: 
lnbox  
24 May 
Manuscript ID bmjopen-2016-015746.R1 entitled "Signs and Symptoms Preceding the Diagnosis of 
Alzheimer's disease: A systematic 
scoping review of literature from 1937-2016." which you submitted to BMJ Open, has been reviewed. 
The comments of the reviewer(s) arE 
included at the bottom of this letter. 
The reviewer(s) have recommended publication, but also suggest some minor revisions to your 
manuscript. Therefore, I invite you to 
respond to the reviewer(s)' comments and revise your manuscript. Please note that reviewer Van Den 
Bossche comments on the paper not being clear enough, but we do not see a problem with the 
sequence of the paper and we do not believe that this needs addressing, unless 
you would like to. Please just provide a sentence in your response explaining that you have not acted 
on this recommendation. 
To revise your manuscript, log into https://mc.manuscriptcentral.com/bmjopen and enter your Author 
Center, where you will find your 
manuscript title listed under "Manuscripts with Decisions." Under "Actions," click on "Create a 
Revision." Your manuscript number has be 
appended to denote a revision. 
You may also click the below link to start the revision process (or continue the process if you have 
already started your revision) for your 
manuscript. If you use the below link you will not be required to login to Scholar One Manuscripts. 
*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a 
webpage to confirm. *** 
https://mc.manuscriptcentral.com/bmjopen?URL MASK=5d76625460d34faabd38fc2f2f0bc2ca 
You will be unable to make your revisions on the originally submitted version of the manuscript. 
Instead, revise your manuscript using a we 
processing program and save it on your computer. Please also highlight the changes to your 
manuscript within the document by using the 
track changes mode in MS Word or by using bold or colored text. 
1/1 
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Appendix XIX: BMJ Open decision to publish. BMJ Open 
<onbehalfof+info.bmjopen+bmj.com@manuscriptcentral.co 
07-Jun-2017 
Dear BATURE: 
 
It is a pleasure to accept your manuscript entitled "Signs and Symptoms Preceding the Diagnosis of 
Alzheimer's disease: A systematic 
scoping review of literature from 1937-2016." in its current form for publication in BMJ Open . 
In order to support making all research published in BMJ Open fully open access, an article-
processing charge is levied. This charge 
supports the peer review process, production costs (typesetting, copy editing, etc.), and the costs of 
maintaining the content online and 
marketing it to readers. 
Therefore, your payment of £1350 (excluding VAT) for accepted manuscript bmjopen-2016-
015746.R2 is now due. 
A separate e-mail will follow shortly with a link to payment options and instructions. This Will be from 
BMJ's partner, Copyright Clearance 
Center, through their Right link system. Please check your spam if this has not arrived, but do allow 
up to 3 days. Using this link you can 
choose to pay by card or invoice. 
Your article will not be processed further until payment is completed. 
If you have reviewed for the journal within the 12 months prior to submitting this paper, please contact 
the editorial office 
(editorial.bmjopen@bmigroup.com) about your discount. Information regarding waivers and discounts 
is included in our instructions for 
authors; however, we anticipate that most authors will have the resources to pay. 
Please note, a number of institutions have taken out Open Access Memberships with BMJ, which 
either covers the cost of open access 
publishing for authors at participating institutes, or allows authors to receive a discount on the article-
processing charge. Please visit our 
open access page to see a full list of participating institutions, find out if you are eligible and how to 
obtain your discount code - 
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Appendix XX: Survey questions for pilot interview study 
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